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A B S T R A C T
Background
Impetigo is a common, superficial bacterial skin infection, which is most frequently encountered in children. There is no generally
agreed standard therapy, and guidelines for treatment differ widely. Treatment options includemany different oral and topical antibiotics
as well as disinfectants. This is an updated version of the original review published in 2003.
Objectives
To assess the effects of treatments for impetigo, including non-pharmacological interventions and ’waiting for natural resolution’.
Search methods
We updated our searches of the following databases to July 2010: the Cochrane Skin Group Specialised Register, the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE (from 2005), EMBASE (from 2007), and LILACS (from 1982). We also
searched online trials registries for ongoing trials, and we handsearched the reference lists of new studies found in the updated search.
Selection criteria
Randomised controlled trials of treatments for non-bullous, bullous, primary, and secondary impetigo.
Data collection and analysis
Two independent authors undertook all steps in data collection. We performed quality assessments and data collection in two separate
stages.
Main results
We included 57 trials in the first version of this review. For this update 1 of those trials was excluded and 12 new trials were added. The
total number of included trials was, thus, 68, with 5578 participants, reporting on 50 different treatments, including placebo. Most
trials were in primary impetigo or did not specify this.
For many of the items that were assessed for risk of bias, most studies did not provide enough information. Fifteen studies reported
blinding of participants and outcome assessors.
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Topical antibiotic treatment showed better cure rates than placebo (pooled risk ratio (RR) 2. 24, 95% confidence interval (CI) 1.61
to 3.13) in 6 studies with 575 participants. In 4 studies with 440 participants, there was no clear evidence that either of the most
commonly studied topical antibiotics (mupirocin and fusidic acid) was more effective than the other (RR 1.03, 95% CI 0.95 to 1.11).
In 10 studies with 581 participants, topical mupirocin was shown to be slightly superior to oral erythromycin (pooled RR 1.07, 95%
CI 1.01 to 1.13). There were no significant differences in cure rates from treatment with topical versus other oral antibiotics. There
were, however, differences in the outcome from treatment with different oral antibiotics: penicillin was inferior to erythromycin, in 2
studies with 79 participants (pooled RR 1.29, 95% CI 1.07 to 1.56), and cloxacillin, in 2 studies with 166 participants (pooled RR
1.59, 95% CI 1.21 to 2.08).
There was a lack of evidence for the benefit of using disinfectant solutions. When 2 studies with 292 participants were pooled, topical
antibiotics were significantly better than disinfecting treatments (RR 1.15, 95% CI 1.01 to 1.32).
The reported number of side-effects was low, and most of these were mild. Side-effects were more common for oral antibiotic treatment
compared to topical treatment. Gastrointestinal effects accounted for most of the difference.
Worldwide, bacteria causing impetigo show growing resistance rates for commonly used antibiotics. For a newly developed topical
treatment, retapamulin, no resistance has yet been reported.
Authors’ conclusions
There is good evidence that topical mupirocin and topical fusidic acid are equally, or more, effective than oral treatment. Due to the
lack of studies in people with extensive impetigo, it is unclear if oral antibiotics are superior to topical antibiotics in this group. Fusidic
acid and mupirocin are of similar efficacy. Penicillin was not as effective as most other antibiotics. There is a lack of evidence to support
disinfection measures to manage impetigo.
P L A I N L A N G U A G E S U M M A R Y
Interventions for the skin infection impetigo
Impetigo causes blister-like sores. The sores can fill with pus and form scabs, and scratching can spread the infection. Impetigo is caused
by bacteria. It is contagious and usually occurs in children. It is the most common bacterial skin infection presented by children to
primary care physicians. Treatment options include topical antibiotics (antibiotic creams), oral antibiotics (antibiotics taken by mouth),
and disinfectant solutions. There is no generally agreed standard treatment, and the evidence on what intervention works best is not
clear.
We identified 68 randomised controlled trials comparing various treatments for impetigo. Altogether, these studies evaluated 26 oral
treatments and 24 topical treatments, including placebo, and results were described for 5708 participants.
Overall, topical antibiotics showed better cure rates than topical placebo.
Two antibiotic creams, mupirocin and fusidic acid, are at least as effective as oral antibiotics where the disease is not extensive. There
was no clear evidence that either of these most commonly studied topical antibiotics was more effective than the other.
Topical mupirocin was superior to the oral antibiotic, oral erythromycin.
We found that the oral antibiotic, oral penicillin, is not effective for impetigo, while other oral antibiotics (e.g. erythromycin and
cloxacillin) can help.
It is unclear if oral antibiotics are superior to topical antibiotics for people with extensive impetigo.
There is a lack of evidence to suggest that using disinfectant solutions improves impetigo. When 2 studies with 292 participants were
pooled, topical antibiotics were significantly better than disinfecting treatments.
Reported side-effects for topical treatments were mild and low in frequency; the treatments sometimes resulted in itching, burning, or
staining. Oral antibiotics produced gastrointestinal complaints, such as nausea and diarrhoea, in 2% to 30% of participants, depending
upon the specific antibiotic.
Worldwide, bacteria causing impetigo show growing resistance rates for commonly used antibiotics. For a newly developed topical
treatment, retapamulin, no resistance has yet been reported.
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B A C K G R O U N D
Description of the condition
Biology and symptoms
Impetigo or impetigo contagiosa is a contagious superficial bac-
terial skin infection most frequently encountered in children. It
is typically classified as either primary (e.g. direct bacterial inva-
sion of previously normal skin), secondary, or common impetigo
(where the infection is secondary to some other underlying skin
disease that disrupts the skin barrier, such as scabies or eczema).
Impetigo is also classified as bullous or non-bullous impetigo. Bul-
lous impetigo simply means that the skin eruption is characterised
by bullae (blisters). The term ’impetigo contagiosa’ is sometimes
used to mean non-bullous impetigo, and at other times it is used
as a synonym for all impetigo.
Non-bullous impetigo is themost common form of impetigo. The
initial lesion is a thin-walled vesicle on previously normal skin that
rapidly ruptures. It then leaves superficial erosion covered with
yellowish-brown or honey-coloured crusts. The crusts eventually
dry, separate, and disappear, leaving a red mark that heals without
scarring. The most frequently affected areas are the face and limbs.
The lesions are sometimes painful. Usually, there are no systemic
symptoms such as fever,malaise, or anorexia. Swelling of the lymph
nodes draining the infected area of skin is common. It is believed
that, inmost cases, spontaneous resolutionmay be expectedwithin
two to three weeks without treatment but more prompt resolution
occurs with adequate treatment. Diagnostic confusion can occur
with a variety of skin disorders including shingles, cold sores, cu-
taneous fungal infections, and eczema (Hay 1998; Resnick 2000).
Pyoderma is sometimes used as a synonym for impetigo in tropical
countries. This is usually to denote streptococcal, as opposed to
staphylococcal, impetigo.
Bullous impetigo is characterised by larger bullae or blisters that
rupture less readily and can persist for several days. Usually there
are fewer lesions and the trunk is affected more frequently than
in non-bullous impetigo. Diagnostic confusion can occur with
thermal burns, blistering disorders (e.g. bullous pemphigoid), and
Stevens Johnson syndrome.
Causes
Staphylococcus aureus (S. aureus) is considered to be the main bac-
terium that causes non-bullous impetigo. However, Streptococcus
pyogenes (S. pyogenes), or both S. pyogenes and S. aureus, are some-
times isolated from the skin. In moderate climates, staphylococ-
cal impetigo is more common, whereas in warmer and more hu-
mid climates, the streptococcal form predominates. In moderate
climates, the relative frequency of S. aureus infections has also
changedwith time (Dagan 1993). Itwas predominant in the 1940s
and 1950s, after which Group A streptococci became more preva-
lent. In the past two decades, S. aureus has become more common
again. Bullous impetigo is always caused by S. aureus.
Secondary impetigo may occur as a complication of many der-
matological conditions (notably eczema). The eruption appears
clinically similar to non-bullous impetigo. Usually S. aureus is in-
volved. The underlying skin disease may improve with successful
treatment of the impetigo, and the converse may also be true.
Complications of non-bullous impetigo are rare, but local and
systemic spread of infection can occur that may result in celluli-
tis, lymphangitis, or septicaemia. Non-infectious complications
of S. pyogenes infection include guttate psoriasis, scarlet fever, and
glomerulonephritis (an inflammationof the kidney that can lead to
kidney failure). It is thought that most cases of glomerulonephritis
result from streptococcal impetigo rather than streptococcal throat
infection, and this has always been an important rationale for an-
tibiotic treatment. The incidence of acute glomerulonephritis has
declined rapidly over the last few decades. Baltimore 1985 stated
that the risk of developing glomerulonephritis is not altered by
treatment of impetigo; however, certain subtypes ofGroupA strep-
tococci are associated with a much greater risk (Dillon 1979b).
Epidemiology
In the Netherlands, most people with impetigo consult their gen-
eral practitioner and only approximately 1% of the cases are re-
ferred to a dermatologist (Bruijnzeels 1993). Although the inci-
dence of impetigo in general practice has been declining, recent
data show an increase in consultations for impetigo (Koning 2006;
Van den Bosch 2007). Impetigo is still a common disease partic-
ularly in young children. It is the third most common skin disor-
der in children after dermatitis/eczema and viral warts (Bruijnzeels
1993; Dagan 1993;Mohammedamin 2006). Impetigo is themost
common skin infection that is presented in general practice by
children aged one to four years of age (Mohammedamin 2006).
In British general practice, 2.8% of children aged 0 to 4 and
1.6% aged 5 to 15 consult their GP about impetigo each year
(McCormick 1995). In theNetherlands in the late 1980s, the con-
sultation rate was 1.7% of all children under 18 years of age; this
increased to 2.1% in 2001 (Koning 2006). Peak incidence occurs
between the ages of one and eight years (Koning 2006). In some
tropical or developing countries the incidence of impetigo seems
to be higher than elsewhere (Canizares 1993; Kristensen 1991).
Description of the intervention
Management options for impetigo include the following:
1. no pharmacological treatment, waiting for natural
resolution, hygiene measures;
2. topical disinfectants (such as saline, hexachlorophene,
povidone iodine, and chlorhexidine);
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3. topical antibiotics (such as neomycin, bacitracin,
polymyxin B, gentamycin, fusidic acid, mupirocin, retapamulin,
or topical steroid/antibiotic combination); and
4. systemic antibiotics (such as penicillin, (flu)cloxacillin,
amoxicillin/clavulanic acid, erythromycin, and cephalexin).
The aim of treatment includes resolving the soreness caused by
lesions and the disease’s unsightly appearance (especially on the
face), as well as preventing recurrence and spread to other people.
An ideal treatment should be effective, cheap, easy to use, and ac-
cepted by people. It should be free from side-effects, and it should
not contribute to bacterial resistance. For this reason, antibiotics
should not have an unnecessarily broad spectrum (Espersen 1998;
Smeenk 1999), and if a topical antibiotic is used, it should, prefer-
ably, not be one whichmay be needed for systemic use (Carruthers
1988; Smeenk 1999).
Waiting for natural resolution could be acceptable if the natural
history were known and benign. Impetigo is considered to be self-
limiting by many authors (Hay 1998; Resnick 2000). However,
there are no robust data on the natural history of impetigo. Re-
ported cure rates of placebo creams vary from 8% to 42% at 7
to 10 days (Eells 1986; Ruby 1973). Topical cleansing used to be
advised in the 1970s as an alternative for antibiotic treatment, but
this was later said to be no more effective than placebo (Dagan
1992). Guidelines and treatment advice often do not mention
topical cleansing as a treatment because the main concern is pre-
venting the spread of the infection to other children.
A choice has to be made between topical and systemic antibiotic
treatment, although in some situations clinicians prescribe both
topical and systemic antibiotics. An advantage of the use of topical
antibiotics is that the drug can be applied where it is needed,
avoiding systemic side-effects such as gastrointestinal upset. Also,
compliance may be better (Britton 1990).
The disadvantages of using topical antibiotics include the risks of
developing bacterial resistance and sensitisation, e.g. developing
an allergic contact dermatitis to one of the constituents of the
topical preparation (Carruthers 1988; Smeenk 1999). This is es-
pecially common with the older antibiotics, such as gentamycin,
bacitracin, and neomycin (Smeenk 1999). Some preparations (e.g.
tetracycline) can cause staining of the skin and clothes.
Staphylococcal resistance against penicillin and erythromycin is
common (Dagan 1992). Bacterial resistance against the newer top-
ical antibiotics, such as mupirocin ointment and fusidic acid oint-
ment, is increasing (Alsterholm 2010; de Neeling 1998). Another
advantage of the newer topical antibiotics is that mupirocin is
never, and fusidic acid not often, used systemically.
How the intervention might work
All treatment options listed above aim to either eradicate or prevent
growth of the bacteria.
Why it is important to do this review
Guidelines concerning treatment vary widely - some recommend
oral antibiotic treatment, others local antibiotic treatment or even
just disinfection in mild cases (Hay 1998; Resnick 2000) - so
clinicians have many treatment options. The evidence on what
works best is not clear. There is potential conflict between what is
in the best interest of the individual and what would best benefit
the community in terms of cost and the increase in antibiotic
resistance.
O B J E C T I V E S
To assess the effects of treatments for impetigo, including waiting
for natural resolution.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials.
Types of participants
We included people who have impetigo or impetigo contagiosa di-
agnosed by a medically trained person (and preferably confirmed
by bacterial culture). We recorded whether or not bacterial cul-
ture was performed. The diagnosis could be either non-bullous
or bullous impetigo. Studies using a broader diagnostic category
such as ’bacterial skin infections’ or ’pyoderma’ were eligible if a
specific subgroup with impetigo could be identified, for which the
results were separately described. Studies on secondary impetigo
or impetiginised dermatoses were included.
Types of interventions
We included any program of topical or systemic (oral, intramuscu-
lar, or intravenous) treatment, including antibiotics, disinfectants,
or any other intervention for impetigo, such as ’awaiting natu-
ral response’. We excluded studies that only compared different
dosages of the same drug.
Types of outcome measures
Primary outcomes
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1) Cure as defined by clearance of crusts, blisters, and redness as
assessed by the investigator.




2) Adverse effects such as pain, allergic sensitisation, and compli-
cations.
3) Development of bacterial resistance.
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
We updated our searches of the following databases on 27 July
2010:
• the Cochrane Skin Group Specialised Register using the
following search terms: (impetig* or pyoderma or
((staphylococc* or streptococc*) and skin and infection*)) and
(therap* or treatment* or intervention*);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library using the search strategy
in Appendix 1;
• MEDLINE (from 2005 to the present) using the search
strategy in Appendix 2;
• EMBASE (from 2007 to the present) using the search
strategy in Appendix 3; and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982 to the present) using the search
strategy in Appendix 4.
Please note: The UK and US Cochrane Centres have an ongoing
project to systematically search MEDLINE and EMBASE for re-
ports of trials which are then included in the CENTRAL database.
Searching has currently been completed in MEDLINE, from in-
ception to 2004 and in EMBASE, from inception to 2006. Fur-
ther searches of these two databases to cover the years not searched
by the UK and US Cochrane Centres for CENTRAL were under-
taken for this review as described above.
A final prepublication search for this review was undertaken on
16 August 2011. Although it has not been possible to incorporate
RCTs identified through this search within this review, relevant
references are listed under Studies awaiting classification. They
will be incorporated into the next update of the review.
Ongoing Trials
We updated our searches of the following ongoing trials databases
on 3 August 2010, using the terms ’impetigo’ and ’pyoderma’:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing
TrialsRegister (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).




We handsearched the Yearbook of Dermatology (1938 to 1966)
and the Yearbook of Drug Therapy (1949 to 1966) for the pre-
PubMed era.
References from published studies
We checked references from published studies, including sec-
ondary review articles, for further studies.
Unpublished literature
We corresponded with authors and pharmaceutical companies to
search for unpublished studies and grey literature.
Language
We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two authors (JCvdW and SK or RvdS) independently read all
abstracts or citations of trials. If one of the authors thought the
article might be relevant, a full copy of the article was acquired for
further data collection. The reasons for exclusion were recorded
for every excluded abstract or citation. Only full reports were in-
cluded. Two authors independently screened all full-copy articles
(LvSS, SK, RvdS, JCvdW). The articles were selected according
to the inclusion criteria. Reasons for exclusion were recorded on
a specially-designed registration form (see the ’Characteristics of
excluded studies’ table). In the case of doubt, the opinion of a
third author was obtained. Many trials studied a range of (skin)
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infections including impetigo. Frequently, the results of the sub-
group of impetigo participants were not reported separately. In
these studies, provided they were published in the last 10 years,
we contacted trial authors and asked them to provide the results of
the subgroup of impetigo participants. We obtained data in this
way in only two instances (Blaszcyk 1998; Claudy 2001).
Data extraction and management
Two authors (ADM and CCB), using a pre-piloted data abstrac-
tion form, carried out the full data extraction. The form contained
key elements such as time and setting of the study, participant
characteristics, bacterial characteristics, type of interventions, out-
comes, and side-effects. We resolved disagreements with the help
of a third author (SK).
For this update, RvdS and JCvdWcarried out data extraction from
newly included papers. When studies assessed outcome measures
more than once, we included the assessment that was nearest to
one week after the start of therapy. When studies had more than
two arms and two of these arms were different dosages of the same
drug, we combined these arms.
Assessment of risk of bias in included studies
Assessment of methodological quality
Two independent authors (JCvdW, RvdS and/or AV) assessed the
methodological quality of all trials according to the updated guide-
lines (Higgins 2008). Because we could not read the Japanese study
by Ishii 1977, this ’Risk of bias’ table was completed by Tetsuri
Matsumura. The two studies on which authors of this review were
co-authors (Koning 2003; Koning 2008) were assessed by other
authors. The items that were addressed are shown in the ’Risk
of bias’ table. For feasibility reasons, the methodological quality
assessment was not performed under masked conditions. There is
no consensus over whether assessment should be done blinded for
authors, institutions, journal, or publication year (Jadad 1998).
Unit of analysis issues
In the case of studies with more than two treatment arms, we
deemed that pooling these studies under separate comparisons,
without adjustment, would result in unit-of-analysis errors (over-
counting). Should this have occurred, the problemwas to be solved
by dividing the group size by the number of comparisons.
Assessment of heterogeneity
We used the I² statistic to assess statistical heterogeneity, with I²
statistic > 50% regarded as substantial heterogeneity.
Data synthesis
Where there was no statistical evidence of heterogeneity we used
the fixed-effect model to estimate effects. Otherwise, we used the
random-effects model. For dichotomous outcomes we reported
risk ratios with 95% confidence intervals.
Sensitivity analysis
We prespecified the following factors for sensitivity analyses:
1. the quality of the studies;
2. whether there was observer blinding;
3. whether there was just a clinical diagnosis or bacterial swab
confirmation;
4. primary versus secondary impetigo;
5. bullous versus non-bullous; and
6. staphylococcal or streptococcal predominance.
During the update, we decided that an overall quality score per
studywas not useful. Furthermore,most trialswere observer-blind,
took bacterial swabs, studied primary impetigo, and had staphy-
lococcal predominance. Sensitivity analyses for these items were,
therefore, not possible.
When we analysed the data we decided to consider the results for
bullous and non-bullous impetigo separately.
R E S U L T S
Description of studies
Results of the search
Our initial search identified approximately 700 papers, 221 of
which were selected for full copy reading. For this update, we iden-
tified more than 1000 additional papers. Two reviewers screened
titles and abstracts, after which, approximately, 60 papers were
studied in full copy.
Included studies
For the first version of the review we included 56 papers describing
57 trials. This update identified 12 additional studies, of which 2
were published before 2000 (Farah 1967; Ishii 1977). One study,
which was previously included, was excluded because it turned
out not to be a randomised trial (Park 1993), bringing the to-
tal number of included studies to 68. The lists of ongoing stud-
ies (Ongoing studies) and studies awaiting assessment (Studies
awaiting classification) show studies that might be eligible for a fu-
ture update of this review. Regarding the excluded studies, we only
report on themost relevant ones (Excluded studies; Characteristics
of excluded studies).
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Most trials were reported in the English language. Four included
studies were reported in Japanese, and one paper each was reported
in Thai, Portuguese, Spanish, French, and Danish (some of these
had abstracts and tables in English). Trials in Russian, Chinese,
German, and French were among those that were excluded (not
for language reasons). In instances where none of the authors were
competent in the language of the paper, translators provided as-
sistance.
We found an appreciable number of studies from the early 1940s
(e.g. MacKenna 1945). These studies were often carried out in
military populations, in which impetigo was a frequent disease at
the time. These study reports did not meet the inclusion criteria
of our review because of inadequate randomisation. The distri-
bution of the included studies by decade is as follows: 1960s - 1
study, 1970s - 5 studies (7%), 1980s - 31 studies (46%), 1990s
- 20 studies (29%), and 2000 to 2008 - 11 studies (16%). Five
included studies evaluating mupirocin were presented at an in-
ternational symposium in 1984; we found no publication other
than the conference proceedings for three of these (Kennedy 1985;
Rojas 1985; Wainscott 1985). Two were published elsewhere as
well (Eells 1986; Gould 1984).
Design
All studies were parallel group trials, but there were important de-
sign differences between the studies. As mentioned before, many
trials included participants with infections other than impetigo,
while some trials studied only impetigo. Ages of included partici-
pants differed widely, as some studies were carried out exclusively
in either adults or children. The average age of study participants
in trials that studied a range of skin infections was usually higher
than in studies focusing on impetigo alone. With the exception of
four studies (Faye 2007; Ishii 1977; Rice 1992; Vainer 1986), all
studies performed bacteriological investigations. Although a num-
ber of studies explicitly stated that participants with a negative
culture were excluded, other studies may also have excluded cul-
ture negative participants without reporting those exclusions. No
study reported a predominantly streptococcal impetigo. The only
studies not to report a preponderance of staphylococcal impetigo
were Mertz 1989 and Ruby 1973 (carried out in Puerto Rico and
Texas respectively).
Sample sizes
The 68 studies had a total of 5578 evaluable participants; this is
an average of 82 participants and a median of 60.5 participants
per study (see the ’Characteristics of included studies’ tables). In
23 studies the number of participants with impetigo was less than
50; in 10 studies it was less than 20.
Setting
Twenty-nine of the studies were carried out in North America (in
13 Canadian/Northern states, in 8 Southern states, in 8 multicen-
tres), 15 in Europe, 9 in Central/South America, 10 in Asia, 1 in
Africa, and 4 were worldwide multicentre trials. Most studies were
carried out in hospital out-patient clinics (paediatrics or derma-
tology, 60 studies), but some were carried out in general practice.
Participants
Only three studies exclusively addressed participants with bullous
impetigo (Dillon 1983; Ishii 1977; Moraes Barbosa 1986). Seven
trials includedboth bullous andnon-bullous impetigo participants
(Barton 1989; Ciftci 2002; Dagan 1992; Koning 2008; Kuniyuki
2005;Oranje 2007; Pruksachat 1993). Three studies on secondary
impetigo were included (Fujita 1984; Rist 2002; Wachs 1992).
Three other trials included both primary and secondary impetigo
participants (Faye 2007; Gonzalez 1989; Tamayo 1991). Thirty-
nine trials studied impetigo alone whereas 29 trials studied par-
ticipants with a range of (usually skin) infections, impetigo being
1 of them. This was the typical study design when a new antibi-
otic was studied. This type of study design imposed problems in
retrieving outcome data as the outcomes were often presented for
all the participants together. We included these studies only if the
main outcome measure was presented separately for the subgroup
of impetigo participants.
Interventions
The 68 trials evaluated 50 different treatments (26 oral treatments
and 24 topical treatments - both including placebo). The systemic
treatments that were studied were all administered orally (tablets).
A total of 74 different comparisons were made. Some compar-
isons were made in several studies; some studies made more than
one comparison. Sixty-eight comparisons were made only once.
Six different comparisons were made in more than 1 trial, espe-
cially when topical mupirocin was studied (topical mupirocin ver-
sus oral erythromycin was considered in 10 studies, mupirocin
versus fusidic acid was considered in 4 studies, mupirocin versus
placebo was considered in 3 studies). For each of these compar-
isons we pooled the outcomes of the different studies (see Data
and analyses).
The most common type of comparison was between 2 differ-
ent oral antibiotic treatments (29 studies including duplicates).
Cephalosporins (15 studies) and macrolide antibiotics, especially
erythromycin and azithromycin (9 studies), were most often in-
volved. A topical antibiotic treatment was compared with an oral
antibiotic treatment in 22 studies. Nineteen of these comparisons
contained erythromycin, mupirocin, or both.
Only two trials studied antiseptic or disinfecting treatments
(Christensen 1994; Ruby 1973).
Only seven placebo controlled trials were found (Eells 1986;
Gould 1984; Ishii 1977; Koning 2003; Koning 2008; Rojas 1985;
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Ruby 1973). The latter is the only trial that compared an oral
treatment with placebo.
Three studies had three arms but the treatment in two of these were
different dosages of the same drug (Blaszcyk 1998; Bucko 2002a;
Bucko 2002b). We combined these arms. Nine other studies had
more than two arms but with different treatments: three arms (Bass
1997; Demidovich 1990; Dux 1986; Rodriguez-Solares 1993;
Vainer 1986; Wachs 1976), four arms (Kuniyuki 2005; Moraes
Barbosa 1986), and five arms (Ruby 1973). Only two of the com-
parisons in these multiple-arm studies could be pooled with other
studies: erythromycin versus penicillin V fromDemidovich 1990,
and mupirocin versus erythromycin from Dux 1986. For this rea-
son we refrained from adjusting for multiple treatment compar-
isons.
Outcomes
Cure as assessed by investigator was our main outcome measure.
This was often not defined. Researchers sometimes combined the
categories ’cured’ and ’improved’ and presented those participants
as one group. The length of follow-up varied widely, and it was
sometimes not even specified; however, we tried to retrieve the
data for follow up as close as possible to seven days after the start
of treatment. The development of bacterial resistance to the study
drug was reported in only 10 studies.
Excluded studies
One hundred and sixty-five of the studies did not meet the in-
clusion criteria for the first version of the review, and 33 more
were excluded when updating the review (see the ’Characteristics
of excluded studies’ tables). The most common reasons included
the following: the study was not about impetigo, the outcomes of
impetigo participants were not reported separately, or studies were
not randomised.
Studies awaiting classification
In the previous version of this review, four studies were awaiting
classification. For this update two of these studies were included
(Ciftci 2002; Claudy 2001) and two were excluded (Liu 1986;
Parish 2000).
Ten studies that were found during the update process are listed
in the ’Characteristics of studies awaiting classification’ tables, as
are a further 6 studies that were identified at the prepublication
search. We are currently unable to include or exclude these due to
insufficient information about them.We hope to fully incorporate
them into future updates of this review.
Ongoing studies
Seven studies that were found during the update process are listed
in the ’Characteristics of ongoing studies’ tables. These will be
fully incorporated into future updates of this review when they are
completed.
Risk of bias in included studies
For many of the items that were assessed, the studies did not
provide enough information (Figure 1; Figure 2).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Sequence generation
Fourteen of the studies reported an adequate generation of the
randomisation scheme. All other papers did not report on this
item.
Allocation
All but two of the included studies were described as randomised
as this was a selection criterion. For two papers in Japanese, this
was unclear, and these papers were given the benefit of the doubt
(see Figure 1). Most papers did not describe the method of ran-
domisation in detail, so the method could not be judged as appro-
priate. Only 19 of the 68 studies provided information on alloca-
tion concealment. In most cases (18 of 19), treatment allocation
was considered to be concealed.
Blinding
In many cases it was not clear whether the participant, the care-
giver, or the outcome assessor were blinded. A total of 15 studies
were considered to be adequately blinded (see Figure 1). In 24
studies, at least 1 party was considered not to be blinded. In 29
papers, the information was insufficient to judge blinding.
Inclusion and exclusion criteria of the trials
In 10 of our included studies, the inclusion and exclusion criteria
of the trial were not specified in more detail than saying ’patients
with impetigo’ (see Figure 1).
Incomplete outcome data
In some studies, high numbers lost to follow up were recorded.
Thirty-four studies either included an intention-to-treat analysis
or had fewer than 10% dropouts balanced between groups. For
some other studies, an intention-to-treat analysis could be calcu-
lated from the data presented in the study.
Effects of interventions
Primary outcomes: 1) clinical cure
The first primary outcome was clinical cure (or improvement) as
assessed by the investigator. When this was assessed more than
once, we only included the assessment that was nearest one week
from commencement of treatment.
Under the following two main headings (’non-bullous impetigo’
and ’bullous impetigo’) we have grouped all studies that either in-
cluded only primary impetigo, combined primary and secondary
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impetigo, or did not specify whether participants had primary or
secondary impetigo. The third heading ’secondary impetigo’ ad-
dresses all studies that focused exclusively on secondary impetigo
(see Background for an explanation).
(a) Non-bullous impetigo
(i) Topical antibiotics
Topical antibiotics versus placebo (six studies, four
comparisons)
Overall topical antibiotics showed better cure rates or more im-
provement than placebo (pooled risk ratio (RR) 2.24, 95% CI
1.16 to 3.13 using a random-effects model, I² = 53%) (see Analysis
1.1). This result was consistent for mupirocin (RR 2.21, 95% CI
1.59 to 3.05; 3 studies - Eells 1986; Gould 1984; Rojas 1985)
(see Analysis 1.1), fusidic acid (RR 4.42, 95% CI 2.39 to 8.17;
1 study - Koning 2003) (see Analysis 1.1), and retapamulin (RR
1.64, 95% CI 1.30 to 2.07; 1 study - Koning 2008) (see Analysis
1.1). In one small study (Ruby 1973), bacitracin did not show
a significant difference in cure rate compared with placebo (RR
3.71, 95% CI 0.16 to 85.29) (see Analysis 1.1).
Topical antibiotic versus another topical antibiotic (14
studies, 15 comparisons)
Only one topical antibiotic showed superiority over another top-
ical antibiotic - in a single study: gentamycin over neomycin (RR
1.43, 95% CI 1.03 to 1.98; Farah 1967) (see Analysis 2.1). Also
from a single study, the difference between retapamulin over fu-
sidic acid was not statistically significant (RR 1.05, 95% CI 1.00
to 1.11; Oranje 2007) (see Analysis 2.1). There were 12 different
comparisons: 4 studies (Gilbert 1989; Morley 1988; Sutton 1992;
White 1989) compared mupirocin with fusidic acid (RR 1.03,
95% CI 0.95 to 1.11) (see Analysis 2.1), and the remaining 11
were all only represented by a single study.
Topical antibiotics versus oral (systemic) antibiotics (16
studies, 17 comparisons)
Pooling 10 studies which compared mupirocin with oral ery-
thromycin showed significantly better cure rates, or more im-
provement, with mupirocin (RR 1.07, 95% CI 1.01 to 1.13) (see
Analysis 3.1). However, no significant differences were seen be-
tween mupirocin and dicloxacillin (Arredondo 1987), cephalexin
(Bass 1997), or ampicillin (Welsh 1987). Bacitracin was signifi-
cantly worse than oral cephalexin in one small study (Bass 1997),
but no difference was seen between bacitracin and erythromycin
(Koranyi 1976), or penicillin (Ruby 1973).
A sensitivity analysis on the influence of blinding the outcome
assessor on the comparison of mupirocin versus erythromycin
(10 studies) revealed that there was no clear relationship between
blinding of the outcome assessor and the outcome.
Pooling the 2 studies with observer blinding (Britton 1990;Dagan
1992) showed high heterogeneity (I² statistic = 79%) and resulted
in a non-significant difference between the 2 drugs (random-ef-
fects model, RR 1.12, 95% CI 0.86 to 1.46) (see Analysis 3.2).
Topical antibiotics versus disinfecting treatment (two studies)
In one study (Ruby 1973), no statistically significant difference
in cure/improvement was seen when bacitracin was compared to
hexachlorophene (RR 3.71, 95% CI 0.16 to 85.29) (see Analysis
4.1). In another study (Christensen 1994), there was a tendency
for fusidic acid cream to be more effective than hydrogen perox-
ide, but this just failed to reach statistical significance (RR 1.14,
95% CI 1.00 to 1.31) (see Analysis 4.1). When the 2 studies were
pooled, topical antibiotics were significantly better than disinfect-
ing treatments (fixed-effect model, RR 1.15, 95% 1.01 to 1.32, I²
statistic 0%) (see Analysis 4.1).
Topical antibiotic versus antifungal (one study)
Only one study compared a topical antibiotic to an antifungal,
comparing topical mupirocin to topical terbinafine (Ciftci 2002).
No statistical difference was seen (RR 1.39, 95% CI 0.98 to 1.96)
(see Analysis 5.1).
Topical antibiotic + oral antibiotic vs topical antibiotic + oral
antibiotic (one study, three comparisons)
In a four-armed study, three arms addressed the following combi-
nations of a topical antibiotic and an oral antibiotic: topical tetra-
cycline combined with oral cefdinir compared to topical tetracy-
cline combined with oral minomycin, topical tetracycline com-
bined with oral cefdinir compared to topical tetracycline com-
bined with oral fosfomycin, and topical tetracycline combined
with oral minomycin compared to topical tetracycline combined
with oral fosfomycin (Kuniyuki 2005). None of the three com-
parisons showed a statistically significant difference (see Analysis
6.1).
Topical antibiotic versus topical antibiotic + oral antibiotic
(one study, three comparisons)
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The fourth arm of the study described under the previous head-
ing (Kuniyuki 2005) was tetracycline. None of the comparisons
with the other three treatments (see above) showed a statistically
significant difference (see Analysis 7.1).
(ii) Oral antibiotics
Oral antibiotics versus placebo (one study)
A single study (Ruby 1973) found no significant difference be-
tween oral penicillin and placebo (RR 7.74, 95% CI 0.43 to
140.26) (see Analysis 8.1).
Oral antibiotic versus another oral antibiotic: cephalosporin
versus another antibiotic (six studies)
All comparisons consisted of single studies (or arms of a sin-
gle study); only one comparison - cephalexin versus penicillin -
showed a significant difference (Demidovich 1990) (see Analysis
9.1).
Oral antibiotic versus another oral antibiotic: one
cephalosporin versus another cephalosporin (seven studies)
No significant differences were seen between cephalexin and ce-
fadroxil (Hains 1989), cefdinir (Giordano 2006; Tack 1997; Tack
1998); cefaclor and cefdinir (Arata 1989a), or cefditoren and ce-
fadroxil (Bucko 2002b). Cefditoren turned out to be less effective
than cefuroxime (Bucko 2002a) (see Analysis 10.1).
Oral antibiotic versus another oral antibiotic: macrolides
(erythromycin, azithromycin, clindamycin) versus penicillins
(penicillin V, dicloxacillin, amoxacillin, cloxacillin,
flucloxacillin) (seven studies)
In two studies (Barton 1987; Demidovich 1990), erythromycin
showed a better cure rate or more improvement than penicillin
(pooled fixed-effect model, RR 1.29, 95% CI 1.07 to 1.56, I²
statistic 0%) (see Analysis 11.1). The other five comparisons con-
sisted of single studies, and they did not show significant differ-
ences between macrolides and penicillins.
Oral antibiotic versus another oral antibiotic: macrolide
versus another macrolide (one study)
In a single study (Daniel 1991a), no difference in cure rate or
improvement was seen between azithromycin and erythromycin
(RR 1.18, 95% CI 0.88 to 1.58) (see Analysis 12.1).
Oral antibiotic versus another oral antibiotic: penicillin
versus other oral antibiotics (including other penicillins)
(four studies)
In 1 study (Dagan 1989), amoxicillin plus clavulanic acid showed
a better cure rate than amoxicillin alone (RR 1.40, 95%CI 1.04 to
1.89) (seeAnalysis 13.1), butwhen amoxicillin plus clavulanic acid
was compared with fleroxacin in another study (Tassler 1993), no
significant difference was seen (RR1.14, 95%CI 0.80 to 1.62) (see
Analysis 13.1). Cloxacillin was significantly superior to penicillin
in 2 studies (Gonzalez 1989; Pruksachat 1993) although these
studies were statistically heterogeneous (I² statistic 57%) (pooled
RR 1.59, 95% CI 1.21 to 2.08) (see Analysis 13.1).
Other comparisons of oral antibiotics (two studies)
In two studies (Arata 1989b; Claudy 2001), no difference in cure
rates/improvement could be detected between lomefloxacin and
norfloxacin nor between (oral) fusidic acid and pristinamycin (see
Analysis 14.1).
Oral antibiotics versus disinfecting treatments (one study)
In a single small study (Ruby 1973), no difference in cure rates/
improvement could be detected between penicillin and hex-
achlorophene (RR 7.74, 95% CI 0.43 to 140.26) (see Analysis
15.1).
(iii) Disinfecting treatments
Disinfecting treatments versus placebo (one study)
In a single small study (Ruby 1973), no participants in either the
hexachlorophene (n = 11) or placebo group (n = 13) showed cure
or improvement. Comparisons of disinfecting treatments with an-
tibiotics are given above.
(b) Bullous impetigo
(i) Topical antibiotics
Topical antimicrobial versus placebo (one study)
In one study (Ishii 1977), topical Eksalbe simplex (a drug con-
taining killed Eschelichia, Staphylococcus, Streptococcus, and Pseu-
domonas) was compared to placebo. The active drug turned out to
be superior (cure/improvement RR 2.30, 95% CI 1.10 to 4.79)
(see Analysis 16.1).
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Topical antibiotics versus other topical antibiotics (one study,
three comparisons)
In a small study (Moraes Barbosa 1986), fusidic acid was signifi-
cantly more effective than both neomycin/bacitracin (RR 10.00,
95% CI 1.51 to 66.43) (see Analysis 17.1) and chlorampheni-
col (RR 5.00, 95% CI 1.38 to 18.17) (see Analysis 17.1). In the
same study, no difference was detected between chloramphenicol
and neomycin/bacitracin (RR 2.00, 95% CI 0.21 to 19.23) (see
Analysis 17.1).
Topical antibiotics versus oral antibiotics (one study, three
comparisons)
The same study (Moraes Barbosa 1986) showed that neomycin/
bacitracin was significantly less effective than oral erythromycin
(RR 0.14 95% CI 0.02 to 0.99) (see Analysis 18.1). There was
no significant difference between either erythromycin and fusidic
acid (RR 1.43, 95% CI 0.83 to 2.45) (see Analysis 18.1) or chlo-
ramphenicol (RR 0.29, 95% CI 0.07 to 1.10) (see Analysis 18.1).
(ii) Oral antibiotics
Oral antibiotic versus another oral antibiotic (one study)
No significant difference was seen between cephalexin and di-




Topical antibiotic versus oral antibiotic (one study)
No significant difference was seen between mupirocin and
cephalexin (Rist 2002) (see Analysis 20.1).
Antibiotic versus steroid versus antibiotic plus steroid (one
study)
In a three-armed study (Wachs 1976), the comparisons of be-
tamethasone with gentamycin alone or with betamethasone plus
gentamycin did not show significant differences (see Analysis 21.1
and Analysis 22.1). The combination of betamethasone and gen-
tamycin cream was significantly more effective than gentamycin
alone (RR 2.43, 95% CI 1.29 to 4.57) (see Analysis 23.1).
(ii) Oral antibiotics
In a very small study, no significant difference was detected be-
tween cephalexin and enoxacin (Fujita 1984) (see Analysis 24.1).
Primary outcomes: 2) relief of symptoms
The second primary outcome was relief of symptoms, such as
pain, itching, and soreness, as assessed by study participants. Al-
though some studies asked about overall satisfaction, acceptabil-
ity, or treatment preference (McLinn 1988; Rice 1992; Rist 2002;
Sutton 1992; White 1989), only one study asked participants to
rate their symptoms at follow-up (Giordano 2006). However, this
was a study addressing not only impetigo but other skin infections
as well, and results for this outcomewere not reported for impetigo
separately.
Secondary outcomes: 1) recurrence rate
No relevant data were provided by any study for this outcome.
Secondary outcomes: 2) adverse effects
(i) Topical antibiotics
The trials included in this review usually reported few, if any, side-
effects from topical antibiotics (see Table 1). The studies compar-
ing mupirocin, bacitracin, and placebo reported none (Eells 1986;
Ruby 1973). The study that compared fusidic acid to placebo
recorded more side-effects in the placebo group (Koning 2003).
Three of 4 studies comparingmupirocinwith fusidic acid recorded
side-effects: minor skin side-effects were reported for mupirocin
by 10 out of 368 participants (3%) and for fusidic acid by 4 out
of 242 participants (2%). The study that compared retapamulin
to placebo found more itching in the group treated with retapa-
mulin (7% vs 1%; P = 0.17) (Koning 2008). In the other study of
retapamulin, this side-effect was reported in less than 1% of cases
(Oranje 2007). Most other trials comparing topical antibiotics re-
ported no side-effects or reported minor skin side-effects in low
numbers (less than 5% of participants).
Topical versus oral treatments
Of the 10 trials comparing erythromycin with mupirocin, 9 re-
ported side-effects. All trials recorded more side-effects from ery-
thromycin, with the exception of two trials (Britton 1990 - equally
divided minor gastrointestinal side-effects - and Rice 1992 - nil re-
ported). Gastrointestinal side-effects (nausea, stomach ache, vom-
iting, diarrhoea)were recorded in 80out of 297 participants (27%)
in the erythromycin groups, versus 17out of 323 participants (5%)
in the mupirocin groups. Skin side-effects (itching, burning) were
recorded in 5 out of 297 participants (2%) in the erythromycin
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groups versus 23 out of 323 participants (7%) in the mupirocin
groups. Most other trials comparing topical and oral antibiotics
did not record data on side-effects (see Table 1).
(ii) Oral antibiotics
Eleven of the 31 trials comparing oral antibiotics did not report
on side-effects (see Table 1). Three of the 6 trials that studied
erythromycin recorded side-effects; the highest frequency was re-
ported by Faye 2007: 11/65 participants reported gastrointestinal
side-effects (mainly diarrhoea). The other trials, usually making
unique comparisons, mainly reported gastrointestinal side-effects
in small percentages. In five trials, a considerable difference in side-
effects was reported. Gastrointestinal complaints were recorded in
1 out of 113 participants (10%) in the enoxacin group compared
to 4 out of 110 participants (4%) in the cefalexin group (Fujita
1984). Fourteen out of 327 (4%) of the cefadroxil-treated partic-
ipants versus 2 out of 234 (1%) flucloxacillin-treated participants
had ’severe’ side-effects, such as stomach ache, rash, fever, and
vomiting (Beitner 1996). Cefaclor caused more diarrhoea than
amoxicillin plus clavulanic acid (5 out of 16 participants (31%)
vs 2 out of 18 participants (11%)) (Jaffe 1985). Pristinamycin
causedmore upper and lower gastrointestinal side-effects than oral
fusidic acid (12% vs 7% and 17% vs 2%, respectively) (Claudy
2001). Finally, the clindamycin group of participants reported
more side-effects (any side-effect) than the dicloxacillin-treated
group (Blaszcyk 1998).
(¡¡¡) Disinfecting treatments
Eleven per cent of the participants using hydrogen peroxide cream
reported mild side-effects (not specified) versus seven per cent in
the fusidic acid group (Christensen 1994). No participant was
withdrawn from the study because of side-effects. No adverse ef-
fects of scrubbing with hexachlorophene were recorded (Ruby
1973) (see Table 1).
Secondary outcomes: 3) Development of bacterial
resistance
Most studies either did not report on susceptibility of isolated
pathogens to the study drugs or presented only baseline data. Ten
studies provided information on the development of resistance
to the study drug during the study period (Barton 1988; Bucko
2002a; Bucko 2002b; Dagan 1992; Giordano 2006; Goldfarb
1988; Gould 1984; Tack 1998; Tassler 1993; White 1989). In
most of these studies, none or only a few of the participants’
pathogens had developed resistance. The only exception was
Dagan 1992, where 14/18 (78%) of positive cultures after 3 days
of follow-up showed resistance to erythromycin, compared to 27/
91 (28%) at baseline. The other study that included erythromycin
(Goldfarb 1988) showed only 3% (1/32) resistance at follow-up.
D I S C U S S I O N
Summary of main results
Overall, topical antibiotics showed better cure rates than topical
placebo. No differences were found between the two most studied
topical antibiotics: mupirocin and fusidic acid. Topical mupirocin
was superior to oral erythromycin. In most other comparisons,
topical and oral antibiotics did not show significantly different
cure rates, nor didmost trials comparing oral antibiotics. Penicillin
V was inferior to erythromycin and cloxacillin, and there is a lack
of evidence to suggest that using disinfectant solutions improves
impetigo.
The reported number of side-effects was low. Oral antibiotic treat-
ment caused more side-effects, especially gastrointestinal ones,
than topical treatment. A striking finding is that the trials compar-
ing erythromycinwithmupirocin recordedmore (gastrointestinal)
side-effects in the erythromycin group than the trials that com-
pared erythromycin with other oral antibiotics.
Overall completeness and applicability of
evidence
The large number of treatments evaluated (50) supports the view
that there is no widely accepted standard therapy for impetigo.
Most studies did not contribute clear answers about the vast choice
of treatment options. Many of the studies were underpowered;
this is partly due to the fact that many trials included several skin
infections, impetigo being only one of them (these studies are di-
rected at the drug rather than at the disease). In many cases, signif-
icant differences became insignificant when impetigo participants
were considered after excluding participants with other sorts of
infection. Another drawback of this type of study is that the age
of participants is much higher than the typical age at which peo-
ple contract impetigo (e.g. Blaszcyk 1998; Bucko 2002a; Bucko
2002b; Kiani 1991). The dosage of studied antibiotics may differ
between studies, complicating the comparability of studies; how-
ever, the same doses were usually used (e.g. erythromycin 40 mg/
kg/day). Cure rates of specific treatments can be different between
studies, e.g. of fusidic acid and mupirocin (Sutton 1992; White
1989). This may be explained by the fact that investigations were
done in different regions and times, and inclusion criteria differed.
Little is known about the ’natural history’ of impetigo. Therefore,
the paucity of placebo-controlled trials is striking, given that im-
petigo can be considered a minor disease. Only seven placebo-
controlled studies have been conducted (Eells 1986; Gould 1984;
Ishii 1977; Koning 2003; Koning 2008; Rojas 1985; Ruby 1973).
The 7-day cure rates of placebo groups in these studies varied but
can be considerable (0% to 42%).
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The disinfectant agents, such as povidone iodine and chlorhex-
idine, recommended in some guidelines (Hay 1998; Resnick
2000), usually as supplementary treatment, have been inade-
quately studied andnot compared toplacebo treatment.Hydrogen
peroxide creamwas not significantly less effective than fusidic acid
(cure rate 72% versus 82%) in a relatively large trial (Christensen
1994). We judged that blinding in this trial was inadequate.
There is a commonly accepted idea that more serious forms of
impetigo (e.g. participants with extensive lesions, general illness,
fever) need oral rather than topical antibiotic treatment. This prin-
ciple cannot be evaluated using the data included in our review as
trials that study local treatments usually exclude participants with
more serious forms of impetigo.
One of our primary outcomes was relief of symptoms, such as
pain, itching, and soreness, as assessed by participants (or parents).
Surprisingly, only one of the studies addressed this outcome (
Giordano 2006).
Resistance patterns of staphylococci - which causes impetigo -
change over time. Outcomes of studies dating back more than 10
years, which form the majority of trials in this review, may not
be applicable to the current prevalence of infecting agents. Also,
resistance between regions and countries may vary considerably.
Thus, up-to-date, local characteristics and resistance patterns of
the causative bacteria should always be taken into account when
choosing antibiotic treatment. In addition, health authorities and
other relevant bodies may advise against prescribing certain antibi-
otics for impetigo, in order to restrict the development of bacterial
resistance and reserve these drugs for more serious infections.
Quality of the evidence
Although the total number of randomised trials we identified was
considerable, the average number of participants per study was
small. In this update, the newly added studies made this average
increase from 62 to 84 per study. This was partly due to studies
that assessed a range of infections and randomised a large num-
ber of participants, but in which those with impetigo were only a
minority. Through the years, we found an increase in the quality
of the studies; the average number of items scored positively in-
creased from less than three in the 1970s to almost five for studies
published in the new millennium. This is a problem shared with
many other reviews. Details of the design of the studies were often
lacking in the published reports, leading to a lot of question marks
in the ’Risk of bias’ tables.
Potential biases in the review process
Several studies included participants with impetigo next to par-
ticipants with other conditions, but they did not report results of
those with impetigo separately. However, as the number of partic-
ipants with impetigo was often small in these studies, we do not
expect that our conclusions would be different.
Three authors on this review are authors of one included trial
(Sander Koning, Lisette WA van Suijlekom-Smit, Johannes C van
der Wouden; Koning 2003), Sander Koning and Johannes C van
der Wouden were also involved in a second trial (Koning 2008)
whichwas initiated by themanufacturer of the drug.These authors
were not involved in the assessment of the risk of bias for both
studies.
Agreements and disagreements with other
studies or reviews
Topical mupirocin and fusidic acid can be considered as effec-
tive as, or more effective than, oral antibiotics, and these topical
agents have fewer side-effects. This finding is in sharp contrast to
the previously held view that oral treatment is superior to topical
treatment (Baltimore 1985; Tack 1998). Other topical antibiotics,
excluding retapamulin, were generally inferior to mupirocin, fu-
sidic acid, and oral antibiotics. The study by Vainer is an excep-
tion: no difference was seen between tetracycline/bacitracin cream,
neomycin/bacitracin cream, and fusidic acid (Vainer 1986). Fu-
sidic acid, mupirocin, and retapamulin are the only topical antibi-
otics that have been compared to placebo (and shown to be more
effective).
For the results of the study comparing topical fusidic acid to reta-
pamulin (Oranje 2007), the P value computed by Review Man-
ager (RevMan) differs from the study report (0.07 in RevMan vs
0.062 in the study report) due to different methods (94.8% vs
90.1% cure, favouring retapamulin).
None of the studies reported cases of acute (post-streptococcal)
glomerulonephritis. This complication has always been an impor-
tant rationale for oral antibiotic treatment. This reported absence
of glomerulonephritismay reflect the reduced importance of strep-
tococci in impetigo. It should be noted that study sizes are small
and glomerulonephritis is rare.
Several of the interventions used for impetigo have also been ap-
plied in other situations where Staphylococcus aureus, themain bac-
terium causing impetigo, plays a role. Here we review some of
these, as reported in recently published Cochrane reviews. The
effect of mupirocin ointment for preventing S. aureus infections in
nasal carriers was superior to that of placebo or no treatment (van
Rijen 2008). Birnie 2008 assessed interventions to reduce S. aureus
in the management of atopic eczema, but the review did not find
clear evidence of benefit for any of these. A review of the treatment
of bacteraemia due to S. aureus is under way (Cheng 2009), as is
a review of antibiotics for S. aureus pneumonia in adults (Shankar
2007).Mastitis in breastfeeding women is also caused by S. aureus.
A recent Cochrane review found insufficient evidence to confirm
or refute the effectiveness of antibiotic therapy (Jahanfar 2009).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Implications for topical disinfectants in clinical
practice
There is a lack of evidence from RCTs for the value of disinfecting
measures in the treatment of impetigo, as a sole or supplementary
treatment.
Implications for topical antibiotics in clinical practice
There is good evidence that the topical antibiotics mupirocin and
fusidic acid are equal to, or possibly more effective than, oral treat-
ment for people with limited disease. Fusidic acid, mupirocin, and
retapamulin are probably equally effective; other topical antibi-
otics seem less effective. In general, oral antibiotics havemore side-
effects than topical antibiotics, especially gastrointestinal side-ef-
fects.
Implications for use of systemic antibiotics in clinical
practice
What is stated in the previous paragraph regarding the comparison
with topical antibiotics is equally relevant here. The only oral
antibiotic that has been compared to placebo is penicillin, and this
was in an old study (Ruby 1973): no difference was found, and the
confidence interval was large. Based on the available evidence on
efficacy, no clear preference can be given for B-lactamase resistant
narrow-spectrum penicillins such as cloxacillin, dicloxacillin and
flucloxacillin, or for broad spectrum penicillins such as ampicillin,
amoxicillin with clavulanic acid, cephalosporins or macrolides.
General considerations regarding the choice of
antibiotics
Other criteria, such as price, (unnecessary) broadness of spectrum,
and wish to reserve a particular antibiotic for specific conditions,
can be decisive. Resistance rates against erythromycin seem to be
rising. In general, oral antibiotics have more side-effects, especially
gastrointestinal ones. There is insufficient evidence to say whether
oral antibiotics are better than topicals for more serious and ex-
tensive forms of impetigo. From a practical standpoint, oral an-
tibiotics might be an easier option for people with very extensive
impetigo.
Implications for research
Trials should be powered to compare treatments for a specific dis-
ease entity, rather than the effectiveness of a specific antibiotic on
a variety of (skin) infections, as treatment may impact differently
on separate subtypes of skin and soft tissue infections. As seen
in this review, trials that study one treatment for several diseases
often show inconclusive results for specific diagnoses. Future re-
search on impetigo should make a careful power calculation as
most included studies included too few participants with impetigo
to meaningfully assess differences in treatment effect.
Establishing the natural course of impetigo without any form of
antibiotic treatment would be useful.However, although impetigo
canbe considered aminor ailment, studieswith a non-intervention
arm seem ethically impracticable. Comparator treatments may in-
clude the best identified options for non-antibiotic management.
The relative absence of data on the efficacy of topical disinfectants
is a research gap that needs to be filled. These agents may not con-
tribute to antibiotic resistance, and they are cheap. This research
may be of particular importance for developing countries.
Preferably, a trial on impetigo should:
• not include participants with a variety of skin diseases and
soft tissue infections. If it does, results should be presented
separately by diagnosis;
• focus on either bullous or non-bullous impetigo and on
either primary or secondary impetigo;
• report resistance rates of causative bacteria against the
studied antibiotic and against reference antibiotics such as
erythromycin, mupirocin and/or fusidic acid, at baseline and at
follow-up;
• use clear and objective outcome measures for cure and
improvement of impetigo, instead of subjective judgements such
as ’improved’, ’satisfactory’, and ’good response’. Key elements
defining clinical cure could be absence of crusts, dryness,
intactness, and absence of redness of skin. A parameter of
improvement could be ’size of affected surface’. Choosing
’standard’ follow-up periods, e.g. 7, 14, or 21 days, will facilitate
the comparison of studies; and
• include a placebo group, or at least a ’gold standard’
reference group. For topical treatments, mupirocin or fusidic
acid could be considered ’gold standard’.
As part of the issue of antibiotic resistance, impetigo studies that
establish the contribution of the studied treatment to the devel-
opment of bacterial resistance are desirable.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arata 1989a
Methods Time NR; Japan; range of infections (impetigo 13/265)
Participants • Age 15 to 82 years
• M/F 150/115 (all participants)
• Mainly S.aureus
Interventions A: cefdinir 100 mg, 3 td
B: cefaclor 250 mg, 3 td
Outcomes Outcomes of the trial
1) 10 days, excellent/good/poor
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available in
the abstract.
Allocation concealment (selection bias) Unclear risk Insufficient information was available in
the abstract.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “....double-blind.”
Comment: There was unclear blinding of
the outcome assessor and caregiver. The
participant was probably blinded (see also
Figure 2). The test drug packages also in-
cluded placebo capsules
Incomplete outcome data (attrition bias)
All outcomes
Low risk 35/300 participants were omitted in the
analysis: 16/147 in the cefdinir group (8
due to no or delayed visit to hospital, others
for several reasons), 19/153 in the cefaclor
group (8 due to no or delayed visit to hos-
pital, others for several reasons) (see table
2)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance.
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Arata 1989a (Continued)
Randomised? Unclear risk Insufficient information was available in
the abstract.
Were both inclusion and exclusion criteria
specified?
Unclear risk Insufficient information was available in
the abstract.
Arata 1989b
Methods Time NR; Japan; range of skin infections (including impetigo 18/259)
Participants • All ages
• M/F 162/97
• Mainly S.aureus (data for all participants)
Interventions A: lomefloxacin 200 mg, 3 td
B: norfloxacin 200 mg, 3 td
Outcomes Outcomes of the trial
1) 7 days, cured/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available in
the abstract.
Allocation concealment (selection bias) Unclear risk This was unclear.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...a double-blind clinical trial.” It
was unclear who was blinded (and how).
The outcome assessor and caregiver were
probably not blinded. The participant was
probably blinded (see Figure 1 Dosing
schedule)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 33/291 participants were omitted in the
analysis: 15/147 in the NY-198 group, 17/
144 in the norfloxacin group. There was
insufficient information in the abstract and
figures
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance.
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Arata 1989b (Continued)
Randomised? Low risk Quote: “...were randomly allocated to one
of the two drugs.”
Were both inclusion and exclusion criteria
specified?
Unclear risk Inclusion (quote): “...skin and soft tissue
infections, patients > 15 years”. There was
no exclusion criteria
Arredondo 1987
Methods Time NR; Mexico city, Mexico; range of skin infections (including impetigo 55/61)
Participants • Average age 7 years
• M/F 30/31
• S.aureus 67%
Interventions A: mupirocin ointment 2%, 3 td, 5 to 10 days
B: dicloxacillin 250 mg, 4 td, 5 to 10 days
Outcomes Outcomes of the trial
1) 10 days, cure
Notes Open trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk This was not mentioned in the article.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “In an open trial...” Participants re-
ceived capsules or ointment. Neither the
participant, caregiver, nor outcome assessor
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/61 participants were omitted in the anal-
ysis: 2/29 in the mupirocin group, 1/32 in
the dicloxacillin group. Reasons for being
non-evaluable for clinical outcome were
not specified (but this was a small %)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias High risk Baseline imbalance: more severe impetigo
in the mupirocin group (9/32 vs 3/29, Ta-
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Arredondo 1987 (Continued)
ble 1). There was no data on compliance
Randomised? Low risk Quote: “After obtaining informed consent,
patients were randomly divided into two
treatment groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...pediatric patients with skin in-
fections of sufficient severity to require
treatment with a antibiotic.” Quote: “Pa-
tients who...were excluded from the trial.”
Barton 1987
Methods June to August 1986; Missouri, USA; outpatients; only impetigo
Participants • Children (age NR)
• M/F 29/32
• S.aureus 35/65, Streptococcus 2/65, both: 30%
PE
Interventions A: penicillin V 50 mg/kg/day in 4 dd, 10 ds
B: erythromycin 40 mg/kg/day in 4 dd, 10 ds
Outcomes Outcomes of the trial
1) 7 days, failure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available
about sequence generation
Allocation concealment (selection bias) Low risk Quote: “The patients were assigned to re-
ceive either erythromycin or penicillin in a
random, double-blind fashion by a phar-
macist.”
Comment: Participants and investigators
enrolling participants could not foresee as-
signment.
Blinding (performance bias and detection
bias)
patient
Unclear risk See above - it was not specified how this
was done. It is unclear whether the care-
giver, participant, or outcome assessor was
blinded
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Barton 1987 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 42/71 participants were omitted in the
analysis - reasons and numbers were not
specified for each group (6 due to negative
culture, 21 not evaluable for effectiveness
(not further specified), 6 due to no ascer-
tained compliance, 3 due to no growth of
S. aureus alone, 6 withS. aureus alone but
not available for follow-up). 14were left for
analysis in the erythromycin group and 15
in the penicillin group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Compliance and baseline comparability
was unclear.
Randomised? Low risk Quote: “The patients were assigned to re-
ceive either erythromycin or penicillin in a
random, double-blind fashion by a phar-
macist.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “All patients examined in the out-
patient department between June and Au-
gust 1986 with primarily non bullous im-
petigowere asked toparticipate in the study
if they were not receiving antibiotics at the
time of being seen at CGH, had not taken
antibiotics during the preceding week...”
Barton 1988
Methods June to August 1987; Missouri, USA; outpatients; only impetigo
Participants • 2 months to 16 years
• M/F 55/45
• S. aureus 46/100, S. pyogenes 9/100, both 25/199
PE
Interventions A: erythromycin 40 mg/kg/day in 4 dd, 10 ds
B: dicloxacillin 25 mg/kg /day in 4 dd, 10 ds
Outcomes Outcomes of the trial
1) 5 to 7 days, cure + improved
Notes -
Risk of bias
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Barton 1988 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “Participants were randomly as-
signed in a double-blind manner by the
hospital pharmacist to receive...” Hence,
participants and investigators enrolling
participants could not foresee assignment
Blinding (performance bias and detection
bias)
patient
Unclear risk See above - not specified how and who was
blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 41/100 participants were omitted in anal-
ysis - not specified for each group (12/
100 were lost to follow up, but not stated
from which group). 29 were left in the
erythromycin group and 30 left in the di-
cloxacillin group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Group assignment of non-compliant par-
ticipants was unclear.
Randomised? Low risk Quote: “Participants were randomly as-
signed in a double-blind manner by the
hospital pharmacist to receive...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “During the months of June, July
and August, 1987, 100 children with im-
petigo, from whom informed consent was
obtained, were consecutively enrolled in
the study.”
Quote: “Exclusion criteria included...”
Barton 1989
Methods June to August 1988; Missouri, USA; outpatients; only impetigo
Participants • 3 months to 16 years
• M/F 49/48
• S. aureus 80%
PNE
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Barton 1989 (Continued)
Interventions A: erythromycin 40 mg/kg/day in 3 dd, 7 days
B: mupirocin ointment 2%, 3 td, 7 days
Outcomes Outcomes of the trial
1) 4 to 7 days, cured + improved
Notes 14% bullous
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk This was not mentioned in the article.
Blinding (performance bias and detection
bias)
patient
High risk Participant and caregiver were not blinded
because they received either capsules or
ointment. It is not mentioned in the article
whether the outcome assessor was blinded
(probably not, because the caregiver and
participant were not blinded)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1(/97) participant was omitted in the anal-
ysis, specified: 1/48 in the erythromycin
group (lost to follow up), 0/49 in the
mupirocin group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Compliance was not reported.
Randomised? Low risk Quote: “Participants were randomly as-
signed to receive either...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children over 6 weeks of age with
a clinical diagnosis of impetigowere invited
to participate in the study. Exclusion crite-
ria included...”
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Bass 1997
Methods Time NR; Honolulu, Hawaii; hospital outpatients; only impetigo
Participants • Average age 3.8 years
• Sex NR
• S. aureus 41/48
PNE
Interventions 3 arms:
A: cephalexin 50 mg/kg/day in 3 dd + placebo ointment, 10 days
B: mupirocin ointment 2%, 3 td + liquid oral placebo
C: bacitracin ointment 500 units/g, 3 td + liquid oral placebo
Outcomes Outcomes of the trial
1) 8 to 10 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...clinical pharmacist assigned
them by a table of random numbers to one
of the three treatment groups”
Allocation concealment (selection bias) Low risk See above and the quote: “The clinician,
patients and their parents were not aware
of which of the three treatment regimens
they were assigned.”
Comment: Central allocation - partici-
pants and investigators enrolling partici-
pants could not foresee assignment.
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “The clinician, patients and their
parentswere not aware ofwhich of the three
treatment regimens they were assigned.”
Comment: The outcome assessor, partici-
pant, and caregiver were all blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 6/32 participants were omitted in the anal-
ysis: 0/10 in the cephalexin group, 5/12 in
themupirocin group, 1/10 in the bacitracin
group (missing Imbalance formissing data)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was a baseline imbalance for size and
type of lesion. Compliance was assessed in
only 17 participants
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Bass 1997 (Continued)
Randomised? Low risk Quote: “...clinical pharmacist assigned
them by a table of random numbers to one
of the three treatment groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quoted from the referred article Demi-
dovich: “Children presenting with im-
petigo to our clinic were eligible for the
study. Exclusion criteria were...”
Beitner 1996
Methods December 1992 to November 1994; 25 centres, Sweden; outpatients; range of skin
infections (impetigo 60/327)
Participants • Age range 3 to 80 years
• S. aureus 86% of 327, Streptococcus 14% of 327
• Included only participants with bacteria sensitive to both drugs
PE
Interventions A: cefadroxil 40 mg/kg/day, 10 days
B: flucloxacillin tablets 750 mg, 2 td, or susp 30 to 50 mg/kg/day in 2 to 3 dd, 10 days
Outcomes Outcomes of the trial
1) 10 to 12 days, cure/improved/failed
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk The method of concealment was not de-
scribed.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “...single blinded.”
Quote: “Statistical analysis was performed
blinded.”
Comment: The participant, outcome as-
sessor, and caregiver were probably not
blinded because participants in both
groups did not receive the same adminis-
trations of study drugs daily
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Beitner 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 334/661 participants were missing mainly
due to a lack of a bacterial culture sensitive
to both drugs, and 351/661 were omitted
from the primary analysis. 33 impetigo par-
ticipantswere included in the primary anal-
ysis. Exact reasons for not being evaluable
and group assignment were not reported.
19/661 were omitted in the “ITT-analysis”
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “The randomization produced two
comparable groups of patients with no dif-
ferences in known prognostic factors.”
Comment: There was no compliance data.
Randomised? Low risk Quote: “In this prospective single-blind
comparative and randomized multicentre
trial...”
Were both inclusion and exclusion criteria
specified?
Low risk Table 1: Inclusion and exclusion criteria for
the subjects participating in the study
Blaszcyk 1998
Methods Period NR; multicentre; Europe, Latin America, Asia; range of skin infections (impetigo
42/539)
Participants • 16 to 70 years (all participants)
PNE
Interventions A: clindamycin caps 150 mg, 4 td
B: clindamycin caps 300 mg, 2 td
C: dicloxacillin caps 250 mg, 4 td
Outcomes Outcomes of the trial
1) 7 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
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Blaszcyk 1998 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “Drug supplies were masked.”
Comment: Insufficient information was
available.
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “Drug supplies were masked.”
Quote: “Patients in all groups received four
administrations of study drugs daily.”
Comment: The outcome assessor, par-
ticipant, and caregiver were probably all
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 48/588 were omitted in the analysis: 16/
196 in the clindamycin caps 150 mg group,
19/198 in the clindamycin caps 300 mg
group, 20/194 in the dicloxacillin caps
group. Proportions of participants who did
not complete the studymedication and rea-
sons were ~ similar (table II). There were
not only impetigo participants
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Compliance data was provided (table II)
and well-balanced. The distribution of
baseline characteristics was not provided
Randomised? Low risk Quote: “This prospective, double mask,
randomized study...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients were selected based on...”
Quote: “Patients were ineligible if...”
Britton 1990
Methods October 1988 to October 1989; Portsmouth, Virginia, USA; outpatients; only impetigo
Participants • 2 months to 12 years
• M/F 27/17
• S. aureus 26/48
PNE
Interventions A: erythromycin 40 mg/kg/day in 4 dd + placebo cream
B: mupirocin ointment 2%, 3 td + placebo susp
Outcomes Outcomes of the trial
1) 10 days, cured + improved
Notes -
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Britton 1990 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a random numbers table,
the hospital pharmacist randomly assigned
each patient to one of the groups.”
Allocation concealment (selection bias) Low risk Quote: “Using a random numbers table,
the hospital pharmacist randomly assigned
each patient to one of the groups.”
Comment: central allocation - pharmacy-
controlled.
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “The child group assignment was
not known to parents or investigators.”
Quote: “...assigned each patient to one
of two groups: orally administered ery-
thromycin plus topically applied placebo
(erythromycin group) or orally admin-
istered placebo plus topically applied
mupirocin (mupirocin group).”
Comment: The outcome assessor, par-
ticipant, and caregiver were probably all
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/54 participants were omitted in the anal-
ysis: 2/24 in the mupirocin group, 4/30 in
the erythromycin group. Participants not
completing the study were left out of the
analysis. Reasons for not completing the
study were not specified for each group. 3
were lost to follow up, 2 dropped out when
misdiagnosis was suspected, and 1 was re-
moved because of S. pyogenes pharyngitis.
< 20% withdrawals and numbers were bal-
anced.
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias High risk Baseline characteristics were imbalanced
(sex, severity), and compliance was also
skewed
Randomised? Low risk Quote: “Using a random numbers table,
the hospital pharmacist randomly assigned
each patient to one of the groups.”
39Interventions for impetigo (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Britton 1990 (Continued)
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children aged 12 years and




Methods Unlear, around 2000; US, multicentre; ambulatory setting; range of skin infections
(including impetigo 58/857)
Participants • 12 to 93 years
• M/F 427/430
• S.aureus 525/1685, S.pyogenes 53/1685 (including Bucko 2002b)
PNE
Interventions A: cefditoren 200 mg, 2 td, 10 days
B: cefditoren 400 mg, 2 td, 10 days
C: cefuroxime 250 mg, 2 td, 10 days
Outcomes Outcomes of the trial
1) 7 to 14 days, cured or improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Low risk Quote: “Study-drug containers were dis-
pensed in numeric sequence at each inves-
tigative site as patients were enrolled to en-
sure random assignment.”
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “...double-blind, double-dummy...
”
Quote: “Patients’ evaluability and out-
comes were assessed under blinded condi-
tions”. The outcome assessor, caregiver, and
participant were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk For only impetigo: 2/58 missing impetigo
participants in total - 0/19 in the cefdi-
toren 200 mg group, 2/21 in the cefditoren
400 mg group, 0/18 in the cefuroxime 250
mg group. Reasons for missing participants
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Bucko 2002a (Continued)
were not specified (but a small %were non-
evaluable)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no compliance data and no base-
line imbalance.
Randomised? Low risk Quote: “Patients were randomized.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Eligible patients included...”
Quote: “Study exclusion criteria included.
..”
Bucko 2002b
Methods Unclear, around 2000; US; multicentre; ambulatory setting; range of skin infections
(including impetigo 74/828)
Participants • 12 to 95 years
• M/F 428/400
• S.aureus 525/1685, S.pyogenes 53/1685 (including Bucko 2002a)
PNE
Interventions A: Cefditoren 200 mg, 2 td, 10 days
B: Cefditoren 400 mg, 2 td, 10 days
C: Cefadroxil 500 mg, 2 td, 10 days
Outcomes Outcomes of the trial
1) 7 to 14 days, cured or improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Low risk Quote: “Study-drug containers were dis-
pensed in numeric sequence at each inves-
tigative site as patients were enrolled to en-
sure random assignment.”
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “...double-blind, double-dummy...
”
Quote: “Patients’ evaluability and out-
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Bucko 2002b (Continued)
comes were assessed under blinded condi-
tions”
Comment: The outcome assessor, care-
giver, and participant were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk For only impetigo: 4/74 missing partic-
ipants - 1/27 in the cefditoren 200 mg
group, 0/25 in the cefditoren 400 mg
group, 3/22 in the cefadroxil 500 mg
group. Reasons for missing participants
were not specified (but a small %were non-
evaluable)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no compliance data and no base-
line imbalance.
Randomised? Low risk Quote: “Patients were randomized...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Eligible patients included...”
Quote: “Study exclusion criteria included.
..”
Christensen 1994
Methods TimeNR; Sweden,Germany,UK;Outpatients (Germany) andGP (UK), both (Sweden)
; only impetigo
Participants • 3 + years
• M/F 131/125
• S.aureus 199/256, S.pyogenes 21/256, both 36/256
PE
Interventions A: hydrogen peroxide cream 1% (Microcid), 2 to 3 td, max 21 days
B: fusidic acid cream gel 2%, 2 to 3 td, max 21 days
Outcomes Outcomes of the trial
1) evaluation time NR, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “...randomized (in blocks of four).
” The process for selecting the blocks was
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Christensen 1994 (Continued)
not specified
Allocation concealment (selection bias) Unclear risk Quote: “The tubes were put into identical
paper boxes, to keep the trials blind.”
Comment: Insufficient information was
available. The tubes may have been differ-
ent
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “The tubes were put into identi-
cal paper boxes, to keep the trials blind.”
There was incomplete blinding - partici-
pantswere probably not blinded (see above)
, and blinding with regard to the outcome
assessor and caregiver is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk 135/391 participants were omitted in the
analysis because they were culture negative
(not specified per group); 11/156 partic-
ipants in the M-group and 3/156 in the
F-group were withdrawn due to deteriora-
tion of their impetigo (statistically signifi-
cant), 3/156 in the F-group and 0/156 in
the M-group were withdrawn due to ad-
verse events (irritation of the skin, burn-
ing, and blistering). All participants fulfill-
ing the prespecified requirement of bacteri-
ologically-verified impetigo were analysed
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no data on baseline compara-
bility and compliance.
Randomised? Low risk Quote: “...randomized (in blocks of four).
”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were included”
Quote: “Patients were not allowed... prior
to start of study...”
Ciftci 2002
Methods 1999; Turkey; hospital outpatient department; only impetigo
Participants • Age 10 to 132 months
• M/F 32/16
• S. aureus around 70%
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Ciftci 2002 (Continued)
Interventions A: topical mupirocin 2% 3td for 10 days
B: topical terbinafine 1% 3td for 10 days
Outcomes Outcomes of the trial
1) 10 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “...mupirocin group was instructed
to use Bactroban 2% ointment and
terbinafine group was instructed to use
Lamisil 1% cream topically three times
daily for ten days”. The outcome assessor,
caregiver, and participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/62 participants were not analysed: 6/31
were missing in the mupirocin group, 8/
31 were missing in the terbinafine group.
Quote: “At the end of the treatment, 25
participants in themupirocin group and 23
participants in the terbinafine group were
considered eligible” . > 20% missing
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias High risk Quote: “The group had similar features ex-
cept for the time from appearance of lesions
to hospital admission.” There was a mean
of 5.44 in the mupirocin group versus 6.78
in the terbinafine group
Randomised? Low risk Quote: “...in a randomized fashion.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were excluded.”
Quote: “....children, less than 12 years old,
presenting with impetigo to...”
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Claudy 2001
Methods Time NR; France; ambulatory setting (dermatology outpatient departments); range of
skin infections (including impetigo 53/334)
Participants • All participants: age > 18 years
• M/F 206/128
• S aureus: 162/334; S pyogenes 34/334
Interventions A: oral fusidic acid 2 x 250 mg 2 td for 7.5 days
B: oral pristinamycin 2 x 500 mg 2 td for 10 days
Outcomes Outcomes of the trial
1) 11 days, cured and improved
Notes Outcome data for impetigo participants was provided by the author (personal commu-
nication)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “Afin de garantir le double insu,
chaque patient recevait le traitement dont
2.5 jours de placebo”. [To ensure dou-
ble blinding, each patient received a
placebo for 2.5 days]. The participantswere
blinded, but blinding is unclear with regard
to the caregiver and outcome assessor.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 313/334participantswere analysed (<10%
not in analysis). There is no data for im-
petigo participants
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no compliance data and no
baseline comparison.
Randomised? Low risk Quote: “Une etude
multicentrique, prospective, randomisée...
” [A randomised, prospective, multicentre
study...]
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Claudy 2001 (Continued)
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Tout patient ambulatoire, âgé de
plus de 18 ans, avec une pyodermite su-
perficielle nécessitant une antibiothérapie
orale et ayant donné son consentement
éclairé pouvait être inclus dans l’essai à con-
dition de ne presenter aucun des critères
d’exclusion suivants.” [Most ambulatory
participants, older than the 18 years old,
with a superficial pyoderma requiring oral
antibiotics and with given informed con-
sent could be included in the study pro-
vided there were none of the following ex-
clusion criteria present.]
Dagan 1989
Methods May to October 1987; Negev region, Israel; outpatients; only impetigo
Participants • 6 months to 9 years
• Sex NR
• S. aureus 37/51, S. pyogenes 14/51
PE
Interventions A: amoxicillin trihydrate syrup 40 mg/kg/day, in 3 dd, 10 days
B: amoxicillin/clavulanic acid syrup 40 + 10 mg/kg/day, in 3 dd, 10 days
Outcomes Outcomes of the trial
1) 5 days, cure + improved
Notes There was missing data from the first follow-upmeasurement for 4/26 participants in the
amoxicillin trihydrate syrup group and 3/25 participants in the amoxicillin/clavulanic
acid syrup group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...in a double-blind fashion”. It is
unclear whether the outcome assessor, par-
ticipant, or caregiver were blinded
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Dagan 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7/52 (< 20%) participants were omitted in
the analysis after 5 days
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias High risk There was a baseline imbalance for lym-
phadenopathy > 20%. There were no com-
pliance data
Randomised? Low risk Quote: “After obtaining the cultures, pa-
tients were randomized to...”
Were both inclusion and exclusion criteria
specified?
High risk Quote: “We included...” Exclusion criteria
was not mentioned
Dagan 1992
Methods July 1989 to October 1990; Negev region, Israel; outpatients; only impetigo (bullous
and non-bullous)
Participants • < 16 years
• M/F 56/46
• S. aureus 90/102, streptococci 1/3 of participants
PNE
Interventions A: erythromycin susp 50 mg/kg/day 3 td + placebo ointment, 7 days
B: mupirocin ointment 2% 3 td + oral placebo susp, 7 days
Outcomes Outcomes of the trial
1) 7 days, failed
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “The randomized code was pre-
pared by Beecham Pharmaceutical and was
not known to the investigators until after
the raw data were tabulated.”
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “The randomized code was pre-
pared by Beecham Pharmaceutical and was
not known to the investigators until af-
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Dagan 1992 (Continued)
ter the raw data were tabulated.” The ery-
thromycin group received a placebo oint-
ment and the mupirocin group received an
oral placebo suspension. The outcome as-
sessor, caregiver, and participant were prob-
ably all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13/102 participants were omitted in the
analysis: 8/51 in the erythromycin group (1
due to side-effects, 7 due to refusal to con-
tinue treatment or to return for the follow-
up visit), 5/51 missing in the mupirocin
group (all due to refusal to continue treat-
ment or to return for the follow-up visit)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were age and sex differences at base-
line (table 1), although they were not sig-
nificant. There were no compliance data
Randomised? Low risk Quote: “...were randomized into two
groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Infants... were enrolled.”
Quote: “Excluded groups were...”
Daniel 1991a
Methods 1987 to 1991; Belgium, France, FRG, Netherlands, Norway, UK; setting unclear; range
of skin infections (including impetigo 69/308)
Participants • 16 to 80 years
• All participants: S. aureus 195/308, streptococci 59/308
PNE
Interventions A: azithromycin 250 mg twice (day 1),once daily (day 2 to 5), 5 days
B: erythromycin 500 mg 4 td, 7 days
Outcomes Outcomes of the trial
1) 11 to 16 days, cured
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Daniel 1991a (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated to treat-
ment with azithromycin or erythromycin
in a 1:1 ratio using a randomization list.”
Allocation concealment (selection bias) Unclear risk See above - it is unclear whether partic-
ipants and investigators enrolling partici-
pants could foresee assignment
Blinding (performance bias and detection
bias)
patient
High risk Participants in both groups did not receive
the same administrations of study drugs
daily. The outcome assessor was likely to
also be the caregiver, so probably all 3 were
not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of impetigo participants not
included in analysis was small and well-bal-
anced (1 vs 2)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no compliance data. Baseline
characteristics were well-balanced
Randomised? Low risk Quote: “Patients were allocated to treat-
ment with azithromycin or erythromycin
in a 1:1 ratio using a randomization list.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “In order to be included...”
Quote: “Exclusion criteria were...”
Daniel 1991b
Methods 1987 to 1989; Belgium, Germany, Ireland, UK; setting unclear; range of skin infections
(including impetigo 17/323)
Participants • Adults 17 to 90 years
• All participants: S aureus 158/323, streptococci 41/323
PNE
Interventions A: azithromycin 250 mg twice (day 1),once daily (day 2 to 5), 5 days
B: cloxacillin 500 mg, 4 td, 7 days
Outcomes Outcomes of the trial
1) 11 to 16 days, cured/improved/failed
Notes -
Risk of bias
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Daniel 1991b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using a presupplied randomiza-
tion list patients were allocated to receive
azithromycin or cloxacillin in the ratio of
2:1.”
Allocation concealment (selection bias) Unclear risk See above - it is unclear whether partic-
ipants and investigators enrolling partici-
pants could foresee assignment
Blinding (performance bias and detection
bias)
patient
High risk Participants in both groups did not receive
the same administrations of study drugs
daily. The outcome assessor, caregiver, and
participant were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 impetigo participant was not in the
analysis.
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no compliance data. Baseline
characteristics were comparable
Randomised? Low risk Quote: “Using a presupplied randomiza-
tion list patients were allocated to receive
azithromycin or cloxacillin in the ratio of
2:1.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “In order to be included...”
Quote: “Exclusion criteria were...”
Demidovich 1990
Methods Time NR; Honolulu, Hawaii; outpatients; only impetigo
Participants • 5 months to 15 years, average 3 years
• S. aureus 45/73, GABHS 6/73, both 14/73
PNE
Interventions A: penicillin V 40 to 50 mg/kg/day in 3 dd, 10 days
B: cephalexin 40 to 50 mg/kg/day in 3 dd, 10 days
C: erythromycin 30 to 40 mg/kg/day in 3 dd, 10 days
Outcomes Outcomes of the trial
1) 8 to 10 days, failed
Notes -
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Demidovich 1990 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “The pharmacist randomly as-
signed them to one of three treatment reg-
imens.”
Central allocation - participants could not
foresee assignment
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “Patients were reevaluated...by one
of the authors, both of whom were blinded
to the treatment each child was receiving.”
Comment: Participants were probably not
blinded. The caregiver and outcome asses-
sor were probably blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/75 participants were omitted in the anal-
ysis: 2 participants were lost to follow up
(not further specified)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “There was not a significant differ-
ence in disease severity among treatment
groups.” Compliance in both groups was
comparable, but low
Randomised? Low risk Quote: “The pharmacist randomly as-
signed them to one of three treatment reg-
imens.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children presenting with im-
petigo to our pediatric clinic were eligible
for the study. Exclusion criteria were...”
Dillon 1983
Methods 1980 summer/fall; Alabama, USA; outpatients; only impetigo (bullous impetigo 57/70)
Participants • Average age 3.2 years
• MF 41/37
• S. aureus: 64/70
PNE
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Dillon 1983 (Continued)
Interventions A: cephalexin 50 mg/kg/day in 2 dd (> 20 kg: 500 mg 2 td)
B: dicloxacillin 15 mg/kg/day in 4 dd (> 40 kg: 125 mg 4 td)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned,
according to a standard table, to receive...”
(Referring to a standard table.)
Allocation concealment (selection bias) Unclear risk See above - it is unclear whether partic-
ipants and investigators enrolling partici-
pants could foresee assignment
Blinding (performance bias and detection
bias)
patient
High risk Participants in both groups did not receive
the same administrations of study drugs
daily. The outcome assessor, caregiver, and
participant were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/78 participants were omitted in the anal-
ysis: 5 vs 3 participants failed to return or,
with a negative culture, were not included
in the analysis (< 20% and balanced)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “Preference was given to patients
with skin infections typical of staphylococ-
cal bullous impetigo.” Comment: Further-
more, there were no baseline differences,
and compliance was not reported
Randomised? Low risk Quote: “Patients were randomly assigned,
according to a standard table, to receive...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “The criterion for enrolment was..
.”
Quote: “...were excluded.”
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Dux 1986
Methods TimeNR;Toronto, Canada; setting unclear; range of skin infections (including impetigo
36/149)
Participants • Average age 22 years
• M/F 81/68
• Bacterial culture results unclear
PNE
Interventions A: mupirocin ointment 2%, 3 td, 7 days
B: erythromycin 250 mg, 4 td, 7 days
C: cloxacillin 250 mg, 4 td, 7 days
Outcomes Outcomes of the trial
1) 7 days, cure/improved/failure.
Clocacillin: no participants with impetigo allocated
Notes 2 cases of secondary impetigo, both in the mupirocin group, were excluded from the
results presented here
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the se-
quence generation process was available,
and there was unexpected distribution (78
vs 50 vs 20)
Allocation concealment (selection bias) Unclear risk Quote: “...were randomized into two treat-
ment groups by each investigator.”
Comment: It is unclear whether partici-
pants and investigators enrolling partici-
pants could foresee assignment
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...single-blind”.
Comment: It is not clear who was blinded
and how this was done. Also, participants
in both groups did not receive the same
administrations of study drugs daily. Par-
ticipants were probably not blinded. The
blinding of outcome assessor and caregiver
is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 (/149) participant was omitted in the
analysis: 1/79 in the mupirocin group due
to an infected cyst (not included in analy-
sis), 0/50 in the erythromycin group, 0/20
in the cloxacillin group
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Dux 1986 (Continued)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Compliance was not reported. There was a
large age difference between groups (mean
22 vs 31 years), unknown for impetigo par-
ticipants
Randomised? Low risk Quote: “In each section of the study, pa-
tients with primary or secondary skin infec-
tions were randomized into two treatment
groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients with primary and sec-
ondary skin infections that were severe
enough were included in three parallel-
study groups.”
Quote: “Patient who did not...”
Eells 1986
Methods October to November 1983; Puerto Rico; outpatients; only impetigo




Interventions A: mupirocin ointment 2%, 3 td, 7 to 9 days
B: vehicle control, 3 td, 7 to 9 days
Outcomes Outcomes of the trial
1) 8 days, cure/improved/failure
1 participant with ecthyma was excluded in each group.
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patientswere randomized between
the two treatment groups by a computer-
generated set of random numbers in blocks
of five per group.”
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
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Eells 1986 (Continued)
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “...double-blind, vehi-
cle-controlled.” Also, participants in both
groups received the same administrations
of study drugs daily. The outcome assessor,
caregiver, and participant were probably all
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/52 participants were omitted in the
analysis: 8/26 in the mupirocin group (5
were “unavailable for follow-up”, 3 for sev-
eral reasons (specified)), 6/26 in the ve-
hicle group (2 were “unavailable for fol-
low-up”, 3 for several reasons (specified))
. There were more than 20% withdrawals
and dropouts
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance. Compli-
ance was not reported
Randomised? Low risk Quote: “Patientswere randomized between
the two treatment groups by a computer-
generated set of random numbers in blocks
of five per group.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were admitted to the study.”
Quote: “Patients were excluded if...”
Esterly 1991
Methods Time NR; Milwaukee, Wisconsin, USA; outpatients; only impetigo
Participants • 3 months to 14 years, average 4.3 years
• S.aureus 33%; GABHS 12%; both 41%
• Exclusions: NR
Interventions A: mupirocin (dose NR)
B: erythromycin (dose NR)
Outcomes Outcomes of the trial
1) Time of evaluation NR, failure
Notes -
Risk of bias
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Esterly 1991 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
High risk Oral versus topical treatment. The out-
come assessor, caregiver, and participant
were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/48 participants were omitted in the anal-
ysis: 4/25 in the mupirocin group (3 due
to “fail to return for follow-up”, 1 reason
not mentioned), 5/23 in the erythromycin
group (3 due to “fail to return for follow-
up”, 2 reasons not mentioned)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no baseline characteristics per
group. There were no compliance data
Randomised? Low risk Quote: “...randomized.”
Were both inclusion and exclusion criteria
specified?
High risk This was not mentioned in the article.
Farah 1967
Methods Time NR; Lebanon; outpatients; probably all impetigo (’superificial pyogenic skin in-
fection’)
Participants • 21 days to 60 years of age
• M/F unknown
• S. aureus 61%, S. pyogenes 30%
Interventions A: gentamycin cream 1% 3 td, duration unknown
B: neomycin ointment 0.5% 3 td, duration unknown
Outcomes Outcomes of the trial
1) Cured, improved after 7 days
Notes -
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Farah 1967 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was provided.
Allocation concealment (selection bias) Unclear risk This was not reported.
Blinding (performance bias and detection
bias)
patient
Unclear risk This was not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 11/139 participants were lost to follow up
(it was not stated in which group)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was an unexplained imbalance of
group size (88 vs. 44). There were no com-
pliance data. There was no baseline com-
parison
Randomised? Low risk Quote: “The persons included in this study
were divided into two groups at random.”
Were both inclusion and exclusion criteria
specified?
High risk Inclusion and exclusion criteria was not
specified.
Faye 2007
Methods 2002 to 2003; Mali; hospital outpatients; only impetigo
Participants • Inclusion > 1 year of age
• Mean age 8.5 years
• M/F 74/58
• No bacteriological investigation
Interventions A: oral amoxicillin 50 mg/kg/day + topical 10% povidone iodine for 7 days
B: oral erythromycin 30 mg/kg/day + topical 10% povidone iodine for 7 days
Outcomes Outcomes of the trial
1) Proportion cured + improved after 7 days
Notes -
Risk of bias
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Faye 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...using a table of random num-
bers”.
Comment: This was an adequate method.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “....an open randomized trial.”
Quote: “Patients and investigators were not
blinded.” The outcome assessor, partici-
pant, and caregiver were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/132 participants were not analysed: 2/66
in the amoxicillin group (2 lost to follow up
on the 7th day), 1/66 in the erythromycin
group (1 lost to follow up on the 7th day)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline comparison. There
were no compliance data
Randomised? Low risk Quote: “...an open randomized trial.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients agedmore than 1 year old.
.. were considered for inclusion.”
Quote: “The following cases were ex-
cluded...”
Fujita 1984
Methods Time NR; Japan; outpatients; range of skin infections (including impetigo 10/204)
Participants • Age 16 to 84 years
• M/F 120/84 (all participants)
Interventions A: enoxacin 500 mg 3 td
B: cephalexin 500 mg 2 td
(double dummy)
Outcomes Outcomes of the trial
1) After .... cured/improved
Notes Secondary impetigo- it only says impetigo above
Risk of bias
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Fujita 1984 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not mentioned in the abstract.
Allocation concealment (selection bias) Unclear risk This was not mentioned in the abstract.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...a double-blind.” They used
placebo capsules (see Figure 1 Dosage
schedule). Participants were probably
blinded. It is not clear how, and if, the care-
giver and outcome assessor were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 22/226 participants were omitted in the
analysis: 14/115 in the enoxacin group (2
due to exclusion (1 overlap administra-
tion and 1 antibiotics before treatment), 12
dropped out (11 shortage of duration, 1 no
successive visit)), 8/111 in the cephalexin
group (all dropped out (7 shortage of dura-
tion, 1 no successive visit). < 20% but not
specified for impetigo participants
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance (table 4),
and compliance was not reported
Randomised? Unclear risk This was not mentioned in the abstract.
Were both inclusion and exclusion criteria
specified?
Unclear risk This was not mentioned in the abstract.
Gilbert 1989
Methods Time NR; Quebec, Canada; outpatients; range of skin infections (including impetigo
19/70)
Participants • Age NR
• S. aureus 41/70; Streptococci 22/70 (all participants)
PE
Interventions A: mupirocin ointment 2%, 3 td, 7 days
B: fusidic acid cream 2%, 3 td, 7 days
Outcomes Outcomes of the trial
1) 7 days, cure/improved/failure
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk The abstract reported the study was dou-
ble-blind, but it is not explained in the ar-
ticle. There is unclear blinding of the out-
come assessor, caregiver, and participant
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 (/70) participant was omitted in the clin-
ical analysis: 0/35 in the fusidic acid group,
1/35 in the mupirocin group. Participants
were not examined if pre-treatment cul-
tures were negative or if post-treatment
evaluation was not possible
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance, and com-
pliance was not reported
Randomised? Low risk Quote: “Patients were randomly divided
into two treatment groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients who... were excluded
from the trial.”
Quote: “...in 70 patients who came to the
dermatologic clinic with primary and sec-
ondary skin infections of sufficient severity
to require antibiotic therapy.”
Ginsburg 1978
Methods Time NR; Dallas, Texas, USA; outpatients; only impetigo
Participants • 8 months to 8 years, average 3.1 years
• Sex NR
• S.aureus 78%, GABHS 64%, both 50%
Part excluded: unclear
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Ginsburg 1978 (Continued)
Interventions A: penicillin G 30 mg/kg/day in 4 dd, duration NR
B: cefadroxil 45 mg/kg/day in 3 dd, duration NR
Outcomes Outcomes of the trial
1) 8 days, cured + improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
High risk Participants in both groups received differ-
ent administrations of study drugs daily.
The outcome assessor, caregiver, and par-
ticipant were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 21/71 participants were omitted in the
analysis due to failure to return for both
follow-up examinations. There were more
than 20%withdrawals; this was not further
specified for each group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “Groups were comparable with re-
gard to age, sex, race and extent of skin le-
sion.” Compliance was unclear
Randomised? Low risk Quote: “Infants and children with im-
petigo were assigned treatment randomly.”
Were both inclusion and exclusion criteria
specified?
High risk Quote: “Infants and children with im-
petigo were assigned...” No exclusion crite-
ria were specified
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Giordano 2006
Methods 2005; US; hospital outpatients; skin infections (including impetigo 16/391)
Participants • All diagnoses: 13 to 93 years
• M/F 206/185
• S. aureus 44%; S. pyogenes 2%
Interventions A: oral cefdinir 300 mg 2 td 10 days
B: cephalexin 200 mg 4 td 10 days
Outcomes Outcomes of the trial
1) Proportion cured + improved after 17 to 24 days
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated random-
ization schedule in a 1:1 ratio was used.”
Quote: “Study drug containers were dis-
pensed in increasing numerical sequence at
each investigative site.”
Allocation concealment (selection bias) Unclear risk Quote: “Tomaintain investigator blinding,
the study drug was dispensed by an un-
blinded third person who did not partici-
pate in the assessments of clinical response.
”
Comment: It is not clear whether this per-
son was involved in participant contacts
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...investigator-blinded.”
Quote: “To maintain investigator blind-
ing, the study drug was dispensed by an
unblinded third person who did not par-
ticipate in the assessments of clinical re-
sponse. Furthermore, the participant was
instructed not to disclose any details about
the study drug (...) to the investigator.”
The outcome assessor and caregiver were
blinded. The participants were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 0/16 missing impetigo partic-
ipants: 0/4 in the cefdinir group, 0/12 in
the cephalexin group. All 391 who took at
least 1 dose of the study drug were analysed
Selective reporting (reporting bias) Unclear risk This was unclear.
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Giordano 2006 (Continued)
Other bias Unclear risk There were no compliance data. There was
no baseline comparison
Randomised? Low risk Quote: “A computer-generated random-
ization schedule...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were enrolled”
Quote: “Study exclusion criteria included.
..”
Goldfarb 1988
Methods Time NR; Cleveland, Ohio, USA; outpatients; only impetigo
Participants • 5 months to 13 years, average 3.8
• M/F 31/31
• S.aureus 49/62, Streptococci 4/62, both 9/62
PE: NR
Interventions A: mupirocin ointment 2%, 3 td, 8 days
B: erythromycin 40 mg/kg/day in 4 dd, 8 days
Outcomes Outcomes of the trial
1) 8 days, cured/failed
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
High risk Topical versus oral treatment. The out-
come assessor, caregiver, and participant
were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/62 participants were lost in total: 5/30
in the mupirocin group (all lost to follow
up), 5/32 in the erythromycin group (all
lost to follow up)
Selective reporting (reporting bias) Unclear risk This was unclear.
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Goldfarb 1988 (Continued)
Other bias Unclear risk The severity of impetigo was not compared
between the 2 groups. There was a differ-
ence in age (range vs mean). Compliance
was not reported
Randomised? Low risk Quote: “Enrolled children were randomly
assigned to groups that...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children 3 months of age and
older were seen at...were eligible for our
study.”
Quote: “Children were excluded if...”
Gonzalez 1989
Methods July to September 1980; Florida, USA; outpatients; only impetigo (bullous and non-
bullous)
Participants • 6 months to 12 years
Participants were excluded if no S. aureus was present
Interventions A: penicillin V potassium 50 mg/kg/day, in 4 dd, 10 days
B: cloxacillin sodium 50 mg/kg/day, in 4 dd, 10 days
Outcomes Outcomes of the trial
1) 10 days: cured + improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Quote: “...on a randomized schedule at the
following dosages”. It is unclear whether
participants and investigators enrolling
participants could foresee assignment
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “The clinical examiners were
blinded to the antibiotic that the patients
received until the study was concluded.”
Quote: “...double-blind schedule.” It is not
clear how patients were blinded, and the
participant was likely to be influenced in
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Gonzalez 1989 (Continued)
the case of lack of blinding. The outcome
assessor and caregiver were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/101 participants were lost due to no S.
aureus growth, 10 were lost in failure to re-
turn to the clinic (reasons for not attending
follow-up visit were not stated). The im-
balance in participants was not evaluated
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline severity compari-
son between groups. Participant compli-
ance data was computed and presented no
significant alterations in therapeutic out-
come
Randomised? Low risk Quote: “...on a randomized schedule at the
following dosages...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...could be enrolled on the study
if the following criteria were met...”
Quote: “There were no prior histories of
allergic phenomena.”
Gould 1984
Methods TimeNR; Edinburgh, UK; general practice; range of skin infections (including impetigo
39/107)
Participants • Average age 18.7 (all participants)
• S. aureus 90/129, streptococci 32/129 (all participants)
PNE
Interventions A: mupirocin ointment 2%, once daily, until cleared
B: placebo cream, once daily, until cleared
Outcomes Outcomes of the trial
1) Time of evaluation NR, cure/improved/failure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Gould 1984 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: “Patientswere allocated a trial num-
ber in the consecutive order of their en-
try in the study. The study was performed
under double blind conditions. Medica-
tion appropriate to the trial number, ei-
ther mupirocin or placebo ointment, was
dispensed according to a pre-determined
randomization which ensured that in each
group of four patients, two received treat-
mentwithmupirocin and twowith placebo
ointment.” The process for selecting the
blocks was not specified
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “The study was performed un-
der double-blind conditions.” It is unclear
whether, and how, the outcome assessor,
caregiver, and participant were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14/107 participants were omitted in the
analysis: 10/54 in the mupirocin group
(they were classified as clinically unassess-
able, 7 did not return for final assessment
(5 were traced later and found to have clini-
cally improved), 3 developed other diseases
requiring systemic treatment), 4/53 in the
placebo group (3 did not return for final
assessment (2 of whom were later found
to have improved and one worsened and
sought alternative treatment), 1 developed
other disease requiring systemic treatment)
. < 20%, 3 vs 1 impetigo participant not
evaluable
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “...well matched”. There was no
compliance data.
Randomised? Low risk Quote: “...according to a pre-determined
randomization.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients with acute primary skin
infections...who had not received topical or
systemic antibiotics during the preceding 3
days were entered in the study.”
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Gratton 1987
Methods Time NR; Montreal, Quebec, Canada; outpatients; range of skin infections (including
impetigo 15/60)
Participants • Age/sex NR
• S. aureus approx 50%
PE: NR
Interventions A: mupirocin ointment 2%, 3 td, 7 days
B: erythromycin 250 mg, 4 td, 7 days
Outcomes Outcomes of the trial
1) 7 days, cure/improved/failure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Quote: “...were randomly divided into two
treatment groups.” It is unclear whether
participants and investigators enrolling
participants could foresee assignment
Blinding (performance bias and detection
bias)
patient
High risk Topical versus oral treatment. The out-
come assessor, caregiver, and participant
were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/60 participants were omitted in the anal-
ysis: 0/30 in the mupirocin group, 0/30 in
the erythromycin group. 1 participant in
the mupirocin group discontinued therapy
due to intolerable side-effects. All impetigo
participants were included in the analysis
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline data. There were no
compliance data.
Randomised? Low risk Quote: “...were randomly divided into two
treatment groups.”
Were both inclusion and exclusion criteria
specified?
High risk Quote: “Sixty patients with primary and
secondary skin infections were randomly
divided.” No exclusion criteria was speci-
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Methods Summer 1986; Birmingham, Alabama, US; outpatients child hospital; only impetigo
Participants • 1 to 18 years
• Sex NR
• S. aureus 35%, GABHS 12%, both 54%
PE: NR
Interventions A: cefadroxil 30 mg/kg/day, max 1 g, in 1 dd, 10 days
B: cephalexin 30 mg/kg/day, max 1 g, in 2 dd, 10 days
Outcomes Outcomes of the trial
1) 14 days, cured
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned
to receive either...” It is unclear whether
participants and investigators enrolling pa-
tients could foresee assignment
Blinding (performance bias and detection
bias)
patient
High risk Participants in both groups received differ-
ent administrations of study drugs daily.
The outcome assessor, caregiver, and par-
ticipant were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13/101 participants were omitted in the
analysis in total: 4/55 in the cefadroxil
group (1 failed to keep all of the appoint-
ments, 3 participants failed to take medica-
tions as prescribed), 9/54 in the cephalexin
group (3 with negative cultures, 4 failed to
keep all of the appointments, 2 participants
failed to take medications as prescribed). <
20% and reasons described
Selective reporting (reporting bias) Unclear risk This was unclear.
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Hains 1989 (Continued)
Other bias Unclear risk There was baseline data. Compliance was
good in both groups.
Randomised? Low risk Quote: “Patients were randomly assigned
to receive either...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...who had a clinical diagnosis of
pyoderma were enrolled.”
Quote: “Children were excluded if...”
Ishii 1977
Methods Summer 1976; Tokyo, Japan; hospital outpatient clinic; bullous impetigo
Participants • 0 to 10 years
• M/F 26/34
• No bacterial investigations
• All participants evaluable
Interventions A: topical Eksalbe simplex (ointment containing killed escherichia, staphylococcus, strepto-
coccus, and pseudomonas) applied once daily under plaster or 3 times daily without plaster
B: placebo
Outcomes Outcomes of the trial
1) Cured/improved after 4 days
Notes Data extraction and risk of bias assessment done by Testuri Matsumura
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Low risk Allocation was concealed (assessed by Tet-
suru Matsumura).
Blinding (performance bias and detection
bias)
patient
Low risk The participant, outcome assessor, and
caregiver were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/40 participants were dropouts and ex-
cluded from the analysis
Selective reporting (reporting bias) Unclear risk This was unclear.
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Ishii 1977 (Continued)
Other bias Unclear risk There were no compliance data.
Randomised? Low risk This trial was randomised (assessed by Tet-
suru Matsumura).
Were both inclusion and exclusion criteria
specified?
High risk Exclusion criteria were not specified.
Jaffe 1985
Methods Time NR; Cleveland, Ohio, USA; outpatients child clinic; range of skin infections
(including impetigo 32/42)
Participants • 6 months to 12 years, average 4.8 years
• S. aureus 33/36, S. pyogenes 8/36
PNE
Interventions A: amoxicillin/clavulanic (125/30) acid, dose equivalent to 20 mg amoxicillin/kg/day in
3 dd, 10 days
B: cefaclor 20 mg/kg/day in 3 dd
Outcomes Outcomes of the trial
1) 10 days, cured/failed
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “Prescription were filled by the hos-
pital pharmacist using double-blind labels.
” Personnel or participants could, probably,
not foresee assignment
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “Prescription were filled by the hos-
pital pharmacist using double-blind labels.
” The outcome assessor, caregiver, and par-
ticipant were probably all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/43 participants were omitted in the anal-
ysis: 0/21 in the amoxicillin/clavulanic acid
group, 0/22 in the cefaclor group
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Jaffe 1985 (Continued)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Low risk Quote: “The two treatment groups were
generally comparable.” Compliance was
good in 75% of participants
Randomised? Low risk Quote: “Children were randomly assigned
to one of the two treatment regimens.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children 6 months to...were eligi-
ble for inclusion in the study.”
Quote: “Exclusion criteria included...”
Jaffe 1986
Methods Time NR; multicentre, Wessex, UK; general practice; range of skin infections (including
impetigo 43/119)
Participants • 2.5 years to 83 years, median 14 to 16 years
• M/F 23/20
• S. aureus 16/34, S. pyogenes 5/34
PNE
Interventions A: 1% hydrocortisone + 0.5% potassium hydroxyquinoline sulphate cream, 2 td, 14
days
B: 1% hydrocortisone + 2% miconazole nitrate cream, 2 td, 14 days




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Quote: “The trial was double-blind, pa-
tients being allocated at random to receive.
..”
Quote: “The randomization was balanced
for each centre, with separate randomiza-
tions for each of the two indications.” It
is unclear whether participants and investi-
gators enrolling participants could foresee
71Interventions for impetigo (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jaffe 1986 (Continued)
assignment
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “Unmarked plain tubes of the mar-
keted formulation of each product were
packed in plain sealed cartons, neither doc-
tors nor patients being aware of the identity
of the products until the end of the study.”
Comment: The outcome assessor, care-
giver, and participant were probably
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/119 participants were omitted in the
analysis: 0/65 in group 1, 0/54 in group 2
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Details of age, duration of condition, and
total symptom severity score were recorded
and were similar. There were no compli-
ance data
Randomised? Low risk Quote: “The trial was double-blind, pa-
tients being allocated at random to receive.
..”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...who presented... were included
in the study.” Exclusion criteria was not
specified
Kennedy 1985
Methods Time NR; Bristol, UK; general practice; only impetigo
Participants • Average age 11 years (mupirocin), 17 years (neomycin)
• M/F 2/1
• S. aureus 23/34, S. pyogenes 10/34
PNE
Interventions A: mupirocin ointment 2%, 2 td, 10 to 11 days
B: neomycin ointment 1%, 2 td, 10 to 11 days
Outcomes Outcomes of the trial
1) Time of evaluation NR, cure/improved/failure
Notes -
Risk of bias
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Kennedy 1985 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Allocation of treatment was on
a randomized basis. In each consecu-
tive group of four patients, two received
Bactroban ointment and two received
neomycin.”
Comment: They probably used blocked
randomisation, but the process of selecting
the blocks was not specified
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “The 15-g tubes differed only in
their code numbers and in both cases the
content was a white ointment.” It is un-
clear how investigators were blinded. The
caregiver and participant were probably
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 9/41 participants were omitted in the anal-
ysis: 8 were excluded due to a “stated diag-
nosis other than uncomplicated impetigo”
(not stated which group), 1 missing from
the mupirocin group due to “failure to at-
tend to follow-up”
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Therewas baseline imbalance for age (mean
11 vs 17 years). There were no compliance
data
Randomised? Low risk Quote: “Allocation of treatment was on a
randomized basis.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients were selected from those
presenting with typical impetigo.”
Quote: “Patients were excluded if...”
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Kiani 1991
Methods Time NR; multicentre USA (Southern States); admitted + outpatients; range of skin
infections (including impetigo 18/179)
Participants • Age > 16, 211/154 (all participants)
• S. aureus 152/179, S. pyogenes 29/179 (all participants)
PE
Interventions A: azithromycin 500 mg day 1, 250 mg, day 2 to 5, 5 days
B: cephalexin 500 mg twice daily, 10 days
Outcomes Outcomes of the trial
1) 11 days, cured/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “In this double blind...”
Quote: “Using a double-dummy tech-
nique, each patient received placebo cap-
sules which were visually identical to the
active drugs.”
Comment: The caregiver and participant
were probably blinded. There was unclear
blinding of the outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk 187/366 participants were omitted in the
analysis: 99/182 in the azithromycin group
(58 due to “no baseline pathogen”, 15 due
to “no end of therapy assessment”, 15 due
to “the presence of a resistant pathogen”
(onlymain reasons mentioned)), 88/184 in
the cephalexin group (55 due to “no base-
line pathogen”, 6 due to “no end of ther-
apy assessment”, 6 due to “the presence of
a resistant pathogen” (main reasons men-
tioned)). > 20% no end of therapy assess-
ment (not specified for impetigo only)
Selective reporting (reporting bias) Unclear risk This was unclear.
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Kiani 1991 (Continued)
Other bias Unclear risk There was a baseline comparison for sex,
race, and primary diagnosis. There was no
baseline imbalance. There were no compli-
ance data
Randomised? Low risk Quote: “Patients were randomly assigned
in a double-blind fashion to one of the two
treatment groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients were entered in the study
based on...”
Quote: “...were excluded by the protocol.”
Koning 2003
Methods February 1999 to November 2000; Rotterdam, Netherlands; general practice; only im-
petigo
Participants • < 12, average age 5.0 years
• M/F 98/62
• S. aureus 127/160, S. pyogenes 5/160, both 8/160, none 20/160
PNE
Interventions A: fusidic acid cream 2%, 3 td + povidone iodine shampoo, 2 td
B: placebo cream, 3 td + povidone iodine shampoo, 2 td
Outcomes Outcomes of the trial
1) 7 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “An independent statistician pro-
vided a computer-generated list of random
set numbers in permuted blocks of six. The
hospital pharmacist packed the study med-
ication in identical blank tubes with a num-
ber according to the randomisation list.”
Allocation concealment (selection bias) Low risk See above - probably done: central alloca-
tion.
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “Unblinding took place after the
primary statistical analysis had been done.
”
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Koning 2003 (Continued)
Quote: “....research nurse was unaware of
treatment allocation.”
Quote: “...placebo cream did not differ.”
Quote: “Unblinding took place after the
primary statistical analysis had been done.
”
Comment: The outcome assessor, care-
giver, and participant were probably all
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/160 participants were omitted in the
analysis (after 1 week): 2/78 in the fusidic
acid cream group (both did not want to fol-
low up), 2/82 in the placebo cream group
(both did not want to follow up)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance. There
was more non-compliance in the placebo
group
Randomised? Low risk Quote: “Patients were randomised block-
wise.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “General practitioners (GP’s) in the
Greater Rotterdamwere asked to report pa-
tients aged 0-12 years with nonbullous im-
petigo presenting at their surgery.”
Quote: “Exclusion criteria were...”
Koning 2008
Methods April to December 2005; India, Mexico, Netherlands, Peru; hospital outpatients and
general practice patients; only impetigo
Participants • 0 to 73 years of age, mean age around 11 years
• M/F 107/103
• S. aureus 146/210, S. pyogenes 42/210
Interventions A: topical retapamulin 1% 2 td for 5 days
B: topical placebo 2 td for 5 days
Outcomes Outcomes of the trial
1) Cured or improved after 7 days
Notes -
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Koning 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “Randomization was centre based
and performed using an automated tele-
phone system.”
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “The packaging and labelling of
study medication was identical for the ac-
tive medication and its placebo counter-
part. All efforts were made to make the
study medication and placebo identical
with respect to appearance and smell.” The
outcome assessor, caregiver, andparticipant
were all blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 50/213 participants missing in total: 18/
140 in the retapamulin group (1 did not re-
ceive intervention, 17 withdrawals (5 lack
of efficacy, 3 disease progression, 2 decided
to withdraw, 1 adverse event, 5 lost to fol-
low up)), 33/73 in the placebo group (2 did
not receive intervention, 31 withdrawals
(18 lack of efficacy, 9 disease progression, 1
adverse event, 3 lost to follow up)). > 20%
missing data
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “The mean total lesion area at base-
line was larger in the retapamulin group
compared with the placebo group.” There
was an imbalance for age. There were no
compliance data
Randomised? Low risk Quote: “We carried out a randomized...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Inclusion criteria were...”
Quote: “...were excluded.”
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Koranyi 1976
Methods 1974; Columbus, Ohio, USA; outpatients; only impetigo
Participants • 2 months to 15 years
• M/F 14/16
• S. aureus 22/30, S. pyogenes 10/30
PNE
Interventions A: bacitracin ointment 500 units/g, 4 td + oral placebo 6 days
B: erythromycin 250 mg 4 td + placebo cream, 6 days
Outcomes Outcomes of the trial
1) 6 days, cured/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Drug assignment was based on
a random distribution table, without the
knowledge of the authors.”
Allocation concealment (selection bias) Low risk See above.
Blinding (performance bias and detection
bias)
patient
Low risk See above. Also double dummydesign. The
outcome assessor, caregiver, andparticipant
were all blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/30 participants were omitted in the anal-
ysis: 0/15 in the bacitracin group, 0/15 in
the erythromycin group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline comparison for the
most important prognostic factors. There
were no compliance data
Randomised? Low risk Quote: “Drug assignment was based on
a random distribution table, without the
knowledge of the authors.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were enrolled in the study.”
Quote: “...were excluded.”
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Kuniyuki 2005
Methods 2002 to 2003; Japan; hospital outpatients; only impetigo
Participants • 2 months to 13 years
• M/F 27/22
• S. aureus 49/49 (inclusion criterion)
Interventions A: topical tetracycline 3% 3 td + oral cefdinir 9 mg/kg/day for 7 days
B: topical tetracycline 3% 3 td + oral minomycin 4 mg/kg/day for 7 days
C: topical tetracycline 3% 3 td + oral fosfomycin 40 mg/kg/day for 7 days
D: topical tetracycline 3% 3 td for 7 days
Outcomes Outcomes of the trial
1) Cured, improved after 7 days
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Unclear risk This was not reported.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “...open-label.” The outcome as-
sessor, caregiver, and participant were not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only participants who were culture posi-
tive were analysed. The number of drop-
outs and withdrawals was not mentioned
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no compliance data. There was
a baseline comparison for age and sex - no
imbalance
Randomised? Low risk Quote: “...randomized”.
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were admitted to the study.”
Quote: “We excluded patients...”
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McLinn 1988
Methods February to May 1986 ; Scottsdale, Arizona, USA; outpatients; only impetigo
Participants • > 6 months, average 5.5 years
• S.aureus 43/60, S.pyogenes 17/60
PE
Interventions A: mupirocin ointment 2%, 3 td, 7 to 9 days
B: erythromycin 30 to 40/mg/kg/day in 3 to 4 doses, 7 to 9 days
Outcomes Outcomes of the trial
1) 8 to 12 days, very much improved/ improved/no change
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patientswere randomized between
the two treatment groups by a computer-
generated set of random numbers in blocks
of four.”
Allocation concealment (selection bias) Low risk Quote: “...investigator was blinded to the
treatment the patient was to receive at the
time of patient entry.”
Blinding (performance bias and detection
bias)
patient
High risk Quote: “The investigator was blinded to
the treatment the patient was to receive at
the time of patient entry andwas unblinded
only in those cases where lesions persisted
requiring additional culturing.” Quote: “.
..open-label”. This was not blinded for all
participants. Also topical versus oral treat-
ment. The outcome assessor and caregiver
were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/60 participants were omitted in the
analysis for clinical efficacy: 0/30 in
the mupirocin group, 0/30 in the ery-
thromycin group (2 participants in the ery-
thromycin group discontinued therapy be-
cause of severe adverse experiences)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was a severe baseline imbalance,
more fever in erythromycin group (12 ver-
sus 3), but they seem to have adjusted for
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McLinn 1988 (Continued)
this in the analysis. There were no compli-
ance data
Randomised? Low risk Quote: “Patientswere randomized between
the two treatment groups by a computer-
generated set of random numbers in blocks
of four.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...were enrolled in the study.”
Quote: “Patients with...were excluded.”
Mertz 1989
Methods Time NR; San Juan, Puerto Rico; outpatients; only impetigo
Participants • 6 months to 32 years, average 5.4 years
• M/F 27/26; S.aureus 44/53, GABHS 37/53
PE
Interventions A: mupirocin ointment 2%, 3 td, 7 to 9 days
C: erythromycin 30 to 50 mg/kg/day in 2 doses, 7 to 9 days
Outcomes Outcomes of the trial
1) 7 to 9 days, cured/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patientswere randomized between
the two treatment groups according to
a computer-generated schedule having a
block size of four.”
Allocation concealment (selection bias) Low risk See above, andQuote: “The randomization
was predetermined by the sponsor and the
schedule for distribution of medications
was entrusted to a team member whose as-
signment was to dispense medication.”
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...were examined in a investigator-
blinded study.”
Quote: “The randomization was predeter-
mined by the sponsor and the schedule for
distribution of medications was entrusted
to a teammember whose assignmentwas to
dispensemedication.” Also, there was treat-
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Mertz 1989 (Continued)
ment with ointment versus capsules. The
outcome assessor was blinded. The care-
giver and the participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 22/75 participants were omitted in the
analysis: 9 were missing in the mupirocin
group (unclearwhy), 13weremissing in the
in the erythromycin group (unclear why)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was an imbalance for sex: 17/28 ver-
sus 10/25 boys (assessable participants) =
61% vs 40%. There was no compliance
data
Randomised? Low risk Quote: “Patientswere randomized between
the two treatment groups according to
a computer-generated schedule having a
block size of four.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients 3months of age and older
of either sex who had no more than seven
lesions of impetigo, cellulitis, abscesses, or
furunculosis were admitted to the study.”
Montero 1996
Methods Time NR; multicentre; Columbia Guatemala, Panama, South Africa; outpatients; range
of skin infections (including impetigo 95/200)
Participants • 6 months to 12 years
• M/F 101/94 (all participants)
• S.aureus 109/200, S.pyogenes 39/200
PNE
Interventions A: azithromycin susp 10 mg/kg/day once daily, 3 days
B: cefaclor susp 20 mg/kg/day in 3 doses, 10 days
Outcomes Outcomes of the trial
1) 10 to 14 days, cured + improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
82Interventions for impetigo (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Montero 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned
in a 1:1 ratio to receive either...” It is un-
clear whether participants and investigators
enrolling participants could foresee assign-
ment
Blinding (performance bias and detection
bias)
patient
High risk Quote: “This open, comparative study...”
Participants in both groups did not receive
the same administrations of study drugs
daily
Comment: The outcome assessor, care-
giver, and participant were probably not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/100 participants were omitted in the
analysis (all attritions): 2/100 in the
azithromycin group (due to loss of follow
up), 2/100 in the cefaclor group (due to
loss of follow up)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance for gen-
der, age, weight, height, and ethnic origin.
There were no compliance data
Randomised? Low risk Quote: “Patients were randomly assigned
in a 1:1 ratio to receive either...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Two hundred children...entered
this multicentre...”
Quote: “Patients were excluded from the
study if...shown in Table I.”
Moraes Barbosa 1986
Methods Time NR; Rio de Janeiro, Brasil; hospital outpatients; only impetigo
Participants • Newborns, age 3 to 14 days, average 11 days
• M/F 25/23
• S.aureus 100% (required for inclusion)
Interventions 4 arms:
A: sodium fusidate ointment 2%, 3 td, 10 days
B: chloramphenicol ointment, 3 td, 10 days
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Moraes Barbosa 1986 (Continued)
C: neomycin/bacitracin ointment, 3 td, 10 days
D: erythromycin oral 50 mg/kg/day, in 4 dd, 10 days
Outcomes Outcomes of the trial
1) 7 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
High risk Oral versus topical treatment. The out-
come assessor, caregiver, and participant
were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All 48 participants were analysed (see table
2).
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no differences for sex. No other
characteristics were reported. There were
no compliance data
Randomised? Low risk Quote: “Estes foram divididos aleatoria-
mente em quatro grupos de 12.” [They
were randomly divided in 4 groups of 12.]
Were both inclusion and exclusion criteria
specified?
High risk Quote: “Quarenta e oito recem-nascidos
entre tres e 14 dias de idade, portadores
de impetigo estafilococico sem tratamento
topica ou oral anterior, foram incluidos
neste estudo.” [40 and 8 neonates between
3 and 14 days old, who were carriers of im-
petigo stafylococcus without previous top-
ical or oral treatment, had been enclosed in
this study.] No exclusion criteria was spec-
ified
84Interventions for impetigo (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Morley 1988
Methods Time NR; Plymouth/Bristol, UK; general practice; range of skin infections (including
impetigo 89/354)
Participants • 1 to 92 years, average 33 years (all participants)
• M/F 162/192 (all participants)
• S.aureus 119/344, S.pyogenes 15/344, both 25/344 (all participants)
PNE
Interventions A: fusidic acid ointment 2%, 3 td, up to 7 days
B: mupirocin ointment 2%, 3 td, up to 7 days
Outcomes Outcomes of the trial
1) 6 to 8 days, excellent/good
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “On entry, patients were allocated
at random to receive one or other treat-
ment, tubes of the ointment beingprovided
in plain sealed numbered containers so that
the investigator was unaware of the treat-
ment given.”
Comment: This was probably done.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “On entry, patients were allocated
at random to receive one or the other treat-
ment, tubes of the ointment beingprovided
in plain sealed numbered containers so that
the investigator was unaware of the treat-
ment given.”
Comment: The participants were probably
blinded because the tubes were plain sealed.
The outcome assessor was blinded. It is un-
clear whether the caregiver was blinded (it
is unclear if the outcome assessor was also
the caregiver)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/354 participants were omitted in the
analysis: 0/191 in the sodium fusidate
group, 0/163 in the mupirocin group.
Therapy was withdrawn in only 2 cases - 1
in each treatment group
85Interventions for impetigo (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Morley 1988 (Continued)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was baseline comparison for sex, age,
and severity. There were no compliance
data
Randomised? Low risk Quote: “On entry, patients were allocated
at random to receive one or other treat-
ment.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “The study involved 354 patients
with acute superficial skin sepsis amenable
to therapy with a topical antibiotic.”
Quote: “Patients who...were excluded.”
Quote: “...were also exclusion factors.”
Nolting 1988
Methods Time NR; Münster, Germany; outpatients; range of skin infections (including impetigo
66/80)
Participants • 1 to 65 years, average 24 years
• M/F 35/31
• S.aureus 41/66, GABHS 8/66, both 17/66
PE
Interventions A: sulconazole nitrate cream 1%, 2 td, 14 days
B: miconazole nitrate cream 2%, 2 td, 14 days
Outcomes Outcomes of the trial
1) 7 days/14 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “When patients enrolled in the
trial, they were allocated, according to a
computer-generated randomization code,
to receive either...”
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...double-blind, parallel compara-
tive study”. It is unclear if, and how, the
outcome assessor, caregiver, andparticipant
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Nolting 1988 (Continued)
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/80 participants were omitted in the anal-
ysis: 0/40 in the sulconazole group, 0/40 in
the miconazole group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk The proportion of micro-organisms iso-
lated at admission differs between groups
(19 vs 6 for streptococcus, 53 vs 71 for S.
aureus). There were no compliance data.
Randomised? Low risk Quote: “...according to a computer-gener-
ated randomization code...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patients...were admitted to the
trial.”
Quote: “...were excluded from the trial.”
Oranje 2007
Methods 2005; Canada, Costa Rica, France, Germany, India, The Netherlands, Peru, Poland,
South Africa; outpatients; only impetigo
Participants • 9 months to 84 years
• M/F 278/239
• S. aureus 341/517, S. pyogenes 137/517
Interventions A: topical retapamulin 1% 2 td for 5 days
B: topical sodium fusidate 2% 3 td for 7 days
Outcomes Outcomes of the trial
1) Cure or improvement after 7 (retapamulin) or 9 days (sodium fusidate)
Notes Randomisation was 2:1.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This was not reported.
Allocation concealment (selection bias) Low risk Quote: “...predetermined, center-based 2:
1 schedule using the telephone-based inter-
active, central Registration andMedication
Ordering System.”
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Oranje 2007 (Continued)
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...observer-blinded...”
Quote: “...helped protect investigator
blinding.”
Quote: “To maintain observer blinding...
” Participants in both groups did not re-
ceive the same administrations of study
drugs daily. Participants were not blinded,
the outcome assessor was blinded, and the
blinding of the caregiver is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk 41/519 participants were missing data in
both groups: 26/346 in the retapamulin
group (26 prematurely discontinued, of
which 8 had disease progression, 8 were
lost to follow up, 1 had adverse events, 1
through lack of efficacy, 1 through proto-
col violation, 1 through potential conflicts
of interest, 3 through ’other’), 15/172 in
the sodium fusidate group (15 prematurely
discontinued, of which 6 had disease pro-
gression, 1 was lost to follow up, 1 through
subject decision [participant decision?], 3
had adverse events, 1 through lack of ef-
ficacy, 3 through ’other’), 1/519 were not
included in the analysis
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance. Compli-
ance was comparable.
Randomised? Low risk Quote: “This was a randomised...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Subjects were included if...”
Quote: “Subjects were excluded if...”
Pruksachat 1993
Methods December 1988 to November 1990; Chiang Mai, Thailand; outpatients; only impetigo
Participants • 1 months to 8 years, median 3.5 years
• M/F 64/46 (all participants)
• S. aureus 77/110
PE
Interventions A: penicillin V potassium 50 mg/kg/day in 4 doses, 7 days
B: cloxacillin sodium 50 mg/kg/day in 4 doses, 7 days
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Pruksachat 1993 (Continued)
Outcomes Outcomes of the trial
1) 7 days, cure
Notes Bullous and non-bullous impetigo.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
High risk Thiswas notmentioned in the article: If the
outcome assessor, caregiver, or participant
was not blinded, he or she is likely to cause
bias. All 3 were probably not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 20/110 participants were omitted in the
analysis: 45 were treated in the penicillin
group and 45 were in the cloxacillin group
(9 were unavailable for follow-up and 11
were negative to culture - not specified per
group)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no baseline characteristics per
group. There were no compliance data
Randomised? Low risk Quote: “Participants were randomly as-
signed to receive either...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children... were invited to partic-
ipate in the study.”
Quote: “Inclusion criteria included...”
Rice 1992
Methods April to November 1989; Baltimore, USA; outpatients and general practice; only im-
petigo
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Rice 1992 (Continued)
Participants • 3 months to 16 years
• MF 53/30
• Culture only in case of therapy failure
PNE
Interventions A: erythromycin ethynyl succinate 40 mg/kg/day in 4 doses, 10 days
B: mupirocin ointment 2%, 3 td, 10 days
Outcomes Outcomes of the trial
1) 9 to 11 days, cure/improved/failure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
High risk Quote: “In any clinical trial that is not
blinded...” Also, oral versus topical treat-
ment. The outcome assessor, caregiver, and
participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/93 participants were omitted in the
analysis. The following were specified: 4/
46 in the erythromycin group (4 did not re-
turn for follow-up), 6/47 in the mupirocin
group (4 did not return for follow-up, 2
were excluded from completing the proto-
col, 1 had cellulites develop within a few
hours after entry into the study, 1 whose
primary provider added an oral antibiotic
to the treatment regimen on day 3 of ther-
apy even though the participant’s condition
was improving)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Low risk The baseline characteristics were compara-
ble. Compliance was good and comparable
(table 6)
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Rice 1992 (Continued)
Randomised? Low risk Quote: “Children were randomly assigned
to the two study groups.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “All children... were invited to par-
ticipate.”
Quote: “Exclusion criteria included...”
Rist 2002
Methods Time NR; USA; outpatients; secondary impetigo (all eczema)
Participants • 9 to 87 years
• M/F 87/72
• S. aureus 74/159, S. pyogenes 0/159
Interventions A: topical mupirocin 2% 3 td + oral placebo for 10 days
B: oral cephalexin 250 mg 4 td + topical placebo for 10 days
Outcomes Outcomes of the trial
1) Cured or improved after 12 to 13 days
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “...double-blind, double-dummy,
parallel-group trial...” The outcome as-
sessor, caregiver, and participant were all
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 33/159 (> 20%) participants did not com-
plete the study (not specified per group).
All 159 were in the ITT analysis. Partici-
pants whose outcome was indeterminable
were considered failures. This may have in-
troduced bias
Selective reporting (reporting bias) Unclear risk This was unclear.
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Rist 2002 (Continued)
Other bias Unclear risk Quote: “Compliance was similar for both
groups.”
Quote: “The mean SIRS scores were 20.5
for the mupirocin group and 19,1 for the
cephalexin group (P = 0.09).” There was an
imbalance for sex
Randomised? Low risk Quote: “In this randomized...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Patientswere eligible for entry into
the trial if...”
Quote: “Patients were excluded from the
study if...”
Rodriguez-Solares 1993
Methods Time NR; multicentre; Costa Rica, Guatemala, Panama, Venezuela; outpatients; range
of skin infections (including impetigo 39/118)
Participants • 2 to 12 years, mean 5 years
• M/F NR
• S. aureus 69/118, S. pyogenes 9/118 (all participants)
PNE
Interventions 3 arms:
A: azithromycin 10 mg/kg/day (max. 500), once daily, 3 days
B: dicloxacillin12.5 to 25 mg/kg/day in 4 doses, 7 days (see notes)
C: flucloxacillin 500 to 2000 mg/day in 4 doses (see notes)
Outcomes Outcomes of the trial
1) 7 to 10 days, cure/improved/failure
Notes Randomisation was between azithromycin and, either, dicloxacillin or flucloxacillin; the
treatment groups dicloxacillin and flucloxacillin are combined in the results
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was provided.
Allocation concealment (selection bias) Unclear risk Insufficient information was provided.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “An open, randomized...” The out-
come assessor, caregiver, and participant
were not blinded
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Rodriguez-Solares 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant was missing (in which
group was not specified)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline comparison (or com-
pliance data) for the subgroup of impetigo
participants
Randomised? Low risk Quote: “An open, randomized...”
Quote: “60 were randomized to receive...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Children...were eligible to enter
this study.”
Quote: “Concurrent treatment with...was
not permitted.”
Quote: “The principal exclusion criteria
were...”
Quote: “Persons were also excluded if...”
Rojas 1985
Methods Time NR; Dominican Republic; hospital outpatients; only impetigo
Participants • Age and M/F ratio NR
• Bacterial results NR
PE
Interventions A: mupirocin ointment 2%, 3 td, 10 to 12 days
B: placebo/vehicle, 3 td, 10 to 12 days
Outcomes Outcomes of the trial
1) 7 to 12 days, cure/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
Unclear risk Quote: “The medication was numerically
labelled; the protocol ensured double-blind
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Rojas 1985 (Continued)
patient comparisons.” Bactroban ointment versus
vehicle ointment. It is not clear whether the
caregiver and outcome assessor are the same
person. There was unclear blinding of the
outcome assessor. The participant and the
caregiver were probably blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Fifty patients completed the study.
” The number of participants that entered
into the study was not specified
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline data. There were no
compliance data.
Randomised? Low risk Bactroban ointment versus vehicle oint-
ment - so, probably randomised but not
clearly described
Were both inclusion and exclusion criteria
specified?
High risk Quote: “Patientswith...entered in the study
sequentially.” No exclusion criteria was
specified
Ruby 1973
Methods Summer 1972; Dallas, USA; outpatients; only impetigo
Participants • Children, age NR
• M/F 43/59
• Only GABHS 33/102, both S. aureus and GABHS 57/102
PNE
Interventions 5 arms:
A: phenoxymethyl penicillin 40 to 60,000 units/kg/day in 3 doses + HS
B: phenoxymethyl penicillin 40 to 60,000 units/kg/day in 3 doses
C: HS + placebo
D: placebo, 3 td
E: bacitracin ointment, 2 td
Outcomes Outcomes of the trial
1) 5 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Ruby 1973 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Patients were assigned to one of
five treatment groups by a randomnumbers
list.”
Quote: “When more than one child from
an household was entered in the study, all
those children received the same treatment.
”
Comment: This was probably done.
Allocation concealment (selection bias) High risk Quote: “Patients were assigned to one of
five treatment groups by a randomnumbers
list.”
Quote: “When more than one child from
an household was entered in the study, all
those children received the same treatment.
” Investigators knew that children in the
same household got the same treatment
Blinding (performance bias and detection
bias)
patient
High risk Quote: “Phenoxymethyl penicillin suspen-
sion and placebo were coded as ’impecillin’
and ’tigocillin”’. Also, ointment versus sus-
pension. The bacitracin was not placebo-
controlled
Comment: The outcome assessor, care-
giver, and participant were probably not
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/102 participants were omitted in the
analysis: 0/20 in group A (penicillin
+ hexachlorophene), 2/20 in group B
(penicillin) (2 not streptococcal positive)
, 12/23 in group C (placebo) (6 not
streptococcal positive, 6 failed to return
for first follow-up), 4/17 in group D
(placebo+hexachlorophene) (2 not strepto-
coccal positive, 2 failed to return for first
follow-up;), 6/22 in group E (bacitracin)
(2 not streptococcal positive, 4 failed to re-
turn for first follow-up)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance. Compli-
ancewas good for penicillin (based onurine
test) but not reported for other therapy
Randomised? Low risk Quote: “Patients were assigned to one of
five treatment groups by a randomnumbers
list.”
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Ruby 1973 (Continued)
Were both inclusion and exclusion criteria
specified?
High risk Quote: “Children with... were excluded.”
Quote: “All patients were seen”.
Sutton 1992
Methods Time NR; UK; general practice (n = 20); only impetigo (only facial)
Participants • 1 months to 77 years, average 22 years
• M/F 84/93
• S. aureus 68/177
PNE
Interventions A: fusidic acid cream 3 td, 6 to 8 days
B: mupirocin ointment 3 td, 6 to 8 days
Outcomes Outcomes of the trial
1) 8 days, cure + improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was provided.
Allocation concealment (selection bias) Unclear risk Insufficient information was provided.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “Investigators were not aware of the
treatment given until the study was com-
pleted.”
Quote: “Treatmentwas allocated randomly
in a double-blind manner, medication
[was] dispensed in numbered, sealed con-
tainers.” There was unclear blinding of the
caregivers because it is unclear whether this
is the same person as the outcome assessor.
The participants were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 24/201 were omitted in the analysis: 93
were left in the fusidic acid group, 84 were
left in the mupirocin group (not further
specified). 177/201 were in the analysis. Of
the 24 participants who were not analysed
for efficacy, 20 returned for follow-up after
more than 8 days, 2 defaulted, and 2 vio-
lated the study protocol
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Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance. There
were no compliance data
Randomised? Low risk Quote: “Treatmentwas allocated randomly
in a double-blind manner.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “A total of 201 patients requiring
topical antibiotic treatment for facial im-
petigo were enrolled”
Quote: “Exclusion criteria were...”
Tack 1997
Methods 1992 July to 1993 August; multicentre; US; outpatients; range of skin infections (in-
cluding impetigo 225/394)
Participants • 0 to 13 years (median 5.4)
• M/F 217/197
• S. aureus 284/394 (all participants)
PE
Interventions A: cefdinir 7 mg/kg/day , 2 td, 10 days
B: cephalexin 10 mg/kg/day, 4 td, 10 days
Outcomes Outcomes of the trial
1) 7 to 14 day, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was provided.
Allocation concealment (selection bias) Unclear risk It is unclear whether participants and inves-
tigators enrolling participants could foresee
assignment
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...a multicenter, randomized, con-
trolled, investigator-blind...” Also, partic-
ipants in both groups did not receive the
same administrations of study drugs daily.
The outcome assessor was blinded. The
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Tack 1997 (Continued)
caregiver and participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “...number of patients excluded for
each reason comparable among groups.”
The proportion of participants not evalu-
able for reasons of non-compliance was un-
clear
Quote: “An intention-to-treat analysis was
also performed. This analysis counted as
failures all patients who had negative ad-
mission cultures or for whom follow-up in-
formation was not available.”
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance (sex, age,
race, infection type). There were no com-
pliance data
Randomised? Low risk Quote: “...a multicenter, randomized, con-
trolled, investigator-blind...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Pediatric patients...were eligible
for study entry.”
Quote: “Patients were prohibited from en-
tering the study if...”
Tack 1998
Methods January to December 1992; multicentre; USA; outpatients, range of skin infections
(including impetigo 62/952)
Participants • 13 to 88 years
• M/F 564/388 (all participants)
• S. aureus 308/382 (all participants)
PE
Interventions A: cefdinir caps 300 mg, 2 td, 10 days
B: cephalexin caps 500 mg, 4 td, 10 days
Outcomes Outcomes of the trial
1) 7 to 16 days, cure/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Insufficient information was provided.
Allocation concealment (selection bias) Unclear risk Insufficient information was provided.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “This was a double-mask, compar-
ative, multicenter study.”
Quote: “Matched placebo capsules were
dispensed appropriately to maintain study
masking.” It is not clear who was blinded
(and how). It is unclear whether the out-
come assessor and caregiver were blinded.
The participants were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk 952 randomised participants.
Quote: “Of these, 178 cefdinir patients and
204 cephalexin patients were considered
microbiologically assessable and were in-
cluded in the efficacy analyses.” > 20% not
included in efficacy analysis because they
were not assessed or the study drug was not
taken as prescribed (table III). There was
no intention-to-treat analysis
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Groups were similar at baseline (table II),
though not specified for impetigo partici-
pants. There were no compliance data
Randomised? Low risk Quote: “Patients were randomized 1:1 to
receive...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Eligible patients were...”
Quote: “Exclusion criteria included...”
Tamayo 1991
Methods Time NR; Mexico; outpatients; only impetigo
Participants • 6 months to 12 years, average 4 years 8 months
• M/F 14/16
• S. aureus 18/30, S. pyogenes 4/30, both 1/30
PE: not clear
Interventions A: rifamycin spray, 2 td, 7 days
B: mupirocin ointment 2%, 2 td, 7 days
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Tamayo 1991 (Continued)
Outcomes Outcomes of the trial
1) 1 week, cure/improved
Notes Both primary (n = 17) and secondary (n = 13) impetigo participants were studied
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “...open trial”. Also, spray versus
ointment. The caregiver, outcome assessor,
and participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0/30 participants were omitted in the anal-
ysis: 0/15 in the rifamycin group, 0/15 in
the mupirocin group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was no baseline imbalance. There
were no compliance data
Randomised? Low risk Quote: “...fueron asignados al azar.” [...
were assigned at random.]
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “En este estudio únicamente se in-
cluyeron pacientes con lesiones localizades,
con área no mayor de 10 cm² Los criterios
de exclusión fueron niños con lesiones con
un tiempo de evolución mayor de un mes.”
[In this study, patients were only included
if the lesions were smaller than 10 cm². Ex-
clusion criteria were children with lesions
present longer than 1 month]
Tassler 1993
Methods Time NR; multicentre; Europe and South America; hospital-admitted and outpatients;
range of skin infections (including impetigo 42/172)
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Participants • Age 18 to 99 years
• M/F 159/125 (all part)
• S. aureus 58% (all participants)
PE
Interventions A: fleroxacin 400 mg, 1 td, 7 to 21 days
B: amoxicillin/clavulanic acid tablets 500/125 mg, 3 td, 7 to 21 days
Outcomes Outcomes of the trial
1) 7 days, cure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available
Blinding (performance bias and detection
bias)
patient
High risk Quote: “...open-label”. Participants in both
groups did not receive the same adminis-
trations of study drugs daily. Also, investi-
gators enrolling participants could possibly
foresee assignment. The outcome assessor,
caregiver, and participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Not only impetigo - it was not specified
how many impetigo participants were ran-
domised and included. 27 were analysed in
the fleroxacin group, 15 were analysed in
the amoxicillin/clavulanic group. Further
data was not specified for impetigo par-
ticipants. Not all participants were assess-
able for the efficacy analysis, but it was not
stated how many
Selective reporting (reporting bias) Unclear risk This was not unclear.
Other bias Unclear risk There was no baseline imbalance. There
were no compliance data
Randomised? Low risk Quote: “This study was designed as a
prospective, randomized, open label...”
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Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Inpatients or outpatients of either
sex were eligible for inclusion in the study
if...”
Quote: “Exclusion criteria were...”
Vainer 1986
Methods March 1982 to January 1984; Denmark; general practice; only impetigo
Participants • Age 1 to 77, average 11 years
• M/F 71/57
• No bacterial culture done
PNE
Interventions 3 arms:
A: fusidic acid cream 2%
B: tetracycline/polymyxin B ointment
C: neomycin/bacitracin ointment
Outcomes Outcomes of the trial
1) 1 week, cure/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “Undersøgelsen var således blindet
for lægen, men ikke for patienten.” [The
study was blinded for the doctor, but not
for the patient.] The outcome assessor and
caregiver were blinded. Participants were
not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/134 participants were not included in the
analysis: unknown group assignment, rea-
sons were given
Selective reporting (reporting bias) Unclear risk This was unclear.
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Other bias Unclear risk There was no baseline imbalance for sever-
ity. The usedmedication is in table 2. There
were no compliance data
Randomised? Low risk Quote: “...randomiseringsnummer.” [...
randomisation number.]
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “For at indgå i study skulle pa-
tienterne have klinisk verificeret impetigo”;
“Udelukket var patienter med impetigenis-
erede eksemer, patienter med...” [Patients
were eligible if they had clinical verified
impetigo; Excluded were patients with im-
petiginised eczema and patients with...]
Wachs 1976
Methods 1974; multicentre; USA; outpatients; only impetigo (secondary)
Participants • Age/sex NR
• S. aureus 62/79
PNE
Interventions 3 arms:
A: betamethasone valerate cream, 3 td
B: gentamycin cream, 3 td
C: betamethasone + gentamycin cream, 3 td
Outcomes Outcomes of the trial
1) 3 weeks, excellent result
Notes Secondary impetigo (impetiginised atopic dermatitis)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available
Blinding (performance bias and detection
bias)
patient
Low risk Quote: “...precautions being observed to
preserve the blinding of both patients
and therapists.” Also, participants in both
groups received the same administrations
of study drugs daily. The outcome assessor,
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Wachs 1976 (Continued)
caregiver, and participant were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/83 participants were omitted in the anal-
ysis (not further specified)
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was a baseline comparison for sever-
ity and no imbalance. There were no com-
pliance data
Randomised? Low risk Quote: “Patients under the care of an in-
dividual investigator were randomly as-
signed.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “All patients enrolled were clini-
cally judged to have moderate to severe im-
petiginized...”
Quote: “In order to be accepted for the
study...”
Quote: “ ...were excluded.”
Wainscott 1985
Methods Time NR; London, UK; outpatients and general practice; range of skin infections (in-
cluding impetigo 16/39)
Participants • Age NR
• M/F 25/14 (all participants)
• S. aureus 31/48 (all participants)
PE: not clear
Interventions A: mupirocin ointment 2%, 2 td, 7 to 14 days
B: chlortetracycline cream 3%, 2 td, 7 to 14 days
Outcomes Outcomes of the trial
1) 7 days, cure/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
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Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “Thirty-nine patients were entered
in a randomized, observer-blind trail.”
Quote: “...but the medications were pack-
aged identically and not opened in the pres-
ence of the physician.” The outcome asses-
sor and caregiver were blinded. Participants
were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/39 participants were omitted in the anal-
ysis: 2/22 in the mupirocin group, 1/17 in
the chlortetracycline group. These 3 were
excluded from the analysis of results as they
received systemic antibiotics for other in-
fections while in the study
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There was a baseline imbalance for age (all
infants were in the Bactroban group). This
was not specified for impetigo. There were
no compliance data
Randomised? Low risk Quote: “Thirty-nine patients were entered
in a randomized, observer-blind trail.”
Were both inclusion and exclusion criteria
specified?
High risk Quote: “Patients with lesions suitable for
treatment with a topical antibiotic were en-
tered in the study.” No exclusion criteria
was specified
Welsh 1987
Methods Time NR; Monterrey, Mexico; outpatients; range of skin infections (including impetigo
15/60)
Participants • Age NR
• M/F 32/28
• S. aureus 47/50
PNE
Interventions A: mupirocin ointment 2%, 3 td, 5 to 10 days
B: ampicillin 50 mg, 4 td, 5 to 10 days
Outcomes Outcomes of the trial
1) 10 days, cure/improved
Notes -
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Welsh 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
High risk Quote: “...in an open trial.” Thereby, the
participants in both groups did not receive
the same administrations of study drugs
daily. The outcome assessor, caregiver, and
participant were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10/60 participants were omitted in the
analysis: 5/32 in the mupirocin group were
lost to follow up, 5/28 in the ampicillin
group were lost to follow up. These 10 par-
ticipants were not analysed
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “Patient characteristics were similar
in both treatment group in terms of sex,
age, and weight.” Table I shows no baseline
imbalance for severity. There were no com-
pliance data
Randomised? Low risk Quote: “A randomized clinical trial...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “...outpatients with primary and
secondary skin infections.”
Quote: “Patients were excluded from entry
into the trial on the basis of...”
White 1989
Methods 1985 to 1987; UK; general practice; range of skin infections (including impetigo 155/
390)
Participants • Age 11 months to 84 years
• M/F NR
• S. aureus 43% (all participants)
PNE
Interventions A: mupirocin ointment 2%, 2 td, 7 days
B: fusidic acid ointment 2%, 3 td, 7 days
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Outcomes Outcomes of the trial
1) 7 days, cure/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Low risk Quote: “...and patients were randomised to
receive treatment with either...”
Quote: “For this purpose, a code was de-
signed in blocks of six...”
Quote: “The tubeswere supplied in a sealed
box labelled with the patient’s number.
Thereby the observer did not know which
antibiotic a patient was receiving.”
Comment: This was probably done.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “Four plain tubes containing the
preparationswere supplied for each patient.
These were labelled with instructions for
use but the name of the antibioticwas omit-
ted. Mupirocin was to be applied twice
daily and sodium fusidate thrice daily.”
Quote: “The tubeswere supplied in a sealed
box labelled with the patient’s number.
Thereby the observer did not know which
antibiotic a patient was receiving.” The
outcome assessor was blinded. The care-
giver and participant were probably not
blinded because they did not receive the
same administrations of study drugs daily
Incomplete outcome data (attrition bias)
All outcomes
High risk 23/413 participants were omitted in the
analysis: 12/275 in the mupirocin group
(8 failed to attend for assessment, 1 with-
drew due to revised diagnosis, 3 were pre-
scribed antibiotics for reasons other than
lack of efficacy), 11/138 in the sodium
fusidate group (3 failed to attend for assess-
ment, 1 withdrew due to revised diagno-
sis, 2 were prescribed antibiotics for reasons
other than lack of efficacy, 4 due to non-
compliance, 1 due to inadequate data). <
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20% dropouts, but reasons were not bal-
anced between the groups
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk Quote: “There was a similar distribution
of type and severity of infection between
the two treatment groups”. There were no
compliance data
Randomised? Low risk Quote: “...observer-blind randomised
multi-centre clinical trial.”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Any patient with primary or sec-
ondary skin infection, other than...was eli-
gible for entry.”
Quote: “Patients were excluded if...”
Wilkinson 1988
Methods Time NR; Quebec, Canada; outpatients; range of skin infections (including impetigo
10/50)
Participants • Age/sex NR
• S. aureus 18/50 (all participants)
PE: not clear
Interventions A: mupirocin 2%, 3 td, 7 days
B: polymyxin B-neomycin (Neosporin), 3 td, 7 days
Outcomes Outcomes of the trial
1) 7 days, cure/improved
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information was available.
Allocation concealment (selection bias) Unclear risk Insufficient information was available.
Blinding (performance bias and detection
bias)
patient
Unclear risk Quote: “...double-blind fashion.” It was
unclear how, and if, the outcome assessor,
caregiver, and participant were blinded
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Incomplete outcome data (attrition bias)
All outcomes
Low risk There were 0/10 missing impetigo partici-
pants: 0/4 missing in the mupirocin group,
0/6 missing in the neosporin group
Selective reporting (reporting bias) Unclear risk This was unclear.
Other bias Unclear risk There were no baseline characteristics.
There were no compliance data
Randomised? Low risk Quote: “...were randomly divided into...”
Were both inclusion and exclusion criteria
specified?
Low risk Quote: “Fifty patients who appeared at the
dermatologic clinic with primary and sec-
ondary skin infections of...were randomly
divided...”
Quote: “...were excluded from the trial.”
all participants = data from all participants in the study, not just the impetigo participants
Abbreviations:
approx = approximately
GABHS = Group A beta Hemolytic Streptococcus
HS = hexachlorophene scrubs
M/F = male/female
NR = not reported
PE = participants excluded from study when culture negative
PNE = participants not excluded
SE = side-effects
susp = suspension
td = times daily
m = months
dd = daily doses
ds = days
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alavena 1987 Randomisation was inadequate.
Anonymous 1998 Results were not separately described for impetigo participants: no randomisation
Arata 1983 Randomisation was inadequate (serial allocation).
Arata 1994 The results were not separately described for impetigo participants
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Arosemena 1977 The results were not separately described for impetigo participants: only 6/343 participants had impetigo
Azimi 1999 The results were not separately described for impetigo participants
Baldwin 1981 The same drug was compared.
Ballantyne 1982 The results were not separately described for impetigo participants: no randomisation
Bastin 1982 The results were not separately described for impetigo participants
Bernard 1997 The results were not separately described for impetigo participants (requested, but no reply)
Bin Jaafar 1987 No participants had impetigo ( “pyoderma”).
Burnett 1963 There was no randomisation.
Cassels-Brown 1981 The design was unacceptable (no RCT).
Colin 1988 The results were not separately described for impetigo participants
Cordero 1976 There was only 1 impetigo participant.
De Waard 1967 There was no randomisation: 2 arms with the same active drug (though different mode of administration)
Dillon 1970 There was no randomisation.
Dillon 1979a The results were not separately described for impetigo participants
Drehobl 1997 The results were not separately described for impetigo participants (requested, but no reply)
el Mofty 1990 The results were not separately described for impetigo participants
Esterly 1970 There was no randomisation.
Faingezicht 1992 The results were not separately described for impetigo participants
Fedorovskaia 1989 Randomisation was inadequate.
Fleisher 1983 The results were not separately described for impetigo participants
Forbes 1952 The same drug was compared.
Free 2006 No participants had impetigo (communication: Nicole E. Scangarella)
Gentry 1985 The results were not separately described for impetigo participants
Gibbs 1987 All impetigo participants received the same treatment.
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Golcman 1997 The results were not separately described for impetigo participants (requested, but no reply)
Goldfarb 1987 The results were not separately described for impetigo participants
Gooch 1991 The results were not separately described for impetigo participants
Hanfling 1992 The results were not separately described for impetigo participants
Harding 1970 There was 1 drug (flucloxacillin) in 2 doses: the results for impetigo participants were not separately described
Heskel 1992 The results were not separately described for impetigo participants
Jacobs 1992 The results were not separately described for impetigo participants
Jennings 1999 There was only 1 impetigo participant.
Jennings 2003 The results were not separately described for impetigo participants (requested, but no reply)
Keeny 1979 The results were not separately described for impetigo participants
Kotrajaras 1973 The results were not separately described for impetigo participants
Kumakiri 1988 There was only 1 impetigo participant.
Kumar 1988 No participants had impetigo: 2 forms of the same drug.
Lassus 1990 The results were not separately described for impetigo participants
Lentino 1984 There was only 1 impetigo participant.
Levenstein 1982 The results were not separately described for impetigo participants
Lewis-Jones 1985 The results were not separately described for impetigo participants
Linder 1978 The results were not separately described for impetigo participants
Linder 1993 The results were not separately described for impetigo participants
Lipets 1987 No comparison was made.
Liu 1986 No participants had impetigo (impetigo herpetiformis).
MacKenna 1945 Randomisation (serial allocation) was inadequate.
Macotela-Ruiz 1988 The results were not separately described for impetigo participants (requested, but no reply)
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Mallory 1991 The results were not separately described for impetigo participants
Manaktala 2009 The results were not separately described for impetigo participants
McCarty 1992 The results were not separately described for impetigo participants
McMillan 1969 The results were not separately described for impetigo participants
Milidiú d Silva 1985 The results were not separately described for impetigo participants
Nakayama 1983 The results were not separately described for impetigo participants, and it was not an RCT
Neldner 1991 The results were not separately described for impetigo participants
Nichols 1997 The results were not separately described for impetigo participants
Nicolle 1990 The results were not separately described for impetigo participants
Nolting 1992 No participants had impetigo (pyoderma).
Orecchio 1986 The results were not separately described for impetigo participants
Pakrooh 1978 No participants had impetigo.
Palazzini 1993 The results were not separately described for impetigo participants
Parish 1984 The results were not separately described for impetigo participants
Parish 1991 The results were not separately described for impetigo participants
Parish 1992 The results were not separately described for impetigo participants
Parish 1997 The results were not separately described for impetigo participants
Parish 2000 The results were not separately described for impetigo participants (requested, but no data available)
Parish 2006 No participants had impetigo (communication: Nicole E. Scangarella)
Park 1993 There was no randomisation (personal communication: Seungsoo Sheen)
Pien 1983 The results were not separately described for impetigo participants
Powers 1991 There were no separate results for clinical cure.
Powers 1993 There were only 2 impetigo participants.
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Pusponegoro 1990 There was only 1 impetigo participant,
Risser 1985 The results were not separately described for impetigo participants
Saenz 1985 The results were not separately described for impetigo participants
Salzberg 1972 There was only 1 impetigo participant.
Schupbach 1992 The results were not separately described for impetigo participants
Schwartz 1996 There was only 1 impetigo participant.
Smith 1985 The results were not separately described for impetigo participants
Smith 1993 There was only 1 impetigo participant.
Sobye 1966 The results were not separately described for impetigo participants
Stevens 1993 There were 5 participants with “pyoderma”.
Tack 1991 The results were not separately described for impetigo participants, and the same drug was compared
Török 2004 The same drug was compared.
Urbach 1966 No randomisation was described.
Van der Auwera 1985 No participants had impetigo.
Villiger 1986 The results were not separately described for impetigo participants
Wachs 1992 The results were not separately described for impetigo participants
Wible 2003 The results were not separately described for impetigo participants (requested, but no reply)
Wolbling 1987 2 doses of 1 drug were compared.
Wong 1989 The results were not separately described for impetigo participants
Yura 1988 The results were not separately described for impetigo participants
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Characteristics of studies awaiting assessment [ordered by study ID]
Chen 2011
Methods This is an RCT.





Outcomes Primary outcomes of the trial
1) Improvement
Secondary outcomes of the trial
1) Complete resolution
Notes This is a result of the CSG searches that were run in August 2011.
It is not known how many participants were impetigo patients
Chosidow 2005
Methods This is an RCT.





Outcomes Outcomes of the trial
1) Cure
Notes This will be included when data on impetigo participants is provided
Davies 1945
Methods Please see the ’notes’ cell below.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes This is a result of the CSG searches that were run in August 2011
We were unable to obtain a copy of this trial.
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Ghosh 1995
Methods This is possibly an RCT.
Participants • 70 participants of different ages suffering from pyoderma, including infective dermatitis of which 30
participants had impetigo
Interventions Intervention
A: neem, haldi, sajina, and garlic oil (Nutriderm oil)
Control intervention
B: gentian violet
Outcomes Primary outcomes of the trial
1) Cure




Methods Please see the ’notes’ cell below.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes This paper was published in Spanish, and we were unable to obtain a copy
Kar 1988
Methods This is possibly an RCT.
Participants • 200 children suffering from various types of pyoderma, 94 of which had impetigo
Interventions Intervention
A: injection benzathine penicillin
Control intervention
B: oral sulphamoxole
Outcomes Outcomes of the trial
1) Cure after 1 and 2 weeks
Notes There did not appear to be separate results for impetigo.
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Kar 1996
Methods This is possibly an RCT.
Participants • 200 children aged 10 months to 12 years suffering from pyoderma
Interventions Intervention
A: 125 mg amoxicilin plus 30 mg clavulanate per 5 ml of suspension, equivalent to 20 mg amoxicillin/kg/day in 3
divided doses
Control interventions
B: amoxicillin 20 mg/kg/day in 3 divided doses
C: erythromycin 30 mg/kg/day in 4 divided doses
D: co-trimoxazole (8 mg trimethoprim + 40 mg sulfamethoxazole/kg/day) in 2 divided dosis
Outcomes Primary outcomes of the trial
1) Presence of S. aureus
Secondary outcomes of the trial
1) Cure
2) Adverse events
Notes It was not clear if pyoderma equated to impetigo.
Luby 2002
Methods This is an RCT.
Participants • 162 households in Pakistan
Interventions Intervention
A: 1.2% triclocarban-containing soap
Control intervention
B: an identically appearing placebo
Outcomes Outcomes of the trial
1) Impetigo incidence
Notes This is a result of the CSG searches that were run in August 2011
Menendez 2007
Methods This is possibly an RCT.
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Menendez 2007 (Continued)
Outcomes Primary outcomes of the trial
1) Clinical cure after possibly 6 days
Notes This paper was written in Spanish.
Motohiro 1992
Methods This is an RCT.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes This is a result of the CSG searches that were run in August 2011.
We were unable to obtain a copy of this trial.
Pierard-Franchimont 2008
Methods This is an RCT.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes This is a result of the CSG searches that were run in August 2011
We were unable to obtain a copy of this trial.
Sharquie 2000
Methods This is possibly an RCT.






Outcomes Primary outcomes of the trial
1) Cure after 7 to 10 days
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Methods This is an RCT.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes This is a result of the CSG searches that were run in August 2011
We were unable to obtain a copy of this trial.
Tong 2010
Methods This is a pilot study.
Participants • 13 participants with skin sores
Interventions Intervention
A: oral cotrimoxazole
B: intramuscular benzathine penicillin
Outcomes Primary outcomes of the trial
1) Resolution of skin sores
Notes Australian Trial Register: Is cotrimoxazole safe and efficacious for treatment of skin sores in Aboriginal children: a
pilot study
Published in the Journal of Pediatrics and Child Health 2010;46:131-133
Wang 1988
Methods This is possibly an RCT.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes We were unable to obtain a copy of this trial.
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Wang 1995
Methods This is possibly an RCT.
Participants Please see the ’notes’ cell below.
Interventions Please see the ’notes’ cell below.
Outcomes Please see the ’notes’ cell below.
Notes We were unable to obtain a copy of this trial.
Characteristics of ongoing studies [ordered by study ID]
ACTRN12609000858291
Trial name or title An open label randomised controlled trial to determine if 5 days of once-daily oral trimethoprim-sulfamethox-
azole or three days of twice-daily oral trimethoprim-sulfamethoxazole will lead to non-inferior cure rates
of impetigo compared to a single dose of intramuscular benzathine penicillin G (the current gold standard
treatment) in children living in remote Aboriginal communities between the age of 12 weeks to less than 13
years
Methods See title.
Participants Inclusion criteria of the trial
1. Age 12 weeks to less than 13 years at the time written consent is obtained
2. Diagnosis of purulent or crusted impetigo by criteria outlined in the Booklet “Recognising and Treating
Skin Conditions” (East ArnhemHealthy Skin Program (EAHSP), Menzies School of Health Research 2006)
3. A resident in 1 of the participating (Aboriginal) communities at the time of enrolment and intending to
stay in that community for the duration of the study (7 days post-randomisation)
Interventions Group 1: single dose intramuscular benzathine penicillin G - weight band-based dosing up to 900 mg (> 3
and < 6 kg = 225 mg; > 6 and < 10 kg = 337.5 mg; > 10 and < 15 kg = 450 mg; > 15 and < 20 kg = 675 mg;
> 20 kg = 900 mg)
Group 2: trimethoprim-sulfamethoxazole oral suspension 8 + 40 mg/kg (max 320 + 1600 mg) daily for 5
days
Group 3: trimethoprim-sulfamethoxazole oral suspension 4 + 20 mg/kg (max 160 + 800 mg) twice daily for
3 days
Outcomes Primary outcomes of the trial
1) The proportion of children successfully treated on day 7 after the commencement of treatment within
each of the respective groups. Successfully treated is defined as a child with impetigo which has been clinically
classified as sore either healed or improved by a person blinded to the allocated randomisation
Secondary outcomes of the trial
1) The proportion of children within each of the respective groups who are defined as being successfully
treated on day 2
2) Prevalence of Staphylococcus aureus (methicillin susceptible and methicillin resistant) and Group A Strep-
tococci per child at day 0, day 2, and day 7 within each treatment group as determined from impetigo swabs
collected at the respective time points
3) Effect of each treatment on the bacterial resolution of sores at days 2 and 7 as determined by impetigo
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ACTRN12609000858291 (Continued)
swabs collected at the respective time points
4) Prevalence of nasal carriage of Staphylococcus aureus at baseline and day 7 (including a comparison of the
prevalence of methicillin-resistant S. aureus at baseline and day 7)
5) Evidence of allergy or other reaction to the medication within 7 days of first administration as determined
by clinical observation and questioning of caregivers
Starting date 1st December 2009
Contact information Ross Andrews (ross.andrews@menzies.edu.au)
Menzies School of Health Research
PO Box 41096 Casuarina, 0811, NT, Australia
Notes Australian New Zealand Clinical Trial Registry: ACTRN12609000858291
CTRI/2008/091/000060
Trial name or title An Open Labelled, Double Arm, Randomized, Multicentric, Prospective And Comparative, Phase-III Trial
To Evaluate The Safety And Efficacy Of Fixed Dose Combination Of Ceftriaxone And Vancomycin Injection
Vs. Vancomycin Injection In Subjects With Various Bacterial Infections
Methods See above.
Participants Inclusion criteria of the trial
• All subjects aged between 18 and 70 years
• Diagnosed subjects of infectious disease (on clinical evaluation).
• Subjects willing to give informed consent
• Subject suffering from any of the following infections - lower respiratory tract infections, skin and skin
structure infections, endocarditic, bacterial meningitis and bone infection
Interventions See above.
Outcomes Primary outcomes of the trial
1) Compare the efficacy of a 3.0 g FDC of ceftriaxone and vancomycin injection vs 1.0 g vancomycin injection
in subjects with mild to severe bacterial infections
Secondary outcomes of the trial
1) Evaluate the safety of the test and comparative product
Starting date 8th April 2008
Contact information kundan.k@nexuscro.com
Notes It is unclear whether impetigo participants will be included
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NCT00202891
Trial name or title Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas
Methods This was to be a randomised, active-control trial.
End point classification - safety/efficacy study
Intervention model - parallel assignment
Masking - open-label
Primary purpose - treatment
Participants Inclusion criteria of the trial
• Participants of either sex, suffering from primary pyodermas requiring topical antibiotic therapy
without occlusive dressing, > = 6 years of age
• Written informed consent
Interventions See title.
Outcomes None were stated.
Starting date May 2007
Contact information Ragunandan Torsekar, MD, FCPS (Principal Investigator)
Rajiv Gandhi Medical College
Notes The current status of the trial is withdrawn (NCT00202891).
NCT00626795
Trial name or title Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic
Lesions (SITL)
Methods Quote: “This is an international, multicentre, prospective 3-arm parallel-group, phase II proof of concept
study comparing the efficacy and safety of 2 dosage regimens (BID 7 days and TID 7 days) of TD1414 2%
cream and 1 dosage regimen (BID 7 days) of Bactroban® (mupirocin) 2% cream in adults and children down
to 2 years of age with impetigo or SITL. Furthermore, an evaluation of the pharmacokinetics of TD1414
2% cream TID for 7 days will be performed. A total of 664 patients will be enrolled in a stepwise manner
according to age groups starting with the oldest age group.”
Participants See above.
Interventions See above.
Outcomes Primary outcomes of the trial
1) Clinical cure at end of treatment according to investigator’s assessment
Secondary outcomes of the trial
1) Clinical cure at follow-up according to investigator’s assessment
2) Clinical cure at end of treatment and follow-up according to investigator’s assessment
3) Bacteriological cure at end of treatment and follow-up
Starting date February 2008
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NCT00626795 (Continued)
Contact information Almena L Free, MD (Principal Investigator)
Anniston Medical Clinic
Anniston, Alabama, United States 36207
Notes www.clinicaltrials.gov
NCT00852540
Trial name or title A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and
Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-




Outcomes Primary outcomes of the trial
1)Number of participants achieving clinical response at follow-upwhohadmethicillin-resistant Staphylococcus
aureus (MRSA) as a baseline pathogen
Secondary outcomes of the trial
1) Number of participants achieving microbiological response at follow-up who had MRSA as a baseline
pathogen
2) Number of participants with clinical response at follow-up
3) Number of participants who achieved microbiological response at follow-up who had a baseline pathogen
4) Number of participants with the indicated clinical outcome at the end of therapy who had MRSA as a
baseline pathogen
5) Number of participants with the indicated microbiological outcome at the end of therapy who had MRSA
as a baseline pathogen
6) Number of participants with the indicated clinical outcome at the end of therapy
7) Number of baseline pathogens with the indicated microbiological outcome at the end of therapy
8) Number of participants with therapeutic response at follow-up
9) Mean scores on the skin infection rating scale at visits 1, 2, 3, 4, and 5
10) Mean wound size at visits 1, 2, 3, 4, and 5
Starting date April 2009
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NCT00986856
Trial name or title A Phase IV StudyComparingClinical and Bacteriological Efficacy of Fucidin®CreamWith Fucidin®Cream
Vehicle in the Treatment of Impetigo in Paediatric Patients
Methods This is a randomised, placebo-controlled trial.
End point classification - safety/efficacy Study
Intervention model: parallel assignment
Masking - double-blind (subject, investigator)
Primary purpose - treatment
Participants Inclusion criteria of the trial
• Participants with a clinical diagnosis of impetigo
• Participants aged 2 to 11 years
• Participants of either sex
• Participants whose parent(s) has/have provided written consent
• Participants with a severity score of 1 for at least 1 of the following signs: pustules/infected bullae,
erythema, or infiltration/induration
Interventions A: Fucidin® cream versus Fucidin® cream vehicle
Outcomes Primary outcomes of the trial
1) The proportion of participants with clinical success (marked improvement or completely cleared) and
bacteriological success (eradication) at end of treatment (EOT)
Secondary outcomes of the trial
1) The proportion of participants with clinical and bacteriological success at visit 2 and 3, and at EOT
2) The actual change in Total Severity Score from baseline to end of treatment
3) The distribution of individual sign scores at end of treatment
Starting date May 2004
Contact information Inga Odenholt (Principal Investigator)
Malmö University Hospital
Notes Infomation was obtained from clinicaltrials.gov. Information was requested in August 2010
NCT01171326
Trial name or title A Randomized, Parallel-group, Double Blind, Clinical Trial, to Asses the Safety and Efficacy of Topically
Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo
Methods This is a randomised, parallel-group, double (Investigator, participant)-blind, comparative dose range-finding
clinical trial
Participants Inclusion criteria of the trial
• Participants with clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering
impetigo
• Participants 2 years of age or older and in general good health
• Participants with no less than 2 lesions and no more than 7 lesions (area 0.5 x 0.5 cm)
• No known medical conditions that, in the Investigator’s opinion, could interfere with study
participation
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NCT01171326 (Continued)
• Participant/participant’s guardian (in the case of children) willing and able to comply with all
requirements of the protocol
• Participant/participant’s guardian willing and able to give written informed consent prior to
participation in the study
Interventions The study will involve 2 treatment groups.
A: Eligible participants will be randomised to receive either FXFM244 - 1% or FXFM244 - 4% in a blinded
fashion. Participants will be treated twice daily for 7 days. Following the screening period and baseline visit,
study subjects will return at days 3, 7 and 14. At each visit, participants will be evaluated via lesion count,
global assessment tolerability, and safety
Outcomes Primary outcomes of the trial
1) Decrease in lesion count 7 days
Secondary outcomes of the trial
1) The severity of the overall impetigo condition will be measured at baseline and at all follow-up visits. The
severity will be assessed and graded based on the scales for Investigator’s Global Assessment and bacteriological
testing (days 3, 7, and 14)
Starting date August 2010
Contact information Foamix Ltd.
Lev Yasmin Clinic
Natanya, Israel
Notes This study is probably not eligible for inclusion as 2 dosages of the same drug are used
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D A T A A N D A N A L Y S E S
Comparison 1. Non-bullous impetigo: topical (Top) antibiotic (Ab) vs placebo (P)




participants Statistical method Effect size
1 Cure/improvement 6 575 Risk Ratio (M-H, Random, 95% CI) 2.24 [1.61, 3.13]
1.1 Mupirocin 3 173 Risk Ratio (M-H, Random, 95% CI) 2.18 [1.58, 3.00]
1.2 Fusidic acid 1 156 Risk Ratio (M-H, Random, 95% CI) 4.42 [2.39, 8.17]
1.3 Bacitracin 1 36 Risk Ratio (M-H, Random, 95% CI) 3.71 [0.16, 85.29]
1.4 Retapamulin 1 210 Risk Ratio (M-H, Random, 95% CI) 1.64 [1.30, 2.07]
Comparison 2. Non-bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 14 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Mupirocin vs rifamycin 1 17 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.96, 3.07]
1.2 Mupirocin vs neomycin 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.98, 1.71]
1.3 Mupirocin vs bacitracin 1 16 Risk Ratio (M-H, Fixed, 95% CI) 2.57 [0.97, 6.80]
1.4 Mupirocin vs
chlortetracycline
1 14 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.78, 1.59]
1.5 Mupirocin vs polymyxin
B/neomycin
1 8 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.56, 2.01]
1.6 Fusidic acid vs neomycin/
bacitracin
1 84 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.66, 1.27]
1.7 Fusidic acid vs
tetracycline/polymyxin B
1 87 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.75, 1.52]
1.8 Retapamulin vs fusidic
acid
1 517 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [1.00, 1.11]




1 43 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [0.89, 4.76]
1.11 Gentamycin vs neomycin 1 128 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.03, 1.98]
1.12 Mupirocin vs fusidic acid 4 440 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.95, 1.11]
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Comparison 3. Non-bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 15 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Mupirocin vs
erythromycin
10 581 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [1.01, 1.13]
1.2 Mupirocin vs dicloxacillin 1 53 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.15]
1.3 Mupirocin vs cephalexin 1 17 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.66, 1.37]
1.4 Mupirocin vs ampicillin 1 13 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [0.65, 4.87]
1.5 Bacitracin vs erythromycin 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.22, 1.11]
1.6 Bacitracin vs penicillin 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.04, 3.25]
1.7 Bacitracin vs cephalexin 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.14, 0.95]




2 137 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.86, 1.46]
Comparison 4. Non-bullous impetigo: topical (Top) antibiotic (Ab) vs disinfecting treatments (Dt)




participants Statistical method Effect size
1 Cure/improvement 2 292 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [1.01, 1.32]
1.1 Bacitracin vs
hexachlorophene
1 36 Risk Ratio (M-H, Fixed, 95% CI) 3.71 [0.16, 85.29]
1.2 Fusidic acid vs hydrogen
peroxide
1 256 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [1.00, 1.31]
Comparison 5. Non-bullous impetigo: topical (Top) antibiotic (Ab) vs antifungal (Af)




participants Statistical method Effect size
1 Cure 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Mupirocin vs terbinafine 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 6. Non-bullous impetigo: topical (Top) antibiotic (Ab) + oral (Or) antibiotic (Ab) vs topical (Top)
antibiotic (Ab) + oral (Or) antibiotic (Ab)




participants Statistical method Effect size
1 Cure 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Tetracyclin + cefdinir vs
tetracyclin + minomycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Tetracyclin + cefdinir vs
tetracyclin + fosfomycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Tetracyclin + minomycin
vs tetracyclin + fosfomycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Non-bullous impetigo: topical (Top) antibiotic (Ab) vs topical (Top) antibiotic (Ab) + oral (Or)
antibiotic (Ab)




participants Statistical method Effect size
1 Cure 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Tetracyclin vs tetracyclin +
cefdinir
1 34 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [0.69, 3.58]
1.2 Tetracyclin vs tetracyclin +
minomycin
1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.62, 1.15]
1.3 Tetracyclin vs tetracyclin +
fosfomycin
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.76, 2.25]
Comparison 8. Non-bullous impetigo: oral (Or) antibiotics (Ab) vs placebo (P)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Penicillin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 9. Non-bullous impetigo: oral (Or) antibiotic (Ab) (cephalosporin) vs another oral (Or) antibiotic
(Ab)




participants Statistical method Effect size
1 Cure/improvement 6 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Cephalexin vs penicillin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Cephalexin vs
erythromycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Cephalexin vs
azithromycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Cefaclor vs azithromycin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Cefaclor vs amoxicillin/
clavulanic acid
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.6 Cefadroxil vs penicillin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.7 Cefadroxil vs flucloxacillin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 10. Non-bullous impetigo: oral (Or) cephalosporin vs other oral (Or) cephalosporin




participants Statistical method Effect size
1 Cure/improvement 7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Cephalexin vs cefadroxil 1 96 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.88, 1.12]
1.2 Cephalexin vs cefdinir 3 201 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.88, 1.03]
1.3 Cefaclor vs cefdinir 1 13 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.23, 1.82]
1.4 Cefditoren vs cefuroxime 1 58 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.55, 0.97]
1.5 Cefditoren vs cefadroxil 1 74 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.78, 1.33]
Comparison 11. Non-bullous impetigo: oral (Or) macrolide vs penicillin




participants Statistical method Effect size
1 Cure/improvement 7 363 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.98, 1.15]
1.1 Erythromycin vs penicillin
V
2 79 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.07, 1.56]
1.2 Erythromycin vs
dicloxacillin
1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.94, 1.13]
1.3 Erythromycin vs
amoxicillin
1 129 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.89, 1.13]
1.4 Azithromycin vs
cloxacillin
1 16 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.57, 3.43]
1.5 Azithromycin vs
flucloxacillin/dicloxacillin
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.61, 1.16]
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1.6 Clindamycin vs
dicloxacillin
1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.80, 1.27]
Comparison 12. Non-bullous impetigo: oral (Or) macrolide vs another oral (Or) macrolide




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Azithromycin vs
erythromycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 13. Non-bullous impetigo: oral (Or) penicillin vs other oral (Or) antibiotic (Ab) (including penicillin)




participants Statistical method Effect size
1 Cure/improvement 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Amoxicillin + clavulanic
acid vs amoxicillin
1 44 Risk Ratio (M-H, Random, 95% CI) 1.4 [1.04, 1.89]
1.2 Amoxicillin + clavulanic
acid vs fleroxacin
1 42 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.80, 1.62]
1.3 Cloxacillin vs penicillin 2 166 Risk Ratio (M-H, Random, 95% CI) 1.59 [1.21, 2.08]
Comparison 14. Non-bullous impetigo: other comparisons of oral (Or) antibiotics (Ab)




participants Statistical method Effect size
1 Cure/improvement 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Lomefloxacin vs
norfloxacin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Fusidic acid vs
pristinamycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
129Interventions for impetigo (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 15. Non-bullous impetigo: oral (Or) antibiotics (Ab) vs disinfecting treatments (Dt)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Penicillin vs
hexachlorophene
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 16. Bullous impetigo: topical (Top) antimicrobial vs placebo (P)




participants Statistical method Effect size
1 Cured/improved after 3 to 4 days 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Eksalb vs placebo 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 17. Bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Fusidic acid vs neomycin/
bacitracin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Fusidic acid vs
chloramphenicol
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Chloramphenicol vs
neomycin/bacitracin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 18. Bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Fusidic acid vs
erythromycin
1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.83, 2.45]
1.2 Neomycin/bacitracin vs
erythromycin
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 0.99]
1.3 Chloramphenicol vs
erythromycin
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.07, 1.10]
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Comparison 19. Bullous impetigo: oral (Or) antibiotic (Ab) vs another oral (Or) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Cephalexin vs dicloxacillin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 20. Secondary impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Mupirocin calcium vs
cephalexin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 21. Secondary impetigo: steroid (S) vs antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Betamethasone vs
gentamycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 22. Secondary impetigo: steroid (S) + antibiotic (Ab) vs steroid (S)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Betamethasone +
gentamycin vs betamethasone
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 23. Secondary impetigo: steroid (S) + antibiotic (Ab) vs antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Betamethasone +
gentamycin vs gentamycin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 24. Secondary impetigo: oral (Or) antibiotic (Ab) vs another oral (Or) antibiotic (Ab)




participants Statistical method Effect size
1 Cure/improvement 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Cephalexin vs enoxacin 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs placebo (P), Outcome 1
Cure/improvement.
Review: Interventions for impetigo
Comparison: 1 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs placebo (P)
Outcome: 1 Cure/improvement









Eells 1986 14/17 8/19 17.4 % 1.96 [ 1.10, 3.46 ]
Gould 1984 10/14 7/21 14.1 % 2.14 [ 1.08, 4.27 ]
Rojas 1985 34/50 15/52 20.9 % 2.36 [ 1.48, 3.76 ]
Subtotal (95% CI) 81 92 52.4 % 2.18 [ 1.58, 3.00 ]
Total events: 58 (Top Ab), 30 (P)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 4.76 (P < 0.00001)
2 Fusidic acid
Koning 2003 42/76 10/80 16.1 % 4.42 [ 2.39, 8.17 ]
0.001 0.01 0.1 1 10 100 1000
Favours P Favours Top Ab
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Subtotal (95% CI) 76 80 16.1 % 4.42 [ 2.39, 8.17 ]
Total events: 42 (Top Ab), 10 (P)
Heterogeneity: not applicable
Test for overall effect: Z = 4.74 (P < 0.00001)
3 Bacitracin
Ruby 1973 1/16 0/20 1.1 % 3.71 [ 0.16, 85.29 ]
Subtotal (95% CI) 16 20 1.1 % 3.71 [ 0.16, 85.29 ]
Total events: 1 (Top Ab), 0 (P)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 Retapamulin
Koning 2008 119/139 37/71 30.4 % 1.64 [ 1.30, 2.07 ]
Subtotal (95% CI) 139 71 30.4 % 1.64 [ 1.30, 2.07 ]
Total events: 119 (Top Ab), 37 (P)
Heterogeneity: not applicable
Test for overall effect: Z = 4.17 (P = 0.000030)
Total (95% CI) 312 263 100.0 % 2.24 [ 1.61, 3.13 ]
Total events: 220 (Top Ab), 77 (P)
Heterogeneity: Tau2 = 0.08; Chi2 = 10.73, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 4.77 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.52, df = 3 (P = 0.02), I2 =68%
0.001 0.01 0.1 1 10 100 1000
Favours P Favours Top Ab
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Analysis 2.1. Comparison 2 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top)
antibiotic (Ab), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 2 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Ab A Ab B Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mupirocin vs rifamycin
Tamayo 1991 8/8 5/9 100.0 % 1.72 [ 0.96, 3.07 ]
Subtotal (95% CI) 8 9 100.0 % 1.72 [ 0.96, 3.07 ]
Total events: 8 (Ab A), 5 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
2 Mupirocin vs neomycin
Kennedy 1985 15/15 13/17 100.0 % 1.29 [ 0.98, 1.71 ]
Subtotal (95% CI) 15 17 100.0 % 1.29 [ 0.98, 1.71 ]
Total events: 15 (Ab A), 13 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
3 Mupirocin vs bacitracin
Bass 1997 6/7 3/9 100.0 % 2.57 [ 0.97, 6.80 ]
Subtotal (95% CI) 7 9 100.0 % 2.57 [ 0.97, 6.80 ]
Total events: 6 (Ab A), 3 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
4 Mupirocin vs chlortetracycline
Wainscott 1985 6/6 7/8 100.0 % 1.11 [ 0.78, 1.59 ]
Subtotal (95% CI) 6 8 100.0 % 1.11 [ 0.78, 1.59 ]
Total events: 6 (Ab A), 7 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
5 Mupirocin vs polymyxin B/neomycin
Wilkinson 1988 2/2 5/6 100.0 % 1.06 [ 0.56, 2.01 ]
Subtotal (95% CI) 2 6 100.0 % 1.06 [ 0.56, 2.01 ]
Total events: 2 (Ab A), 5 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
6 Fusidic acid vs neomycin/bacitracin
Vainer 1986 26/43 27/41 100.0 % 0.92 [ 0.66, 1.27 ]
Subtotal (95% CI) 43 41 100.0 % 0.92 [ 0.66, 1.27 ]
0.002 0.1 1 10 500
Favours Ab B Favours Ab A
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Study or subgroup Ab A Ab B Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 26 (Ab A), 27 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
7 Fusidic acid vs tetracycline/polymyxin B
Vainer 1986 26/43 25/44 100.0 % 1.06 [ 0.75, 1.52 ]
Subtotal (95% CI) 43 44 100.0 % 1.06 [ 0.75, 1.52 ]
Total events: 26 (Ab A), 25 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
8 Retapamulin vs fusidic acid
Oranje 2007 327/345 155/172 100.0 % 1.05 [ 1.00, 1.11 ]
Subtotal (95% CI) 345 172 100.0 % 1.05 [ 1.00, 1.11 ]
Total events: 327 (Ab A), 155 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
9 Sulcanozol vs miconazole
Nolting 1988 5/32 1/34 100.0 % 5.31 [ 0.66, 43.04 ]
Subtotal (95% CI) 32 34 100.0 % 5.31 [ 0.66, 43.04 ]
Total events: 5 (Ab A), 1 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
10 Hydrocortisone + hydroxyquinoline vs hydrocortisone + miconazole
Jaffe 1986 13/24 5/19 100.0 % 2.06 [ 0.89, 4.76 ]
Subtotal (95% CI) 24 19 100.0 % 2.06 [ 0.89, 4.76 ]
Total events: 13 (Ab A), 5 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
11 Gentamycin vs neomycin
Farah 1967 60/84 22/44 100.0 % 1.43 [ 1.03, 1.98 ]
Subtotal (95% CI) 84 44 100.0 % 1.43 [ 1.03, 1.98 ]
Total events: 60 (Ab A), 22 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
12 Mupirocin vs fusidic acid
Gilbert 1989 4/8 6/11 2.9 % 0.92 [ 0.38, 2.21 ]
Morley 1988 32/38 45/51 22.1 % 0.95 [ 0.80, 1.13 ]
Sutton 1992 82/84 90/93 49.1 % 1.01 [ 0.96, 1.06 ]
White 1989 81/106 33/49 25.9 % 1.13 [ 0.91, 1.42 ]
Subtotal (95% CI) 236 204 100.0 % 1.03 [ 0.95, 1.11 ]
Total events: 199 (Ab A), 174 (Ab B)
0.002 0.1 1 10 500
Favours Ab B Favours Ab A
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Study or subgroup Ab A Ab B Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 2.03, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
0.002 0.1 1 10 500
Favours Ab B Favours Ab A
Analysis 3.1. Comparison 3 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab),
Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 3 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Top Ab Or Ab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mupirocin vs erythromycin
Barton 1989 47/49 43/48 17.6 % 1.07 [ 0.96, 1.20 ]
Britton 1990 20/22 24/26 8.9 % 0.98 [ 0.83, 1.17 ]
Dagan 1992 45/46 33/43 13.8 % 1.27 [ 1.08, 1.51 ]
Dux 1986 17/24 8/12 4.3 % 1.06 [ 0.66, 1.71 ]
Esterly 1991 21/22 18/20 7.6 % 1.06 [ 0.89, 1.26 ]
Goldfarb 1988 29/29 27/29 11.1 % 1.07 [ 0.95, 1.21 ]
Gratton 1987 7/7 6/8 2.5 % 1.30 [ 0.83, 2.02 ]
McLinn 1988 28/30 25/30 10.1 % 1.12 [ 0.93, 1.35 ]
Mertz 1989 26/28 24/25 10.3 % 0.97 [ 0.85, 1.10 ]
Rice 1992 30/41 34/42 13.6 % 0.90 [ 0.71, 1.14 ]
Subtotal (95% CI) 298 283 100.0 % 1.07 [ 1.01, 1.13 ]
Total events: 270 (Top Ab), 242 (Or Ab)
Heterogeneity: Chi2 = 10.14, df = 9 (P = 0.34); I2 =11%
Test for overall effect: Z = 2.14 (P = 0.032)
0.5 0.7 1 1.5 2
Favours Or Ab Favours Top Ab
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Study or subgroup Top Ab Or Ab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Mupirocin vs dicloxacillin
Arredondo 1987 26/26 26/27 100.0 % 1.04 [ 0.94, 1.15 ]
Subtotal (95% CI) 26 27 100.0 % 1.04 [ 0.94, 1.15 ]
Total events: 26 (Top Ab), 26 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
3 Mupirocin vs cephalexin
Bass 1997 6/7 9/10 100.0 % 0.95 [ 0.66, 1.37 ]
Subtotal (95% CI) 7 10 100.0 % 0.95 [ 0.66, 1.37 ]
Total events: 6 (Top Ab), 9 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
4 Mupirocin vs ampicillin
Welsh 1987 8/9 2/4 100.0 % 1.78 [ 0.65, 4.87 ]
Subtotal (95% CI) 9 4 100.0 % 1.78 [ 0.65, 4.87 ]
Total events: 8 (Top Ab), 2 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
5 Bacitracin vs erythromycin
Koranyi 1976 5/15 10/15 100.0 % 0.50 [ 0.22, 1.11 ]
Subtotal (95% CI) 15 15 100.0 % 0.50 [ 0.22, 1.11 ]
Total events: 5 (Top Ab), 10 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
6 Bacitracin vs penicillin
Ruby 1973 1/16 3/18 100.0 % 0.38 [ 0.04, 3.25 ]
Subtotal (95% CI) 16 18 100.0 % 0.38 [ 0.04, 3.25 ]
Total events: 1 (Top Ab), 3 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
7 Bacitracin vs cephalexin
Bass 1997 3/9 9/10 100.0 % 0.37 [ 0.14, 0.95 ]
Subtotal (95% CI) 9 10 100.0 % 0.37 [ 0.14, 0.95 ]
Total events: 3 (Top Ab), 9 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.040)
0.5 0.7 1 1.5 2
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Analysis 3.2. Comparison 3 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab),
Outcome 2 Cure/improvement.
Review: Interventions for impetigo
Comparison: 3 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)
Outcome: 2 Cure/improvement








1 Mupirocin vs erythromycin: observer blinded studies
Britton 1990 20/22 24/26 49.8 % 0.98 [ 0.83, 1.17 ]
Dagan 1992 45/46 33/43 50.2 % 1.27 [ 1.08, 1.51 ]
Total (95% CI) 68 69 100.0 % 1.12 [ 0.86, 1.46 ]
Total events: 65 (topical antibiotic), 57 (oral antibiotic)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.65, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 4.1. Comparison 4 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs disinfecting treatments
(Dt), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 4 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs disinfecting treatments (Dt)
Outcome: 1 Cure/improvement
Study or subgroup Top Ab Dt Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Bacitracin vs hexachlorophene
Ruby 1973 1/16 0/20 0.5 % 3.71 [ 0.16, 85.29 ]
Subtotal (95% CI) 16 20 0.5 % 3.71 [ 0.16, 85.29 ]
Total events: 1 (Top Ab), 0 (Dt)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 Fusidic acid vs hydrogen peroxide
Christensen 1994 105/128 92/128 99.5 % 1.14 [ 1.00, 1.31 ]
Subtotal (95% CI) 128 128 99.5 % 1.14 [ 1.00, 1.31 ]
Total events: 105 (Top Ab), 92 (Dt)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
Total (95% CI) 144 148 100.0 % 1.15 [ 1.01, 1.32 ]
Total events: 106 (Top Ab), 92 (Dt)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
0.5 0.7 1 1.5 2
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Analysis 5.1. Comparison 5 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs antifungal (Af), Outcome
1 Cure.
Review: Interventions for impetigo
Comparison: 5 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs antifungal (Af)
Outcome: 1 Cure
Study or subgroup Top Ab Af Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mupirocin vs terbinafine
Ciftci 2002 25/31 18/31 1.39 [ 0.98, 1.96 ]
0.02 0.1 1 10 50
Favours Top Ab Favours Af
Analysis 6.1. Comparison 6 Non-bullous impetigo: topical (Top) antibiotic (Ab) + oral (Or) antibiotic (Ab)
vs topical (Top) antibiotic (Ab) + oral (Or) antibiotic (Ab), Outcome 1 Cure.
Review: Interventions for impetigo
Comparison: 6 Non-bullous impetigo: topical (Top) antibiotic (Ab) + oral (Or) antibiotic (Ab) vs topical (Top) antibiotic (Ab) + oral (Or) antibiotic (Ab)
Outcome: 1 Cure
Study or subgroup tetra+cefdini tetra+minomycin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tetracyclin + cefdinir vs tetracyclin + minomycin
Kuniyuki 2005 3/6 5/5 0.55 [ 0.25, 1.19 ]
2 Tetracyclin + cefdinir vs tetracyclin + fosfomycin
Kuniyuki 2005 3/6 6/10 0.83 [ 0.32, 2.15 ]
3 Tetracyclin + minomycin vs tetracyclin + fosfomycin
Kuniyuki 2005 5/5 6/10 1.55 [ 0.90, 2.68 ]
0.01 0.1 1 10 100
Fav topic tetra + oral A Fav topic tetra + oral B
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Analysis 7.1. Comparison 7 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs topical (Top) antibiotic
(Ab) + oral (Or) antibiotic (Ab), Outcome 1 Cure.
Review: Interventions for impetigo
Comparison: 7 Non-bullous impetigo: topical (Top) antibiotic (Ab) vs topical (Top) antibiotic (Ab) + oral (Or) antibiotic (Ab)
Outcome: 1 Cure
Study or subgroup Top Ab Top Ab + Or Ab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tetracyclin vs tetracyclin + cefdinir
Kuniyuki 2005 22/28 3/6 100.0 % 1.57 [ 0.69, 3.58 ]
Subtotal (95% CI) 28 6 100.0 % 1.57 [ 0.69, 3.58 ]
Total events: 22 (Top Ab), 3 (Top Ab + Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Tetracyclin vs tetracyclin + minomycin
Kuniyuki 2005 22/28 5/5 100.0 % 0.85 [ 0.62, 1.15 ]
Subtotal (95% CI) 28 5 100.0 % 0.85 [ 0.62, 1.15 ]
Total events: 22 (Top Ab), 5 (Top Ab + Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 Tetracyclin vs tetracyclin + fosfomycin
Kuniyuki 2005 22/28 6/10 100.0 % 1.31 [ 0.76, 2.25 ]
Subtotal (95% CI) 28 10 100.0 % 1.31 [ 0.76, 2.25 ]
Total events: 22 (Top Ab), 6 (Top Ab + Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
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Analysis 8.1. Comparison 8 Non-bullous impetigo: oral (Or) antibiotics (Ab) vs placebo (P), Outcome 1
Cure/improvement.
Review: Interventions for impetigo
Comparison: 8 Non-bullous impetigo: oral (Or) antibiotics (Ab) vs placebo (P)
Outcome: 1 Cure/improvement
Study or subgroup Or Ab P Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Penicillin
Ruby 1973 3/18 0/20 7.74 [ 0.43, 140.26 ]
0.005 0.1 1 10 200
Favours P Favours Or Ab
Analysis 9.1. Comparison 9 Non-bullous impetigo: oral (Or) antibiotic (Ab) (cephalosporin) vs another oral
(Or) antibiotic (Ab), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 9 Non-bullous impetigo: oral (Or) antibiotic (Ab) (cephalosporin) vs another oral (Or) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Or Ab Other Or Ab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cephalexin vs penicillin
Demidovich 1990 23/23 19/25 1.31 [ 1.04, 1.64 ]
2 Cephalexin vs erythromycin
Demidovich 1990 23/23 24/25 1.04 [ 0.93, 1.16 ]
3 Cephalexin vs azithromycin
Kiani 1991 6/8 5/10 1.50 [ 0.72, 3.14 ]
4 Cefaclor vs azithromycin
Montero 1996 49/51 41/44 1.03 [ 0.94, 1.14 ]
5 Cefaclor vs amoxicillin/clavulanic acid
Jaffe 1985 13/16 16/18 0.91 [ 0.69, 1.22 ]
0.5 0.7 1 1.5 2
Favours other Or Ab Favours Or Ab
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Study or subgroup Or Ab Other Or Ab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Cefadroxil vs penicillin
Ginsburg 1978 21/24 23/26 0.99 [ 0.81, 1.21 ]
7 Cefadroxil vs flucloxacillin
Beitner 1996 25/33 25/27 0.82 [ 0.66, 1.02 ]
0.5 0.7 1 1.5 2
Favours other Or Ab Favours Or Ab
Analysis 10.1. Comparison 10 Non-bullous impetigo: oral (Or) cephalosporin vs other oral (Or)
cephalosporin, Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 10 Non-bullous impetigo: oral (Or) cephalosporin vs other oral (Or) cephalosporin
Outcome: 1 Cure/improvement
Study or subgroup cephalosporin A cephalosporin B Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cephalexin vs cefadroxil
Hains 1989 41/45 47/51 100.0 % 0.99 [ 0.88, 1.12 ]
Subtotal (95% CI) 45 51 100.0 % 0.99 [ 0.88, 1.12 ]
Total events: 41 (cephalosporin A), 47 (cephalosporin B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
2 Cephalexin vs cefdinir
Giordano 2006 10/12 4/4 6.9 % 0.90 [ 0.60, 1.33 ]
Tack 1997 73/76 72/74 77.6 % 0.99 [ 0.93, 1.05 ]
Tack 1998 11/17 15/18 15.5 % 0.78 [ 0.52, 1.17 ]
Subtotal (95% CI) 105 96 100.0 % 0.95 [ 0.88, 1.03 ]
Total events: 94 (cephalosporin A), 91 (cephalosporin B)
Heterogeneity: Chi2 = 2.76, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.32 (P = 0.19)
3 Cefaclor vs cefdinir
0.2 0.5 1 2 5
Favours cephalosporin B Favours cephalosporin A
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(. . . Continued)
Study or subgroup cephalosporin A cephalosporin B Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arata 1989a 2/4 7/9 100.0 % 0.64 [ 0.23, 1.82 ]
Subtotal (95% CI) 4 9 100.0 % 0.64 [ 0.23, 1.82 ]
Total events: 2 (cephalosporin A), 7 (cephalosporin B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
4 Cefditoren vs cefuroxime
Bucko 2002a 26/40 16/18 100.0 % 0.73 [ 0.55, 0.97 ]
Subtotal (95% CI) 40 18 100.0 % 0.73 [ 0.55, 0.97 ]
Total events: 26 (cephalosporin A), 16 (cephalosporin B)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
5 Cefditoren vs cefadroxil
Bucko 2002b 41/52 17/22 100.0 % 1.02 [ 0.78, 1.33 ]
Subtotal (95% CI) 52 22 100.0 % 1.02 [ 0.78, 1.33 ]
Total events: 41 (cephalosporin A), 17 (cephalosporin B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
0.2 0.5 1 2 5
Favours cephalosporin B Favours cephalosporin A
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Analysis 11.1. Comparison 11 Non-bullous impetigo: oral (Or) macrolide vs penicillin, Outcome 1
Cure/improvement.
Review: Interventions for impetigo
Comparison: 11 Non-bullous impetigo: oral (Or) macrolide vs penicillin
Outcome: 1 Cure/improvement
Study or subgroup Oral macrolide Penicillin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Erythromycin vs penicillin V
Barton 1987 14/14 11/15 7.3 % 1.34 [ 0.98, 1.85 ]
Demidovich 1990 24/25 19/25 12.5 % 1.26 [ 1.00, 1.60 ]
Subtotal (95% CI) 39 40 19.7 % 1.29 [ 1.07, 1.56 ]
Total events: 38 (Oral macrolide), 30 (Penicillin)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.66 (P = 0.0078)
2 Erythromycin vs dicloxacillin
Barton 1988 28/28 29/30 18.7 % 1.03 [ 0.94, 1.13 ]
Subtotal (95% CI) 28 30 18.7 % 1.03 [ 0.94, 1.13 ]
Total events: 28 (Oral macrolide), 29 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Erythromycin vs amoxicillin
Faye 2007 58/65 57/64 37.7 % 1.00 [ 0.89, 1.13 ]
Subtotal (95% CI) 65 64 37.7 % 1.00 [ 0.89, 1.13 ]
Total events: 58 (Oral macrolide), 57 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
4 Azithromycin vs cloxacillin
Daniel 1991b 7/10 3/6 2.5 % 1.40 [ 0.57, 3.43 ]
Subtotal (95% CI) 10 6 2.5 % 1.40 [ 0.57, 3.43 ]
Total events: 7 (Oral macrolide), 3 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
5 Azithromycin vs flucloxacillin/dicloxacillin
Rodriguez-Solares 1993 18/25 12/14 10.1 % 0.84 [ 0.61, 1.16 ]
Subtotal (95% CI) 25 14 10.1 % 0.84 [ 0.61, 1.16 ]
Total events: 18 (Oral macrolide), 12 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
6 Clindamycin vs dicloxacillin
Blaszcyk 1998 23/26 14/16 11.4 % 1.01 [ 0.80, 1.27 ]
0.5 0.7 1 1.5 2
Favours penicillin Favours macrolide
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(. . . Continued)
Study or subgroup Oral macrolide Penicillin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 26 16 11.4 % 1.01 [ 0.80, 1.27 ]
Total events: 23 (Oral macrolide), 14 (Penicillin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 193 170 100.0 % 1.06 [ 0.98, 1.15 ]
Total events: 172 (Oral macrolide), 145 (Penicillin)
Heterogeneity: Chi2 = 7.91, df = 6 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.46 (P = 0.15)
Test for subgroup differences: Chi2 = 7.61, df = 5 (P = 0.18), I2 =34%
0.5 0.7 1 1.5 2
Favours penicillin Favours macrolide
Analysis 12.1. Comparison 12 Non-bullous impetigo: oral (Or) macrolide vs another oral (Or) macrolide,
Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 12 Non-bullous impetigo: oral (Or) macrolide vs another oral (Or) macrolide
Outcome: 1 Cure/improvement
Study or subgroup Azithromycin Erythromycin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Azithromycin vs erythromycin
Daniel 1991a 28/35 21/31 1.18 [ 0.88, 1.58 ]
0.2 0.5 1 2 5
Favours azithromycin Favours erythromycin
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Analysis 13.1. Comparison 13 Non-bullous impetigo: oral (Or) penicillin vs other oral (Or) antibiotic (Ab)
(including penicillin), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 13 Non-bullous impetigo: oral (Or) penicillin vs other oral (Or) antibiotic (Ab) (including penicillin)
Outcome: 1 Cure/improvement








1 Amoxicillin + clavulanic acid vs amoxicillin
Dagan 1989 21/22 15/22 100.0 % 1.40 [ 1.04, 1.89 ]
Subtotal (95% CI) 22 22 100.0 % 1.40 [ 1.04, 1.89 ]
Total events: 21 (Ab A), 15 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
2 Amoxicillin + clavulanic acid vs fleroxacin
Tassler 1993 12/15 19/27 100.0 % 1.14 [ 0.80, 1.62 ]
Subtotal (95% CI) 15 27 100.0 % 1.14 [ 0.80, 1.62 ]
Total events: 12 (Ab A), 19 (Ab B)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 Cloxacillin vs penicillin
Gonzalez 1989 33/33 23/43 45.1 % 1.84 [ 1.40, 2.44 ]
Pruksachat 1993 42/45 30/45 54.9 % 1.40 [ 1.12, 1.75 ]
Subtotal (95% CI) 78 88 100.0 % 1.59 [ 1.21, 2.08 ]
Total events: 75 (Ab A), 53 (Ab B)
Heterogeneity: Tau2 = 0.02; Chi2 = 2.34, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 3.34 (P = 0.00085)
0.5 0.7 1 1.5 2
Favours Ab B Favours Ab A
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Analysis 14.1. Comparison 14 Non-bullous impetigo: other comparisons of oral (Or) antibiotics (Ab),
Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 14 Non-bullous impetigo: other comparisons of oral (Or) antibiotics (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Lomefloxacin Norfloxacin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Lomefloxacin vs norfloxacin
Arata 1989b 6/10 3/8 1.60 [ 0.57, 4.47 ]
2 Fusidic acid vs pristinamycin
Claudy 2001 21/25 23/25 0.91 [ 0.74, 1.12 ]
0.05 0.2 1 5 20
Favours norfloxacin Favours lomefloxacin
Analysis 15.1. Comparison 15 Non-bullous impetigo: oral (Or) antibiotics (Ab) vs disinfecting treatments
(Dt), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 15 Non-bullous impetigo: oral (Or) antibiotics (Ab) vs disinfecting treatments (Dt)
Outcome: 1 Cure/improvement
Study or subgroup Or Ab Dt Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Penicillin vs hexachlorophene
Ruby 1973 3/18 0/20 7.74 [ 0.43, 140.26 ]
0.005 0.1 1 10 200
Favours Dt Favours Or Ab
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Analysis 16.1. Comparison 16 Bullous impetigo: topical (Top) antimicrobial vs placebo (P), Outcome 1
Cured/improved after 3 to 4 days.
Review: Interventions for impetigo
Comparison: 16 Bullous impetigo: topical (Top) antimicrobial vs placebo (P)
Outcome: 1 Cured/improved after 3 to 4 days
Study or subgroup Eksalb Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Eksalb vs placebo
Ishii 1977 15/28 7/30 2.30 [ 1.10, 4.79 ]
0.2 0.5 1 2 5
Favours placebo Favours eksalb
Analysis 17.1. Comparison 17 Bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top)
antibiotic (Ab), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 17 Bullous impetigo: topical (Top) antibiotic (Ab) vs another topical (Top) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Top Ab A Top Ab B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fusidic acid vs neomycin/bacitracin
Moraes Barbosa 1986 10/12 1/12 10.00 [ 1.51, 66.43 ]
2 Fusidic acid vs chloramphenicol
Moraes Barbosa 1986 10/12 2/12 5.00 [ 1.38, 18.17 ]
3 Chloramphenicol vs neomycin/bacitracin
Moraes Barbosa 1986 2/12 1/12 2.00 [ 0.21, 19.23 ]
0.001 0.01 0.1 1 10 100 1000
Favours Ab B Favours Ab A
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Analysis 18.1. Comparison 18 Bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab),
Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 18 Bullous impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Top Ab Or Ab Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fusidic acid vs erythromycin
Moraes Barbosa 1986 10/12 7/12 100.0 % 1.43 [ 0.83, 2.45 ]
Subtotal (95% CI) 12 12 100.0 % 1.43 [ 0.83, 2.45 ]
Total events: 10 (Top Ab), 7 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
2 Neomycin/bacitracin vs erythromycin
Moraes Barbosa 1986 1/12 7/12 100.0 % 0.14 [ 0.02, 0.99 ]
Subtotal (95% CI) 12 12 100.0 % 0.14 [ 0.02, 0.99 ]
Total events: 1 (Top Ab), 7 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
3 Chloramphenicol vs erythromycin
Moraes Barbosa 1986 2/12 7/12 100.0 % 0.29 [ 0.07, 1.10 ]
Subtotal (95% CI) 12 12 100.0 % 0.29 [ 0.07, 1.10 ]
Total events: 2 (Top Ab), 7 (Or Ab)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
0.01 0.1 1 10 100
Favours Or Ab Favours Top Ab
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Analysis 19.1. Comparison 19 Bullous impetigo: oral (Or) antibiotic (Ab) vs another oral (Or) antibiotic
(Ab), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 19 Bullous impetigo: oral (Or) antibiotic (Ab) vs another oral (Or) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Cephalexin Dicloxacillin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cephalexin vs dicloxacillin
Dillon 1983 26/28 23/29 1.17 [ 0.95, 1.45 ]
0.2 0.5 1 2 5
Favours dicloxacilli Favours cephalexin
Analysis 20.1. Comparison 20 Secondary impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab),
Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 20 Secondary impetigo: topical (Top) antibiotic (Ab) vs oral (Or) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Favours cephalexin Favours mupirocin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mupirocin calcium vs cephalexin
Rist 2002 52/82 44/77 1.11 [ 0.86, 1.43 ]
0.01 0.1 1 10 100
Favours cephalexin Favours mupirocin
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Analysis 21.1. Comparison 21 Secondary impetigo: steroid (S) vs antibiotic (Ab), Outcome 1
Cure/improvement.
Review: Interventions for impetigo
Comparison: 21 Secondary impetigo: steroid (S) vs antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup S Ab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Betamethasone vs gentamycin
Wachs 1976 15/27 8/27 1.88 [ 0.96, 3.67 ]
0.1 0.2 0.5 1 2 5 10
Favours Ab Favours S
Analysis 22.1. Comparison 22 Secondary impetigo: steroid (S) + antibiotic (Ab) vs steroid (S), Outcome 1
Cure/improvement.
Review: Interventions for impetigo
Comparison: 22 Secondary impetigo: steroid (S) + antibiotic (Ab) vs steroid (S)
Outcome: 1 Cure/improvement
Study or subgroup S + Ab S Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Betamethasone + gentamycin vs betamethasone
Wachs 1976 18/25 15/27 1.30 [ 0.85, 1.97 ]
0.1 0.2 0.5 1 2 5 10
Favours S Favours S + Ab
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Analysis 23.1. Comparison 23 Secondary impetigo: steroid (S) + antibiotic (Ab) vs antibiotic (Ab),
Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 23 Secondary impetigo: steroid (S) + antibiotic (Ab) vs antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup S + Ab Ab Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Betamethasone + gentamycin vs gentamycin
Wachs 1976 18/25 8/27 2.43 [ 1.29, 4.57 ]
0.05 0.2 1 5 20
Favours Ab Favours S + Ab
Analysis 24.1. Comparison 24 Secondary impetigo: oral (Or) antibiotic (Ab) vs another oral (Or) antibiotic
(Ab), Outcome 1 Cure/improvement.
Review: Interventions for impetigo
Comparison: 24 Secondary impetigo: oral (Or) antibiotic (Ab) vs another oral (Or) antibiotic (Ab)
Outcome: 1 Cure/improvement
Study or subgroup Cephalexin Enoxacin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cephalexin vs enoxacin
Fujita 1984 2/4 4/6 0.75 [ 0.24, 2.33 ]
0.05 0.2 1 5 20
Favours enoxacin Favours cephalexin
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A D D I T I O N A L T A B L E S
Table 1. Adverse events
Study Adverse events: nature and number or percentage by treatment group
Arata 1989a; Arata 1989b mainly gastrointestinal: cefdinir 9/142, cefaclor 4/145
Arredondo 1987 mupirocin: nil reported
dicloxacillin: abdominal pain 1/ 31, vomiting 2/31
Barton 1987 not reported
Barton 1988 abdominal pain: erythromycin 1/ 49, dicloxacillin 1/51
vomiting + rash: dicloxacillin 1/51
Barton 1989 gastrointestinal: erythromycin 8/48, mupirocin 4/49
Bass 1997 not reported
Beitner 1996 diarrhoea: cefadroxil 14/327, flucloxacillin 87/324 (all participants)
severe (stomach ache/rash/fever/vomiting): cefadroxil 14/327, flucloxacillin 2/234 (all participants)
Blaszcyk 1998 mainly gastro-intestinal (half ofwhichwere considered treatment-related): clindamycin 150mg (19%)
, clindamycin 300 mg (17%), dicloxacillin 10% (all participants)
Britton 1990 minor gastrointestinal: 11 total, equally divided
Bucko 2002a; Bucko 2002b unclear and not specified for impetigo participants
Christensen 1994 led to withdrawal: skin irritation 1, burning 1, blistering 1 (all fusidic acid - hydrogen peroxide: 0)
mild SE: fusidic acid 9, hydrogen peroxide 13
Ciftci 2002 burning, stinging, itching: 1 in each group
rash: 1 in terbinafine group
Claudy 2001 upper gastrointestinal: fusidic acid 6.8% vs pristinamycin 11.6%
lower gastrointestinal: 2.5% vs 16.7%
hypersensibility: 1.9% vs 5.8%
Dagan 1989 vomiting: amoxicillin 1, amoxicillin and clavulanic acid (augmentin) 0
diarrhoea: amoxicillin 1, amoxicillin and clavulanic acid (augmentin) 0
Dagan 1992 gastrointestinal: erythromycin 11/47, mupirocin 4/51
Daniel 1991a; Daniel 1991b no subgroup data
Demidovich 1990 nil reported
Dillon 1983 not reported
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Table 1. Adverse events (Continued)
Dux 1986 pruritus: mupirocin 1/78
nausea and abdominal pain: erythromycin 1/50, cloxacillin 0/20 (all participants)
Eells 1986 not reported
Esterly 1991 mupirocin: nil reported
erythromycin: stomach pain and nausea 1/20, vomiting and irritability 1/20, hysterical attacks 1/20
Farah 1967 not reported
Faye 2007 diarrhoea: amoxicillin 2/64 vs erythromycin 11/65
Fujita 1984 mainly gastrointestinal: enoxacin 11/113, cephalexin 4/110 (all participants)
Gilbert 1989 nil reported
Ginsburg 1978 1 child removed from cefadroxil group because of vomiting; no other SE reported
Giordano 2006 diarrhoea: cefdinir 10% vs cephalexin 4%
nausea: cefdinir 3% vs cephalexin 6%
vaginal mycose of females: cefdinir 3% vs cephalexin 6%
Goldfarb 1988 mild diarrhoea: amupirocin 0/30, erythromycin 5/30
Gonzalez 1989 not reported
Gould 1984 not reported
Gratton 1987 mostly gastrointestinal: erythromycin 8/29
mupirocin: nil reported
Hains 1989 nil reported
Ishii 1977 nil reported
Jaffe 1985 mild diarrhoea: Augmentin® 2/18, cefaclor 5/16 (all participants)
Jaffe 1986 mild staining: hydrocortisone + potassiumhydroxyquinoline sulphate cream2/24, 1%hydrocortisone
+ 2% miconazole nitrate cream 0/24
Kennedy 1985 nil reported
Kiani 1991 mainly gastrointestinal: azithromycin 30/182, cephalexin: 20/184
Withdrawn: azithromycin 5 (4 gastrointestinal; 1 dizziness and somnolence), cephalexin 1(euphoria)
(all participants)
Koning 2003 mainly pain and burning due to povidone iodine: fusidic acid 7/76, placebo 19/80
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Table 1. Adverse events (Continued)
Koning 2008 any: retapamulin 15/139 vs placebo 2/71
application site pruritis: 9 vs 1
Koranyi 1976 mild abdominal cramps: erythromycin 2/15, bacitracin 0/15
Kuniyuki 2005 not reported
McLinn 1988 gastrointestinal: mupirocin 0/30, erythromycin 6/30
Mertz 1989 nil reported
Montero 1996 mild skin side-effects: azythromycin 3/100, cefaclor 2/100
Moraes Barbosa 1986 not reported
Morley 1988 all local skin reactions: sodium fusidate 2/191, mupirocin 12/163 (all participants)
Nolting 1988 mild burning: sulconazole 0/32, miconazole 1/34
Oranje 2007 local irritation: retapamulin 6/346 vs sodium fusidate 0/173
Pruksachat 1993 not reported
Rice 1992 stomach ache/diarrhoea/vomiting/itching/burning (%): erythromycin 24/10/7/5/0, mupirocin 2/2/
0/12/10
Rist 2002 diarrhoea: mupirocin 2/82 vs cephalexin 3/77
Rodriguez-Solares 1993 gastrointestinal: azithromycin 2/25, dicloxacillin/flucloxacillin 2/14
Rojas 1985 nausea/vomiting: mupirocin 0/52, vehicle 1/52
Ruby 1973 not reported
Sutton 1992 local: fusidic acid 2/104, mupirocin 4/97
Tack 1997 mainly gastrointestinal: cefdinir 16%, cephalexin 11% (all participants)
Tack 1998 no subgroup data was available; it included only participants that had pathogens susceptible to both
study drugs
Tamayo 1991 nil reported
Tassler 1993 mainly gastrointestinal: fleroxacin 17%, amoxicillin/clavunalate 21% (all participants)
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Table 1. Adverse events (Continued)
Vainer 1986 total 3%
skin rash: fusidic acid 1/43
burning and itching: tetracycline/polymyxin B ointment and neomycin/bacitracin ointment both 1/
44 and 1/41 respectively
Wachs 1976 not reported
Wainscott 1985 nil reported
Welsh 1987 nil reported
White 1989 minor itching or burning: mupirocin 6/263, fusidic acid 2/127 (all participants)
Wilkinson 1988 rash: mupirocin 0/24, neomycin 1/26 (all participants)
Table 2. Declared sponsorship or funding
Study Sponsor (product)
Barton 1987 Fleur de Lis Foundation
Barton 1988 Warner-Lambert Corporation
Barton 1989 Warner- Lambert Corporation
Beitner 1996 Bristol-Myers Squibb (cefadroxil)
Blaszcyk 1998 Pharmacia & Upjohn Asia (clindamycin)
Britton 1990 US Navy Bureau of Medicine and Surgery Clinical Investigation Program
Bucko 2002a, Bucko 2002b TAF Pharmaceutical Products (cefditoren)
Daniel 1991a; Daniel 1991b Pfizer Central Research (azithromycin)
Dillon 1983 Eli Lilly Research (cephalexin)
Giordano 2006 Abott Laboratories (cefdinir)
Goldfarb 1988 Beecham Laboratories (mupirocin)
Hains 1989 Bristol-Myers Squibb (cefadroxil)
Jaffe 1985 Beecham Laboratories (amoxicillin+clavulanic acid)
Koning 2003 Dutch College of General Practitioners
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Table 2. Declared sponsorship or funding (Continued)
Koning 2008 GlaxoSmithKline (retapamulin)
Mertz 1989 Beecham Laboratories (mupirocin)
Oranje 2007 GlaxoSmithKline (retapamulin)
Rist 2002 GlaxoSmithKline (mupirocin)
Sutton 1992 Leo Laboratories (fusidic acid)
Tack 1997 Parke-Davis pharmaceutical research (cefdinir)
Tack 1998 Parke-Davis pharmaceutical research (cefdinir)
Wainscott 1985 Beecham Pharmaceuticals (mupirocin)
White 1989 Beecham Pharmaceuticals (mupirocin)
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1(impetig* or pyoderma ):ti
#2MeSH descriptor Impetigo explode all trees in MeSH products
#3(#1 OR #2)
#4SR-SKIN in All Fields in all products
#5(#3 AND NOT #4)
Appendix 2. MEDLINE (OVID) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (human and animals)).sh.
10. 8 not 9
11. exp Staphylococcal Infections/ or stapylococcal skin infections.mp.
12. impetigo.mp. or exp Impetigo/
13. exp Pyoderma/ or pyoderma.mp.
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14. 11 or 13 or 12
15. 10 and 14
Appendix 3. EMBASE (OVID) search strategy
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. impetigo.mp. or exp IMPETIGO/
15. exp PYODERMA/ or pyoderma.mp.
16. exp Staphylococcus Aureus/ or stapylococcus aureus.mp.
17. 16 or 15 or 14
18. 13 and 17
Appendix 4. LILACS search strategy
((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CON-
TROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND
METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or
tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw
clinic$)) ANDNOT ((CT ANIMALS ORMH ANIMALS OR CT RABBITS OR CTMICE ORMH RATS ORMH PRIMATES
ORMH DOGS ORMH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Palavras] and (impetigo
or pyoderma or piodermia or piodermitis or (staphyloccus aureus) or estafilococo) [Palavras]
WH A T ’ S N E W
Last assessed as up-to-date: 27 July 2010.
Date Event Description
9 June 2015 Amended Author information (affiliation) updated
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H I S T O R Y
Protocol first published: Issue 4, 2001
Review first published: Issue 2, 2004
Date Event Description
7 March 2012 Amended The lead author’s contact details have been updated.
8 November 2011 New citation required but conclusions have not
changed
A substantial amount of new information has been
added in the form of 12 newly included studies
8 November 2011 New search has been performed New search for studies
29 July 2011 Feedback has been incorporated In response to peer reviewers’ comments, the following
major changes were implemented: (1) removed sum-
score for risk of bias items; (2) dropped intention to
treat analysis as separate risk of bias item; (3) provided
more precise information on subjective assessment of
symptoms; (4) made a separate table for adverse events
4 August 2010 Amended When finalizing the update, new searches were run
(2009-July 2010), resulting in the addition of eight
papers to the list of Studies awaiting assessment
23 February 2009 New citation required and conclusions have changed New search (2002-2008), 12 new trials found, one
trial previously included discarded. Tables with out-
comes ofmethodological assessments replaced by ’Risk
of bias’ tables. New author added
3 October 2008 Amended Converted to new review format.
2 September 2004 New search has been performed Minor update
4 January 2003 Amended New studies found but not yet included or excluded
27 November 2002 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review - SK, JCvdW, and LvSS
Designing the review - SK, JCvdW, LvSS, CCB, and AM
Co-ordinating the review - SK and JCvdW
Data collection for the review - SK, JCvdW, and RvdS
Developing the search strategy - JCvdW
Undertaking searches - JCvdW, SK, and RvdS
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Screening search results - JCvdW, SK, and RvdS
Organising retrieval of papers - JCvdW, SK, and RvdS
Screening retrieved papers against inclusion criteria - LvSS, SK, and RvdS
Appraising quality of papers - JCvdW, AV, and RvdS
Abstracting data from papers - CCB, AM, RvdS, and JCvdW
Writing to trial authors of papers for additional information - SK, RvdS, and JCvdW
Obtaining and screening data on unpublished studies - JCvdW, SK, and RvdS
Data management for the review - SK, RvdS, and JCvdW
Entering data into RevMan - SK, JCvdW, and RvdS
Analysis of data - SK, RvdS, and JCvdW
Interpretation of data - all authors
Providing a methodological perspective - JCvdW
Providing a clinical perspective - SK and CCB
Providing a policy perspective - SK and CCB
Writing the review - SK, RvdS, and JCvdW
Providing general advice on the review - all authors
Securing funding for the review - JCvdW
Performing previous work that was the foundation of current study - LvSS, JCvdW, and SK
D E C L A R A T I O N S O F I N T E R E S T
Three authors of this review are authors of one included trial (Sander Koning, Lisette WA van Suijlekom-Smit, Johannes C van der
Wouden; Koning 2003).
Sander Koning and Johannes C van der Wouden were also involved in a second trial (Koning 2008), which was initiated by the
manufacturer of the drug. As employees of ErasmusMC, Rotterdam, Johannes C van derWouden and Sander Koning received research
funding from GlaxoSmithKline for participating in a study comparing retapamulin to placebo in participants with impetigo. The
funding was used to pay staff involved in field work. They were also involved in publishing the results. The study was included in the
update of this review.
S O U R C E S O F S U P P O R T
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Internal sources
• Department of General Practice, Erasmus MC - University Medical Center Rotterdam, Netherlands.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In case of studies assessing cure at more than one point in time, the protocol did not specify what time point to select for data extraction.
From the start of the review, we chose the assessment that was closest to one week from the start of treatment.
For this update, the scoring of methodological quality was changed into the newly recommended ’Risk of bias’ table (Higgins 2008).We
also used risk ratio as recommended by the Cochrane Skin Group.
N O T E S
Sponsored research
Industry sponsorship or organisation of the trial was declared to be present in 20 trials (29%): 5 mupirocin studies (Goldfarb 1988;
Mertz 1989; Rist 2002; Wainscott 1985; White 1989), 2 with cefdinir (Tack 1997; Tack 1998), 2 with cefadroxil (Beitner 1996;
Hains 1989), 2 with azithromycin (Daniel 1991a; Daniel 1991b), 2 with cefditoren (Bucko 2002a; Bucko 2002b); 2 with retapamulin
(Koning 2008; Oranje 2007); 1 of amoxicillin plus clavulanic acid (Jaffe 1985), cefalexin (Dillon 1983; Giordano 2006), clindamycin
(Blaszcyk 1998), and fusidic acid (Sutton 1992). Five trials (9%) were supported by other organisations. In the remaining 48 (67%)
trials, no statement of sponsorship or funding was made (see Table 2 ’Declared sponsorship or funding’).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Administration, Topical; Anti-Bacterial Agents [administration & dosage; ∗therapeutic use]; Erythromycin
[administration & dosage; therapeutic use]; Fusidic Acid [administration & dosage; therapeutic use]; Impetigo [∗drug therapy];
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